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Energy production  
 
Living creatures require energy for the performance of mechanical work in 
muscle contraction and other cellular movements, the active transport of ions 
and molecules and the synthesis of macromolecules and other bio-molecules 
from simple precursors. The starting point of energy generation necessary for 
aforementioned cellular processes is our daily food, which is degraded into 
useful particles with mechanical help (e.g. chewing) and enzymes present in the 
digestive track. The nutrients present in food in the form of proteins and fat are 
degraded into amino acids and fatty acids, respectively, whereas carbohydrates 
are converted into glucose, fructose and galactose. During these processes no 
useful energy is produced. The generated components are absorbed by the small 
intestines and transported via the blood to the cells where they are used to 
generate ATP (Figure 1). In the cytoplasm, glucose, fructose and galactose enter 
the glycolysis where they are degraded to pyruvate. This compound is 
transported over the mitochondrial outer and inner membrane where pyruvate is 
immediately converted to acetyl coenzyme A by the pyruvate dehydrogenase 
complex (PDHc). Acetyl coenzyme A, which is also the end product of the 
breakdown of the fatty acids and some amino acids, is completely oxidized to 
CO2 in the citric acid cycle. During this oxidation process electrons are 
transferred to NAD+ and FAD leading to the formation of NADH and FADH2. The 
transferred electrons are used for the oxidative phosphorylation. During this 
phase most of the ATP is produced. 
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Figure 1: Degradation of amino acids, glucose, galactose, fructose and fatty acids in the cell. Glucose 
is degraded to pyruvate in the glycolysis. Pyruvate enters the mitochondrion and is directly converted 
to acetyl CoA. Fatty acids are oxidized to acetyl CoA in a separate pathway. Acetyl CoA is used in the 
citric acid cycle situated in the mitochondrial matrix to generate NADH and FADH2. Electrons from these 
two components are donated to the oxidative phosphorylation system (see Figure 2). Amino acids 
depicted in grey are used at different stages in the diverse pathways. 
 
 
Oxidative phosphorylation 
 
The oxidative phosphorylation takes place in the mitochondrion, the major 
energy producing organelle of the cell. A mitochondrion consists of two 
membranes surrounding a matrix [1]. Five multi protein complexes and two 
electron carriers, together forming a functional unit located in the highly folded 
inner membrane of the mitochondrion, are responsible for oxidative 
phosphorylation. The first four protein complexes together are called the 
respiratory chain whereas together with the fifth complex the chain is called the 
oxidative phosphorylation (OXPHOS) system (Figure 2). 
ATP generation by oxidative phosphorylation starts with the re-oxidation of 
NADH derived from the oxidation of fatty acids, amino acids and pyruvate. This 
results in the donation of two electrons from NADH to complex I 
(NADH:ubiquinone oxidoreductase). Complex I is the largest multi protein 
assembly of the OXPHOS system. Complex I is L-shaped with one arm 
embedded in the inner mitochondrial membrane whereas the other arm is 
protruding into the matrix. The electrons accepted by complex I pass through 
the prosthetic groups of the complex and are finally donated to the electron 
carrier ubiquinone (Coenzyme Q). Complex II or succinate:ubiquinone 
oxidoreductase also passes electrons to ubiquinone but these are in contrast to 
the electrons from complex I generated by FADH2 produced in the citric acid 
cycle or fatty acid oxidation instead of NADH. Ubiquinone carries the electrons to 
the third complex ubiquinone: cytochrome c oxidoreductase (Complex III), 
which on its turn transfers the electrons via the second electron carrier 
cytochrome c to the last complex of the electron transport chain, complex IV or 
cytochrome c oxidase.  
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Figure 2: Mitochondrial oxidative phosphorylation system. The oxidative phosphorylation system 
consists of two electron carriers, co-enzyme Q (CoQ) and cytochrome c (Cytc), and five multi protein 
enzymes complexes, complex I-V (complex I = NADH:ubiquinone oxidoreductase, complex II = 
succinate:ubiquinone oxidoreductase, complex III = ubiquinone:cytochrome c oxidoreductase, complex 
IV = cytochrome c oxidase and complex V = ATP synthase). The number of subunits encoded by 
mtDNA or nDNA is depicted below the schematic representation of the OXPHOS system. Subunits ND1-
6 (NADH dehydrogenase subunits 1-6 and ND4L), Cyt b (Cytochrome b), CO I-III (cytochrome c 
oxidase subunits I-III), A6 and A8 (ATP synthase subunits 6 and 8) are encoded by mtDNA. ims = 
intermembrane space, im = innermembrane, ······· eP-P = electron flow, BHP+P = proton flow. 
 
 
This complex uses the electrons for the reduction of oxygen to water. During 
electron transport through the complexes of the OXPHOS system protons are 
transported across the mitochondrial inner membrane by complexes I, III and IV 
from the matrix to the mitochondrial inter membrane space. The fifth complex 
(ATP synthase) of the oxidative phosphorylation system uses the generated 
proton gradient to produce ATP. ATP synthase is a cylindrical structure, which 
spans over the mitochondrial inner membrane. The protons flow through this 
structure from the inter membrane space to the matrix. During this proton flow 
ATP is produced from ADP (adenosine diphosphate) and Pi (inorganic phosphate) 
by the matrix part of ATP synthase [2]. The generated ATP is partly used for 
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energy demanding processes in the mitochondrion; the majority is used 
elsewhere in the cell. A substantial part of the intra-mitochondrial ATP is 
exchanged for extra-mitochondrial ADP by the integral inner membrane protein 
adenine nucleotide translocator (ANT). 
 
 
Mitochondrial disorders 
 
Mitochondrial disorders are diseases with a defect present in the mitochondrion 
but they commonly refer to diseases that are caused by disturbances in the 
OXPHOS system [3]. Mitochondrial disorders are most often multi-system 
disorders mainly affecting organs with a high-energy demand like brain, heart 
and skeletal muscle. These disorders can have their initial clinical presentation at 
any age. A mitochondrial disorder should be considered in young children 
displaying a combination of clinical symptoms affecting multiple tissues, 
particularly progressive, myopathy, endocrine dysfunction, epileptic seizures and 
cognitive decline [4]. In adults, the mitochondrial disease symptoms might 
affect only one organ or tissue, leading for example to chronic progressive 
external ophthalmoplegia or diabetes. The most frequently encountered 
mitochondrial disorder is Leigh’s syndrome [5]. This syndrome is a prototypic 
example of biochemical and genetic heterogeneity while the phenotypic 
appearance is similar. The majority of patients reported in literature with Leigh’s 
syndrome have a profound defect of complex IV [6;7]. Leigh’s syndrome is one 
of the most frequently observed clinical phenotypes in mitochondrial diseases 
and will therefore be discussed in more detail. Leigh’s syndrome is a progressive 
neurodegenerative disorder with a characteristic neuropathology, which usually 
affects children. The first symptoms usually appear before the age of two years. 
Typical clinical signs are hypotonia, developmental arrest in infancy, ataxia, 
dystonia, optic atrophy and muscle weakness. Specific neurological features help 
to distinguish Leigh’s syndrome from other brain diseases. These features 
consist of focal, symmetrical necrotic lesions extending from the thalamus to the 
pons and involving the inferior olives and the posterior columns of the spinal 
cord. Most patients die a few years after the first diagnosis. 
The clinical and genetic heterogeneity of mitochondrial disorders makes their 
investigation and diagnosis a challenge. The pathological investigation of the 
muscle biopsy remains one of the most important diagnostic tools. In addition 
enzyme studies can be performed in muscle biopsies, cultured fibroblasts or 
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other cell types. Many problems are associated with diagnosing mitochondrial 
disorders [8]. This is partly related to the muscle samples used as some 
laboratories e.g. for geographical reasons, only have access to frozen muscle 
specimens. The measurement of substrate oxidation rates requires intact 
mitochondria and for that reason it is required that shortly after sampling the 
biopsy is used for these studies [9]. It has been suggested to make consensus 
diagnostic criteria to overcome these problems [10-12]. The final diagnosis of a 
mitochondrial disorder can be a guide to molecular studies, a model has been 
proposed by Taylor et al [8]. 
The five OXPHOS system complexes are large multi subunit complexes, which 
are genetically unique as the building blocks are encoded by nuclear (n) and 
mitochondrial DNA (mtDNA), with the exception of complex II which is 
composed only out of proteins from nuclear origin (Figure 2).  
Mitochondrial DNA consists out of 16,569 base pairs and codes for 2 ribosomal 
RNAs (rRNA), 22 transfer RNAs (tRNA) and 13 messenger RNAs. Mutations in 
the circular mitochondrial DNA can lead to defects in the OXPHOS system 
complexes affecting the enzyme activity of one or more OXPHOS system enzyme 
complexes. Under normal conditions mtDNA is only inherited from the mother. 
Table 1 provides a summary of the described mutations in the mtDNA encoding 
for the structural subunits of the OXPHOS system. Mutations in the genes coding 
for mitochondrial rRNA and tRNA are not presented in Table 1.  
Mutations in these rRNAs cause non-syndromic sensorineural deafness and an 
enhanced sensitivity of the cochlea to aminoglycoside antibiotics [145]. The 
most frequently observed point mutations in tRNA genes are A3243G in the 
tRNA(Leu) gene and A8344G in the tRNA(Lys) gene. Mitochondrial disorders 
associated with mtDNA mutations are especially interesting, as there seems to 
be a potential relationship between the different defects and the clinical signs 
they produce.  
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Table 1: Structural mitochondrial DNA mutations as have been described in literature leading to an 
isolated OXPHOS system disorder. 
OXPHOS system 
complex 
Subunit Number of 
mutations 
Disorder References 
ND1 6 
1 
 
1 
2 
1 
LHON 
Sudden infantile death 
syndrome 
Mitochondrial myopathy 
MELAS 
Adult-onset dystonia 
[13-21] 
[22] 
 
[23] 
[24;25] 
[26] 
ND2 3 
1 
LHON 
Skeletal myopathy 
[18;27;28] 
[29] 
ND3 2 
1 
Encephalopathy 
Leigh’s syndrome 
[30;31] 
[32;33] 
ND4 2 
1 
1 
1 
LHON 
LHON and dystonia 
MELAS 
Exercise intolerance 
[15;21;34-53] 
[54] 
[55;56] 
[57] 
ND4L 1 LHON [58] 
ND5 2 
2 
4 
1 
LHON 
Leigh’s syndrome 
MELAS 
Leigh/MELAS 
[18;27;59] 
[33;60-62] 
[63-67] 
[68] 
NADH: ubiquinone 
oxidoreductase 
ND6 6 
1 
1 
1 
LHON 
Leigh’s syndrome 
MELAS 
Progressive generalized 
dystonia 
[54;69-82] 
[33;83] 
[84] 
[85] 
Ubiquinone 
cytochrome c 
oxidoreductase 
Cytochrome b 2 
10 
1 
2 
2 
1 
LHON 
Exercise intolerance 
Encephalomyopathy 
Multisystem disorder 
Cardiomyopahty 
MELAS/parkinsonism 
[27;82;86;87] 
[88-95] 
[96] 
[97;98] 
[99;100] 
[101] 
COI 1 
2 
2 
1 
1 
1 
LHON or McArdle’s disease 
Sideroblastic anemia 
Encephalopathy 
Myoglobinuria 
Motor neuron degradation 
Epilepsy 
[102-105] 
[106] 
[107;108] 
[109] 
[110] 
[111] 
COII 1 
2 
1 
1 
Encephalopathy 
Lactic acidosis 
Multisystemic 
Alpers-Huttenlocher-like 
disease 
[112] 
[113;114] 
[115] 
[116] 
Cytochrome c 
oxidase 
COIII 2 
1 
1 
1 
1 
LHON 
Myoglobinuria 
Exercise intolerance 
Leigh like syndrome 
MELAS 
[41;103] 
[117] 
[118] 
[119] 
[120] 
ATP synthase ATPase 6 3 
1 
1 
Leigh’s syndrome 
LHON 
Mental retardation and 
ataxia 
[121-142] 
[143] 
[144] 
The table is based on the data present in OMIM. For each subunit Pubmed has been searched for 
mutations not present in OMIM using the name of the subunit in combination with mitochondrion. LHON 
= Leber’s hereditary optic neuropathy, MELAS = mitochondrial encephalomyopathy, lactic acidosis and 
strokelike episodes. 
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Three diseases constitute the most frequent phenotypes associated with mtDNA 
mutations; mitochondrial encephalopathy with lactic acidosis and stroke-like 
episodes (MELAS), myoclonic epilepsy with ragged red fibers (MERRF) and Leber 
‘s hereditary optic neuropathy (LHON) [146-148]. The clinical hallmarks of 
MELAS are the stroke-like episodes with hemiparesis or hemianopia. Common 
additional features are focal or generalized seizures, recurrent migraine like 
headache and vomiting and dementia. It is mainly maternally inherited. 
Distinctive features involve short stature, hearing loss and diabetes. MERRF is 
characterised by myoclonus, generalised seizures, cerebellar ataxia and 
myopathy. The disease can present in childhood or in adult life and the course 
can be slowly or rapidly downhill. LHON causes loss of vision in young adults 
[148]. The majority of LHON patients do not suffer from additional neurological 
symptoms. LHON is mainly caused by one of three missense mutations in 
mitochondrial complex I genes, but only 40% of males and 10% of females 
develop the disease. This might be due to a modifier locus on the X chromosome 
or another gender specific modifier. 
Mutations in nuclear genes coding for the structural building blocks of the 
OXPHOS system mainly affect the activity of one complex. Such mutations have 
been described e.g. in genes necessary for the formation of complex I and II. A 
summary of these mutations and the corresponding clinical phenotypes is 
depicted in Table 2. This table also illustrates the genetic heterogeneity of 
mitochondrial disorders; Leigh’s syndrome is one of the most often encountered 
clinical phenotypes due to mutations in nuclear encoded genes. Recently, the 
first mutation in a structural subunit of complex III has been described [149]. 
The mutations found in the nuclear as well as the mitochondrial DNA lead to the 
elucidation of the cause of many mitochondrial disorders. Despite this progress 
the genetic origin of the majority of mitochondrial diseases is still unknown.  
 
 
 
 
 
The table is based on the data present in OMIM. For each subunit Pubmed has been searched for 
mutations not present in OMIM using the name of the subunit in combination with mitochondrion. LHON 
= Leber’s hereditary optic neuropathy, MELAS = mitochondrial encephalomyopathy, lactic acidosis and 
strokelike episodes. 
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Table 2: Structural nuclear DNA mutations as have been described in literature leading to an isolated 
OXPHOS system disorder. 
OXPHOS 
system 
complex 
Origin 
DNA 
Subunit Number of 
mutations 
Disorder Referenc
es 
NDUFV1 
(51 kDa) 
3 
 
6 
Leukodystrophy and myoclonic 
epilepsy 
Hypotonia or ataxia 
[150] 
 
[151] 
NDUFV2 
(24 kDa) 
1 Cardiomyopathy and 
encephalomyopathy 
[152] 
NDUFS1 
(75 kDa) 
6 Psychomotor retardation 
hypotonia or 
Leigh’s syndrome 
[151] 
NDUFS2 
(49 kDa) 
3 Cardiomyopathy and 
encephalomyopathy 
[153] 
NDUFS3 
(30 kDa) 
2 Leigh’s syndrome [154] 
NDUFS4 
(AQDQ) 
5 Leigh like syndrome [155-158] 
NDUFS6 
(13 kDA) 
2 Lactic acidosis and 
hypoventilation 
[159] 
NDUFS7 
(PSST) 
1 Leigh’s syndrome [160] 
NADH: 
ubiquinone 
oxidoreductase 
Structural 
NDUFS8 
(TYKY) 
2 Leigh’s syndrome [161] 
Succinate CoQ 
oxidoreductase  
Structural SDHA 3 
1 
Leigh’s syndrome 
Respiratory infection and 
severe hypoglycemia 
[162;163] 
[164] 
UQCRB 
 
1 
 
Hypoglycemia and lactic 
acidosis 
[149] 
 
Ubiquinone 
cytochrome c 
oxidoreductase 
Structural 
 
Assembly BCS1L 4 
 
1 
2 
Tubulopathy, encephalopathy 
and liver failure 
Gracile syndrome 
Congenital lactic acidosis 
[165] 
 
[166] 
[167] 
SURF1 36 
2 
2 
Leigh’s syndrome 
Leukodystrophy 
Villous atrophy and 
hypertrichosis 
[168-187] 
[188] 
[189] 
SCO1 2 Neonatal-onset hepatic failure 
and encephalopathy 
[190] 
SCO2 6 
 
1 
2 
1 
1 
Fatal infantile 
cardioencephalomyopathy 
Cardiomyopathy neuropathy 
Werdnig-Hoffman disease like 
Spinal muscular atrophy 
Hypertrophic cardiomyopathy 
[191] 
 
[192] 
[193] 
[194] 
[185] 
COX10 1 
1 
1 
Encephalopathy 
Anemia and Leigh syndrome 
Anemia, sensorineural deaffnes 
and fatal infantile hypertrophic 
cardiomyopathy 
[195] 
[196] 
[196] 
COX15 1 Early onset fatal hypertrophic 
cardiomyopathy 
[197] 
Cytochrome c 
oxidase 
Assembly 
LRPPRC 2 Leigh’s syndrome, French 
Canadian type 
[198] 
ATP synthase Assembly ATP12 1 Lactic acidosis, dysmorphic 
features and methyl glutaconic 
aciduria 
[199] 
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Many more proteins than the structural building blocks are involved in the 
proper formation of the OXPHOS system complexes. Besides proteins for the 
transcription, translation and transport across the mitochondrial membranes 
also proteins for the proper assembly of the multi protein subunits are necessary 
to make sure that the complexes end up in the mitochondrial inner membrane in 
the correct order. SURF1, the first described assembly protein in man, is 
necessary for the assembly of complex IV [168;169]. The discovery of this gene 
was followed by the characterization of other assembly genes (Table 2) and shed 
a complete new light on how the OXPHOS system is assembled. 
OXPHOS defects due to mutations in non-structural nuclear genes can in certain 
cases lead to inter-genomic communications defects or homeostasis and import 
defects. Defective inter-genomic communication can be caused by mutations in 
the gene for thymidine phosphorylase (TP) [200]. Mutations in this gene are 
associated with mitochondrial neurogastrointestinal encephalomyopathy 
syndrome (MNGIE) [201]. The clinical features include ophthalmoparesis, 
peripheral neuropathy, leucoencephalopathy and gastrointestinal syndromes. 
The TP activity is markedly decreased in these patients whereas the plasma level 
of the substrate is increased in these patients. Analysis of mtDNA shows 
deletions, depletions or both. The precise mechanism by which TP deficiency 
leads to mtDNA rearrangement has not been elucidated yet. A second gene 
involved in a defective inter-genomic communication is the heart and skeletal 
muscle isoform of ANT1 [202]. Patients with a defect in this gene present with 
autosomal dominant progressive autosomal ophthalmoplegia (adPEO) [203]. 
adPEO is an adult-onset mitochondrial disorder characterised by progressive 
external ophthalmoplegia and variable additional features for instance exercise 
intolerance, ataxia, depression. The disease manifestation is in agreement with 
an ANT1 knock-out mouse model, and indicates that ANT1 is involved in mtDNA 
maintenance [204]. Another gene (twinckle) has recently been associated with 
some cases of adPEO [205]. This gene may be involved in mitochondrial 
replication as it has similarities to bacteriophage T7 primase/helicase. Also 
mutations in polymerase gamma (POLG), which is the DNA polymerase 
responsible for mtDNA replication, have been identified in patients with adPEO 
[206]. Two genes have been identified that are involved in mitochondrial DNA 
depletion syndromes. Mutations in thymidine-kinase 2 (TK2) have been 
identified in patients with a mitochondrial DNA depletion syndrome and isolated 
myopathy [207]. Whereas mutations in deoxyguanosinekinase (dGK) have been 
identified in patients with a systemic form of mtDNA depletion [208]. All these 
General introduction and objectives of this thesis 
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mutations seem to result in an impaired control of the mitochondrial nucleotide 
pool. Genes, involved in homeostasis and import are frataxin, paraplegin, 
deafness/dystonia peptide (DDP) and optic atrophy 1 gene (OPA1). Studies 
suggest that frataxin present in the mitochondria has a specific role in 
mitochondrial iron homeostasis [209]. The clinical phenotype associated with 
expansion of the frataxin gene is Friedreich’s ataxia (FA) [210]. FA is an 
autosomal recessive neurodegenerative disorder characterised by onset before 
the age of 25 years, progressive limb and gait ataxia, dysarthria, absent deep 
tendon reflexes, sensory loss and pyrimidal weakness. Paraplegin is thought to 
be involved in the assembly or import of the OXPHOS system subunits or 
cofactors [211]. Deletions in this gene lead to an autosomal recessive form of 
hereditary spastic paraplegia, a neurodegenerative disorder which is 
characterised by progressive spasticity and weakness of the lower limbs or in 
more complicated forms with epilepsy and ataxia [212]. Human deafness 
dystonia is an X-linked neurodegenerative disorder with progressive 
sensorineural deafness, dystonia cortical blindness and mental deterioration as 
characteristics [213]. This phenotype is associated with deletions or truncations 
of DDP [214]. Work in yeast has demonstrated that DDP is similar to small 
proteins located in the mitochondrial inter-membrane space, which mediate the 
import of metabolite transporters from the cytoplasm to the mitochondrial inner 
membrane. Mutations in OPA1 lead to defects in a dynamin-related protein that 
is targeted to the mitochondria and might exert its function in mitochondrial 
biogenesis and in stabilisation of mitochondrial membrane complexes [215;216]. 
OPA1 is associated with autosomal dominant optic atrophy. This is characterised 
by an insidious onset of visual impairment in early childhood with moderate to 
severe loss of visual acuity [217].  
The majority of the above-described mutations lead to an enzymatic defect in 
only one of the OXPHOS system complexes whereas thirty percent of the 
patients with a mitochondrial disorder have a deficiency in more than one 
complex, a so-called combined deficiency (Table 3). Such defects may originate 
from a mutation in mtDNA, but can also be related to a mutation in one of the 
structural building blocks of the OXPHOS system, as has been shown for a 
mutation present in a gene for complex I leading to a combined deficiency of 
complex I and III [157]. The close interplay of the OXPHOS system complexes 
makes it very likely that proteins exist necessary for the formation of more than 
one complex [218]. No such gene has been described yet, although one disorder 
affecting the activity of the OXPHOS system complexes as well as other 
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mitochondrial proteins has been mapped to chromosome 2 [219]. The 
identification of genes involved in the proper assembly of more OXPHOS system 
complexes would not only be beneficial for a good diagnosis of mitochondrial 
diseases but would also give us more insight on how the OXPHOS system is 
generated in the mitochondrial inner membrane. 
 
 
Therapeutic options and counselling 
 
Currently, besides supportive care, no successful treatment is available for 
patients with a deficiency of the mitochondrial OXPHOS system complexes. We 
can offer only genetic counselling and prenatal diagnosis. Mostly prenatal 
diagnostics is performed by measuring OXPHOS system enzyme complex activity 
in chorionic villi. Prenatal diagnosis is only offered when a systemic defect of the 
enzyme complexes is present in the family and at least expressed in fibroblasts 
[220]. When the disease causing nuclear gene mutation is known we can also 
check whether the mutation is present in the villi, allowing a more reliable 
procedure than performing prenatal diagnostics at the enzyme level. 
Unfortunately, only in a limited number of cases DNA diagnostics can be offered, 
as the underlying genetic defect is not known in the majority of OXPHOS system 
affected patients.  
 
 
Objectives and outline of the thesis 
 
Measurement of enzyme complex activities of the OXPHOS system in skeletal 
muscle has over the years shown that mitochondrial patients may have an 
enzyme-complex deficiency involving only one complex but also that more than 
one enzyme-complex can display a decreased activity (see Table 3). In fact, our 
experience with more than 25 years of mitochondrial enzyme diagnostics shows 
that all kind of combinations of deficient OXPHOS enzyme complexes exists.  
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Table 3: Occurrence percentages of isolated and combined OXPHOS system disorders 
Single enzyme complex deficiencies Combined enzyme complex deficiencies 
Deficiency % patients Deficiency % patients 
CI 22.7 CI and CIV 7.9 
PDHc 19.9 CIV and PDHc 4.8 
CIII 10.3 CI, CIII and CIV 3.9 
CIV 10.0 CI and PDHc 3.6 
Suc. cyt. c oxidoreductase 3.3 CI, CIV and PDHc 3.3 
CII 1.3 CI and CIII 3.0 
  Other combinations 6.0 
    
Total 67.5 Total 32.5 
Occurrence percentages of isolated and combined OXPHOS system disorders (and combinations with 
pyruvate dehydrogenase (PDHc) deficiency) as published by Loeffen et al [221]. Biochemical analysis 
has been performed in skeletal muscle tissue at our centre over a period of five years (n = 331). Suc. 
Cyt. c =  succinate cytochrome c. 
 
 
The main objective of this study was to gain more insight in the underlying 
molecular defects of OXPHOS system in affected patients. The focus of our study 
in this respect involves both isolated complex IV and combined OXPHOS system 
deficiencies. Isolated complex IV deficient patients are, with 10%, an important 
contributor to the patient group with an OXPHOS system deficiency. Patients 
diagnosed with complex IV deficiency are first routinely checked for common 
mtDNA mutations. However, these mutations are only found in a minority of 
such patients. When it became clear that mutations in nuclear assembly genes 
were a cause for complex IV deficiency we started to investigate our patient 
group for mutations in these genes, like SURF1. This led to the identification of 
several new mutations. Like complex IV deficient patients, patients with a 
combined OXPHOS system deficiency may harbour mutations in mtDNA, but also 
in these patients mutations in the mtDNA were not frequently observed. This led 
to the hypothesis that nuclear genes must be involved in the formation of more 
than one OXPHOS system complex. Therefore, we started to search for nuclear 
genes, which could explain the mitochondrial disorder in these patients. 
Identification of these genes would help us to gain more insight in the basic 
understanding of the OXPHOS system, and improve the possibilities for prenatal 
diagnostics and genetic counselling.   
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A summary of deficiencies leading to a defect in the assembly of the diverse 
OXPHOS system complexes is given in chapter 2. Chapter 3-6 of this thesis 
focuses on complex IV of the OXPHOS system. The presence of mutations in the 
nuclear encoded structural subunits was tested as well as a search for mutations 
in the known assembly genes for complex IV. This was performed in patients 
with a reduced complex IV enzyme activity in fibroblasts and muscle. The next 
two chapters (7 and 8) deal with patients having a combined enzymatic 
deficiency of two or more complexes of the OXPHOS system. We have used two 
different strategies to elucidate the genetic defect in these patients. In chapter 7 
we have performed mutation analysis in genes of which it is known that they 
play a role in combined deficiencies in yeast. In chapter 8, following exclusion of 
mutations in the mitochondrial DNA by a rho-zero cell complementation, we 
used microcell mediated chromosome transfer in order to locate the 
chromosome harbouring the gene responsible for a combined OXPHOS system 
deficiency in one family. Microsatellite markers were used to pinpoint the 
location of the defective gene. Mutation analysis of candidate genes in this 
region revealed the disease causing mutation. 
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Summary 
 
The human oxidative phosphorylation (OXPHOS) system consists of five multi 
subunit complexes of which the individual subunits, with the exception of 
complex II, are encoded either by mitochondrial (mt) or nuclear (n) DNA. 
Consequently, a deficient enzyme activity of one or more of the complexes can 
be caused by mitochondrial or nDNA mutations. In the past 5 years numerous 
mutations have been found in structural nuclear OXPHOS system genes. 
However, in a substantial number of patients with OXPHOS system deficiencies, 
despite extensive investigations, no mutations in the mtDNA or the structural 
nuclear genes have been found. Genetic defects in such patients are therefore 
suspected at the transcriptional, translational, post-translational level or in gene 
products involved in the assembly of the OXPHOS system. The latter is a 
complicated process, as the proteins encoded by the two genomes have to be 
brought together in a proper stochiometric way to form five functional 
complexes. In the past year progress in the knowledge of the human OXPHOS 
assembly process has been made. Several human assembly genes have been 
identified, and mutations in these genes responsible for human OXPHOS system 
complex-related diseases have been detected. In this chapter current knowledge 
about human OXPHOS system assembly genes in health and disease is 
summarized. 
 
 
Introduction 
 
The oxidative phosphorylation (OXPHOS) system, the final biochemical network 
involved in cellular energy production situated in the mitochondrial inner 
membrane, consists of five multi-subunit complexes (complex I-V) and two 
electron carriers, co-enzyme Q and cytochrome c. The first two complexes of the 
OXPHOS system reduce nicotinamide adenine dinucleotide, reduced form, and 
flavine adenine dinucleotide, respectively. By these reductions electrons are 
released and transported from complex I to complex IV of the OXPHOS system. 
Together with the electron transport a proton gradient is created over the 
mitochondrial inner membrane by complex I, III and IV. This proton gradient is 
used by complex V or ATP synthase to generate ATP. All complexes of the 
OXPHOS system except for complex II (only nuclear encoded proteins) contain 
nuclear (n) as well as mitochondrial (mt) DNA encoded protein subunits. 
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The 88 structural subunits encoded by the two different DNA systems have to be 
brought together to form the five functional complexes. Defects in the mtDNA 
and the nDNA encoding for the structural complexes, but also incorrect folding 
and or assembly of the subunits, due to mutations in assembly genes may cause 
OXPHOS system disorders [1]. 
In this chapter, the assembly of the OXPHOS system will be discussed for those 
complexes in which assembly defects have been found (complex III and IV) or 
are highly suspected (complex I, V and combined deficiencies). 
 
 
Isolated deficiencies 
 
OXPHOS system defects can affect one complex (isolated deficiencies) or more 
than one complex of the system (combined deficiencies). 
 
Complex I 
The first complex (NADH:ubiquinone oxidoreductase, complex I) of the OXPHOS 
system consists in human of 46 subunits, seven of these are encoded by 
mitochondrial DNA. Recently the 46th subunit has been characterised. This is 
most probably the last subunit of the complex [2]. Mutations have been 
described in nuclear as well as mitochondrial-encoded subunits. [3;4] 
Nuclear complex I gene mutations mainly affect structural subunits, which play 
an important role in the normal function of complex I [5-7]. Mimicking of the 
human TYKY and PSST subunit mutations in the yeast Yarrowia lipolytica 
confirmed the pathogenicity of these mutations [8]. 
Petruzzella et al. showed with two-dimensional electrophoresis that expression 
of the NDUFS4 subunit is essential for the formation of fully assembled complex 
I [9]. 
It was shown in Neurospora crassa that the matrix arm and the membrane arm 
of the complex are formed separately. In this process, the nuclear encoded 
complex I intermediate-associated proteins (CIA) 84 and CIA 30 also play an 
important role [10]. These two CIA proteins are associated with the membrane 
arm intermediate during the assembly of complex I. The deletion of a cia gene 
results in the disruption of the assembly process. The human homologue of 
CIA30 has been characterized and mutation analysis has been performed in 
patients with a complex I deficiency. This has not led to the identification of 
mutations [11]. 
Mitochondrial oxidative phosphorylation system assembly in man: recent achievements 
 49
Although some indications about the existence of a disrupted complex I 
assembly have been obtained, no human assembly genes for complex I have 
been linked to a mitochondrial disorder yet. A thorough analysis of the mtDNA 
and all structural nuclear complex I genes in a cohort of 24 patients with an 
isolated complex I deficiency revealed disease causing mutations in 
approximately half of the patients investigated, suggesting that other genes 
than only the structural building blocks of complex I might be involved in the 
disease process [1]. On the basis of results of sucrose gradient centrifugation 
studies with monoclonal antibodies a defect in an assembly gene is suspected at 
least in some of the so-far genetically unsolved patients [12]. The same result 
was obtained performing native gel electrophoresis with mitochondria extracted 
from patient cell lines [13]. This study also demonstrated that it is possible to 
discriminate between patients with an assembly defect or a catalytic defect. 
Assembly studies of complex I in human cell lines have demonstrated that 
complex I assembly differs significantly from the assembly pathway in 
Neurospora crassa, showing that precaution should be taken when mimicking 
human physiological conditions in lower species [13;14]. 
 
Complex III 
Complex III (cytochrome bc1 complex) consists of 11 subunits, 10 encoded by 
the nuclear genome. Until recently, only mutations in the mitochondrial DNA 
encoded cytochrome b complex gene have been described. Mutations in the 
cytochrome b gene are associated with different clinical phenotypes [15]. As 
expected, not all complex III-deficient patients bear a mutation in the 
mitochondrial-encoded subunit [16]. Recently the first deletion in the nuclear 
UQCRB gene encoding for subunit VII of complex III has been described [17]. 
Additional studies have shown that the subunit might play a role in the assembly 
and maintenance of complex III [17]. 
The only characterized human gene, which may play a role in complex III 
assembly, is BCS1L [18]. Yeast BCS1 mutations affect the amount of the Rieske 
iron-sulfur subunit of complex III, and complementation experiments indicate 
that BCS1 protein is involved in either forming the active site of the iron-sulfur 
cluster or in providing a chaperone-like function in assembling the Rieske protein 
with other subunits of the complex. Rötig and co-workers have described BCS1L 
mutations in 6 patients from 4 unrelated families, presenting neonatal proximal 
tubulopathy and hepatic involvement [19]. After this first publication more 
mutations have been detected in patients with a mitochondrial localized 
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deficiency, all patients present diverse clinical phenotypes [20;21]. In one report 
concerning patients with Gracile syndrome it was shown that patients with a 
mutation in BCS1L could have normal complex III activities [20]. This shows 
that BCS1L might have other cellular functions than only the assembly of 
complex III. 
 
Complex IV 
Complex IV (cytochrome c oxidase) is a multi-protein enzyme complex 
consisting of 13 subunits of which three are encoded by the mtDNA. Mutations in 
the mtDNA genes of complex IV can affect the assembly of the complex as has 
been demonstrated for COIII, a structural mitochondrial-encoded subunit of 
complex IV. A frameshift mutation in this gene resulted in the accumulation of 
incomplete assembled complex IV as was shown by two-dimensional blue-native 
gel electrophoresis [22]. 
So far no mutations have been described in the structural nuclear encoded 
subunits of complex IV, which has certainly contributed to an extensive search 
for other disease-causing genes such as those involved in complex IV assembly, 
although studies in patients with a complex IV deficiency have shown that some 
patients might harbour mutations in the structural subunits of the complex [23-
26]. 
The most extensive knowledge about the OXPHOS system assembly process is 
presently available for complex IV. It is without doubt that complex IV studies in 
humans have had enormous profit from earlier and ongoing investigations in the 
yeast Saccharomyces cerevisiae. This will be illustrated by studies as performed 
in the human complex IV assembly genes: SURF1, SCO1, SCO2, COX10, COX15. 
The first OXPHOS system assembly gene mutations, those of SURF1, were found 
in families with isolated complex IV deficiency, applying microcell mediated 
chromosome transfer [27;28]. Although initial findings suggested that the 
phenotype of SURF1 mutated patients was restricted to Leigh’s disease, this 
general believing was disputed by the detection of SURF1 mutations in patients 
with other phenotypes [29;30]. 
Before the first human SURF1 mutations had been described it was only known 
that shy 1, the yeast homologue of SURF1, was involved in mitochondrial 
respiration in general [31]. The assembly of complex IV has been investigated 
using blue native two-dimensional gel electrophoresis and can be divided into 
four steps. During the first step hemea, hemea3 and a copper ion (CuB) bind to 
subunit I in the mitochondrial membrane. The second step involves the 
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incorporation of COX4. The other subunits are added in the third step except for 
7b and 6a, which complete the assembly. The effect of mutations on the 
assembly of complex IV has been studied with patient cells bearing various 
SURF1 mutations, resulting in the accumulation of the first two assembly 
intermediates. This indicates that SURF1 is involved in the formation of the third 
sub-complex [25;32;33]. Studies with Shy1-disruptant yeast strains have 
revealed similar results [34]. 
Patients with a mutation in the SCO2 gene, another complex IV assembly gene, 
show clinically infantile cardioencephalomyopathy [35;36]. SCO2 is thought to 
function in the copper trafficking of complex IV, as is also the true for the 
functional homologue SCO1. Even though SCO1 and SCO2 are functional 
homologues, mutations in these genes give a clinical different outcome [35;36]. 
COX10 encodes for heme A: farnesyltransferase, which is also required for the 
biogenesis of complex IV [37]. Additional studies with human cells and yeast 
have identified the function of these assembly proteins of complex IV and their 
relationship to each other [38-42]. COX10 (and also COX 11) are involved in the 
maturation of heme. COX10 is necessary for the proper incorporation of heme 
into complex IV. The human homologue of COX10 has been cloned, and the first 
mutation has been described in this gene in a patient with a complex IV 
deficiency [37]. In a second report on patients with a COX10 mutation it was 
demonstrated the formation of complex IV is severely affected by mutations in 
this gene [43]. Almost no fully assembled complex IV is present in patients’ 
mitochondria. 
With the use of a panel of retroviral vectors expressing complex IV assembly 
genes a patient has been identified harbouring mutations in COX15 [44]. COX15 
is like COX10 involved in the maturation of heme. A mutation in COX15 let to a 
general decrease of fully assembled complex IV [44]. These results are 
comparable with the patients harbouring a COX10 mutation. 
Complex IV assembly genes have also been studied in yeast. Genes involved in 
the delivery of copper to complex IV are COX17, SCO1 and SCO2 [45;46]. A 
COX17 null mutant could be rescued by the addition of copper. SCO1 and SCO2 
are also involved in the copper delivery to complex IV as over-expression of 
these genes could also rescue a COX17 null mutant. Until now no mutations 
have been detected in COX17 in man [35;47-49]. The mutations described in 
the human SCO2 gene are highly conserved in yeast sco1 proteins. This has 
been used for the generation of sco1 mutant yeast strains with the same 
mutations as the described human SCO2 mutations. A mutation introduced 
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immediately adjacent to the copper-binding site did not influence the function of 
sco1 and sco2 protein in yeast. A mutation in the C-terminal portion in the yeast 
SCO1 gene led to a misassembled complex IV [40]. 
Other assembly genes for complex IV in yeast are COX18, COX20, PET197 and 
COX14 [50;51]. The exact functions of these yeast assembly genes have not 
been elucidated yet. Much is known about the assembly of complex IV, but the 
exact assembly mechanism of complex IV has yet to be elucidated. 
Recently the disease causing gene has been elucidated in patients with Leigh’s 
syndrome, the French Canadian type [52]. The mutated gene (LRPPC) encodes a 
mRNA binding protein and is likely involved in mtDNA transcript processing. 
Other complex IV assembly genes might also be involved, as the disease-
causing gene has certainly not yet been found in all complex IV-deficient 
patients. 
 
Complex V 
The last complex of the OXPHOS system consists of 14 subunits. So far only 
mutations in ATPase 6, one of the mitochondrial-encoded subunits of the 
complex, have been found, and a nuclear defect related to complex V has been 
suggested [4;53]. 
ATP11p and ATP12p and FMC1 are assembly factors for the F1 sector of complex 
V [54;55]. Recently the first mutation in the assembly gene ATP12 has been 
identified in a patient with a complex V deficiency [56]. The patient suffered 
from lactic acidosis, dysmorphic features and methyl glutaconic aciduria. Genetic 
manipulation of the complex V subunits has lead to a better insight in the 
interaction of the complex V subunits and the interaction with other 
mitochondrial complexes in yeast [57]. 
 
 
Combined deficiencies 
 
Besides isolated deficiencies, combined OXPHOS system deficiencies also occur, 
suggesting the presence of genes involved in the assembly of more than one 
human OXPHOS system complex. One study has been performed in a patient 
with multiple mitochondrial dysfunctions. This led to the identification of a region 
on chromosome 2 where the disease-causing gene should be located [58]. With 
the use of yeast knock-out strains it has been shown that several yeast genes 
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are involved in the correct functioning of more than one complex of the OXPHOS 
system. 
Oxa1p, for example, is necessary for complex IV assembly in yeast. Knockout 
strains have demonstrated that the assembly defect may be caused by a 
defective import of pre COX-2 [59]. Whereas studies in Neurospora crassa have 
demonstrated that also complex I is affected when Oxa1 is not functioning. 
Afg3, Rca1 and Yme1 also play a role in the Oxa1 pathway [60;61]. These three 
genes are involved in the turnover of mistranslated polypeptides [62]. MBA1 is 
another gene involved in the insertion of mitochondrial translation products into 
the membrane. Mba1 has overlapping functions with Oxa1, but they can act 
independently [63]. 
The OXPHOS system assembly can also be affected by mutations in MRS2 and 
LPE10 [64;65]. These genes have a function in the magnesium homeostasis and 
are involved in the splicing of group II introns. 
Until now only one study has addressed the question whether one gene could 
affect multiple mitochondrial functions. Unfortunately this did only result in the 
identification of a locus on chromosome two. The gene still has to be discovered 
[58]. 
The list of assembly factors involved in combined deficiencies is still growing, 
which demonstrates the complexity of the assembly process. 
 
 
Conclusions 
 
The recent discovery of mutations in human OXPHOS-system assembly genes 
has resulted in the search for other assembly genes. Until now only human 
assembly genes for complex III, IV and V have been described. Patients with an 
enzymatic OXPHOS system deficiency, in which no mutations have been 
detected in the structural building blocks, might have a deficiency in an 
assembly gene. 
The first step in the search for assembly genes is the exclusion of mutations in 
the nuclear or mitochondrial encoded structural subunits. The presence of 
mutations can be established by sequencing the genes. A mitochondrial DNA 
mutation can also be excluded by making cybrids from a patient cell line and 
rho0 cells (lacking functional mtDNA). The rho0 cells will restore the OXPHOS 
system activity when the patient cell line bears a nDNA mutation. 
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When mtDNA mutations are excluded, microcell mediated chromosome transfer 
can be used to search for the defective gene, as has been used for SURF1. 
Another method to identify the disease-causing gene is a genome scan or 
complementation with retroviral vectors carrying genes involved in the 
functioning of the OXPHOS system [44]. 
The generation of a SURF1 knock out mouse has shown that these mice have a 
similar disease phenotype as patients with SURF1 mutations proving that these 
models can give us better insight in OXPHOS system functioning [66]. 
The techniques described above as well as the introduction of new techniques 
such as proteomics or DNA microarrays and mouse models dealing with other 
OXPHOS system related genes will lead to a better understanding of the system 
[67]. This will hopefully lead to the early discovery of the disease-causing gene, 
making prenatal diagnosis of these often early fatal disorders in siblings 
possible, and will consequently supply us with a better insight into the cell 
biological consequences necessary to develop new treatment strategies. 
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Abstract 
 
The mitochondrial oxidative phosphorylation (OXPHOS) system, the main energy 
producing system of the cell, is composed of five multi-protein complexes and 
two mobile electron carriers. The fourth complex of this system, cytochrome c 
oxidase (complex IV), consists of thirteen subunits: three encoded by 
mitochondrial DNA, ten encoded by the nuclear genome.  
Patients with an isolated cytochrome c oxidase deficiency frequently harbour, in 
contrast to other isolated OXPHOS system deficiencies, mutations in nuclear 
genes encoding for proteins necessary for the assembly of the complex. 
Strikingly, until now no mutations have been detected in the nuclear encoded 
structural subunits of cytochrome c oxidase in patients with isolated complex IV 
deficiency. Here, we report the results of a mutational analysis study in ten 
isolated complex IV deficient patients screened for mutations in all structural 
genes as well as assembly genes known to cause cytochrome c oxidase 
deficiency. Four of the ten patients carried mutations in the complex IV 
assembly gene SURF1 associated with Leigh’s syndrome. One patient harboured 
a mutation in the COX10 gene involved in heme A synthesis. Mutations in the 
ten nuclear encoded structural genes were not present.  
 
 
Introduction 
 
Cytochrome c oxidase (complex IV, COX) deficiency is one of the most 
frequently encountered defects causing mitochondrial disease [1]. This fourth 
complex of the oxidative phosphorylation (OXPHOS) system is among others 
involved in proton pumping across the mitochondrial inner membrane. In this 
way the complex contributes to a proton gradient used by the fifth complex, ATP 
synthase, for the production of ATP, the major energy source of the cell [2]. 
Complex IV consists of thirteen subunits, three of which are encoded by 
mitochondrial DNA (mtDNA) whereas the other ten subunits are of nuclear 
origin. Defects in complex IV caused by mutations in the mtDNA-encoded 
subunits give rise to a wide variety of clinical presentations of which anaemia, 
exercise intolerance and myoglobinuria are frequently observed 
symptoms/syndromes [1;3;4].  
Besides the structural subunits of complex IV a whole orchestra of proteins is 
necessary to generate a proper assembled and functional complex in the 
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mitochondrial inner membrane [5]. Extensive research has led to the discovery 
of many non-structural genes linked to cytochrome c oxidase deficiency in man 
[1]. The first described nuclear gene associated with cytochrome c oxidase 
deficiency was SURF1, which is necessary for complex IV assembly [6;7]. SURF1 
is the most frequently encountered mutated nuclear gene involved in 
cytochrome c oxidase deficiency. Mutations in this gene are mainly associated 
with Leigh’s disease. Other nuclear encoded proteins, involved in the proper 
formation of complex IV which have been associated with cytochrome c oxidase 
deficiency are SCO1, SCO2, COX10 and COX15 [8-11]. The proteins SCO1 and 
SCO2 are involved in the insertion of Cu atoms in the CuA site on the COXII 
subunit [12]. First the copper is thought to be delivered to the cytosolic protein 
COX17, which then delivers it to the mitochondrial inner membrane proteins 
SCO1 or SCO2 [13]. Studies in yeast strains with a mutation in COX17 have 
demonstrated that SCO1 and SCO2 have overlapping but not similar functions 
[14]. The exact mechanism of the copper delivery and the relation between 
SCO1 and SCO2 is still under investigation. COX10 and COX15 are both involved 
in the formation of heme A, a prosthetic group of complex IV. Recently LRPPRC, 
a gene probably involved in the processing and trafficking of mtDNA-encoded 
transcripts, has been linked to the cytochrome c oxidase deficient Leigh 
syndrome, French-Canadian type [15].  
Many mutations in the structural nuclear encoded subunits of the OXPHOS 
system complexes have been associated with a mitochondrial disorder in man. 
This is not the case for complex IV where mutations in the ten nuclear encoded 
structural building blocks have not been detected so far [2]. Until now only a 
limited number of studies have addressed the question whether mutations in 
structural nuclear-encoded subunits of complex IV lead to a deficiency of this 
complex in patients [16;17]. Here we sequenced the open reading frames of the 
thirteen structural subunits of cytochrome c oxidase in a group of ten patients 
with an isolated deficiency of this complex. Besides we screened for mutations in 
assembly genes linked to a cytochrome c oxidase deficiency.  
 
 
Materials and methods 
 
Patients 
Ten patients with an isolated COX deficiency in muscle or in muscle and 
fibroblasts were included in this study.  
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Tissue culture and enzymatic measurements 
Human skin fibroblasts were cultured until confluency in medium 199 (Gibco Brl, 
The Netherlands) supplemented with 10% fetal calf serum (Invitrogen, The 
Netherlands) and antibiotics (Gibco Brl, The Netherlands). 
The activities of the mitochondrial respiratory chain complexes were measured 
in skin fibroblasts or muscle of the patients [18]. The method for fibroblasts was 
slightly modified from that used for muscle tissue [18]. Values are expressed 
relative to the mitochondrial marker enzyme citrate synthase.  
 
DNA, RNA isolation and cDNA production 
DNA was isolated from fibroblasts using salt extraction [19]. RNA was isolated 
from 106 fibroblasts using RNAzol (Campro Scientific, The Netherlands) following 
the manufacturers protocol. 5 µg RNA was used to synthesize cDNA. RNA was 
reverse transcribed using superscript II RNAse H¯ reverse transcriptase 
(Invitrogen, The Netherlands) with oligo(dT) (Promega, The Netherlands) and 
random hexamers primers (Promega, The Netherlands). 
 
Mutation analysis 
PCR products of the 13 structural complex IV subunits and SCO1 were generated 
by amplification of cDNA and for SURF1, COX10 and SCO2 by the amplification 
of genomic DNA. Primers were designed according to the published sequences 
(primer sequences are available on request). Amplification was carried out in a 
total volume of 25 µl containing 1 µl DNA/cDNA, 50 ng forward and reverse 
primer, 0.25 mM dNTPs (Life Technologies, The Netherlands), 1-2 mM MgCl2 and 
0.5 unit Taq Polymerase in the manufacturer’s recommended buffer (Life 
Technologies, The Netherlands). Both strands were used for direct sequencing.  
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Results 
 
The clinical presentation of the patients and enzyme activities of the complexes 
of the OXPHOS system are presented in Table 1. 
 
 
Table 1: Cytochrome c oxidase activities of the ten patients as have been determined in cultured 
fibroblasts. 
Patient 
number 
Clinical 
presentation 
Cytochrome c 
oxidase activities 
in mU/mU citrate 
synthase 
% Cytochrome 
c oxidase 
activity 
compared to 
lowest control 
value 
Mutated 
nuclear 
encoded 
gene 
MtDNA 
mutations 
1 Leigh’s syndrome 0.10 15 SURF1 na 
2 Leigh’s syndrome 0.18 27 SURF1 na 
3 Leigh’s syndrome 0.087 13 SURF1 na 
4 Leigh’s syndrome 0.12 18 SURF1 na 
5 Leigh’s syndrome 0.53 78 nd nd 
6 Leigh-like syndrome 0.22 32 COX10 na 
7 NCLA 0.15 22 nd nd 
8 NCLA 0.17# 49# nd nd 
9 FILA 0.55 80 nd nd 
10 SMA-like* 0.41 60 nd nd 
In these patients a mutation screen of the structural complex IV genes as well as that of assembly 
genes of complex IV has been performed. The values are expressed as milliunits per milliunit citrate 
synthase (mU/mU); control values in fibroblasts are 0.68-1.19 mU/mU citrate synthase. # In this 
patient the cytochrome c oxidase activity was measured in a fibroblast cell suspension instead of a 
mitochondrial enriched fraction; control values as measured in fibroblasts are 0.342-0.627 mU/mU 
citrate synthase. FILA is fatal infantile lactic acidosis; NCLA is neonatal cardiomyopathy and lactic 
acidosis and SMA-like is spinal muscular atrophy like complex IV deficiency [25]. nd: no mutations 
detected in the structural subunits and the assembly genes SURF1, COX10, SCO1 and SCO2 of complex 
IV. na: mtDNA not analysed. 
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In a cohort of ten isolated complex IV deficient patients, we searched first for 
mutations in assembly genes. One of the patients (patient 6) harboured a 
homozygous mutation in the startcodon of the complex IV assembly gene 
COX10. The mutation resulted in the substitution of a T by a C in the startcodon 
ATG. One polymorphism was detected in this gene in exon three (mRNA 
G475A), which resulted in the substitution of arginine by glutamine. 
Mutations in the SURF1 assembly gene could be detected in four patients. 
Patient one harboured a homozygous mutation G372A leading to the 
substitution of glycine by arginine in the SURF1 protein. Patient two harboured 
two heterozygous mutations: a substitution of G by A at position 239 of the 
mRNA resulted in the change of amino acid glutamate by arginine. On the other 
strand a TCTGCCAGCC stretch was deleted and replaced by AT at position 312-
321 of the mRNA. This last mutation was also heterozygous present in patient 
three. The second mutation in this patient was a nonsense mutation at position 
244 (C244T). Patient four is homozygous for the common 
312insATdelTCTGCCAGCC mutation.  
The assembly genes SCO1 and SCO2 did not harbour any mutations in this 
cohort of patients.  
In five patients we were unable to detect mutations in the assembly genes. 
Therefore we screened the nuclear encoded structural subunits for complex IV, 
which did not reveal any mutations. One heterozygous polymorphism was 
detected in patient 8. In this patient C was replaced by a T at position 204 in the 
gene COX6b (genbank accession number NM_001863). This base-substitution 
did not alter the amino acid threonine.  
Besides mutation detection in the nuclear encoded genes we also searched for 
mutations in the three mitochondrial encoded complex IV subunits. Also in these 
genes no mutations could be detected. However eight polymorphisms were 
detected in the three mitochondrial encoded COX genes. Patient seven 
harboured a polymorphism in COI (C7028A) not affecting the amino acid 
alanine. Five polymorphisms were detected in COII. In patient nine a 
polymorphism was present at nucleotide position 7789 (G>A). This change has 
no influence on the amino acid leucine. Patient five carried two polymorphisms 
in COII. One did not affect the amino acid alanine (nucleotide position T8143C). 
The other polymorphism (G7830A) results in the substitution of arginine by 
histidine. In patient ten a nucleotide change was present at position 7930 (A>T). 
This results in the replacement of glycine by aspartic acid. Patient eight carried 
one polymorphism in COII and two polymorphisms in COIII. In COII the last 
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codon was changed from TAG to TAA. These are both stop codons. In COIII one 
nucleotide substitution (G9390A) lead to the replacement of alanine by 
threonine, the other nucleotide change (G9947A) does not influence the amino 
acid valine. 
 
 
Discussion 
 
In this report we did not find evidence that the underlying molecular defect of 
cytochrome c oxidase deficiency in ten patients is localised in the DNA of the 
thirteen structural complex IV subunits.  
However we have detected mutations in the complex IV assembly genes COX10 
and SURF1. One patient harboured a homozygous mutation in the start codon of 
COX10 (ATG>ACG). The patient presented with Leigh-like disease, showing that 
mutations in one gene can lead to a wide variety of clinical presentations 
[10;20]. This patient will be described elsewhere in more detail. Four patients 
carried mutations in SURF1. Patient two and three harboured both the 
312del10,insAT mutation. This mutation is often detected in the SURF1 gene in 
patients with an isolated complex IV deficiency [6;7]. Patient one was 
homozygous for a G372A mutation. A more detailed paper concerning this 
patient is in preparation. All patients with a SURF1 mutation suffered from 
Leigh’s disease, which is the most frequently encountered phenotype in patients 
with a SURF1 mutation. Diverse mutations have been described in the genes 
SCO1 and SCO2. We were unable to detect any mutations in these genes. Other 
studies show that SCO2 mutations occur relatively frequent [9;21;22].  
The absence of mutations in the ten nuclear encoded structural subunits of 
complex IV is in line with earlier reports. Until now cytochrome c oxidase 
deficiencies are only explained by mutations in mitochondrial encoded subunits 
and nuclear non-structural genes necessary for the assembly of a normal 
functioning complex [5;16;17]. The described polymorphism in the subunit 
COX6b (patient 8) is present in public databases.  
In five patients we were unable to detect any mutations in the ten nuclear 
encoded subunits or in the COX assembly genes. Therefore a mutation screen of 
the three mitochondrial-encoded subunits was performed. In these genes we 
could only detect polymorphisms. All other nucleotide changes were either 
present in the mitomap database or are frequently encountered in other species. 
The amino acid change in COII (G3780A) present in patient five is not a 
Sequence analysis of the structural nuclear encoded subunits and assembly genes of cytochrome c 
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common change. Blast searches revealed that this change was only present in 
the African Elephant (Loxodonta Africana) suggesting that also this one 
represents a polymorphism. 
An important question remains: why are mutations in structural subunits of 
complex IV not encountered in relation to a cytochrome c oxidase deficiency, 
this in contrast for instance to complex I deficiency in which many mutations in 
structural nuclear genes have been described in patients suffering from an 
enzymatic deficiency of this complex [23]. More extensive research should be 
performed to detect possible mutations in nuclear encoded COX subunits. This 
may lead to the discovery of complex IV deficiencies explained by mutations in 
nuclear encoded genes. Some previously described assembly patterns indeed 
point to a defect in nuclear encoded subunits but if this is the case still remains 
a question [24]. 
As more and more genes seem to be involved in OXPHOS system deficiencies it 
is almost impossible to sequence every candidate gene in patients. An elegant 
method to overcome this problem is the use of retroviral vectors expressing 
human OXPHOS system genes. Expression of these candidate genes in patients’ 
fibroblasts will elucidate the defective gene. This has been successfully used for 
the discrimination of complex IV deficient patients with a mutated COX10 or 
COX15 gene. Another method, which can be used to search new genes related 
to mitochondrial disorders, is microcell-mediated chromosome transfer. This has 
been successfully used for SURF1 [6]. In the future proteomics might also help 
to identify mutated genes in OXPHOS system patients. Protein electrophoresis 
has already shown that patients with mutations in different genes involved in 
complex IV assembly display diverse protein patterns. However the methods 
used so far yield for some genes the same assembly patterns [11;20]. Therefore 
better discriminating techniques are necessary for pinpointing the defective 
genes.  
The identification of new genes involved in the proper formation and functioning 
of the OXPHOS system, like those involved in the assembly of complex IV, will 
lead to the elucidation of the disease causing mutations in so far genetically not 
characterized patients and families. This will be of great diagnostic value but will 
also lead to a better understanding of the assembly and functioning of the 
OXPHOS system.  
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Abstract 
 
Leigh’s syndrome, a progressive often fatal neurodegenerative disorder, is 
frequently associated with a deficiency in the activity of cytochrome c oxidase 
(COX), the last enzyme of the mitochondrial respiratory chain. In contrast to 
NADH: ubiquinone oxidoreductase and succinate dehydrogenase deficiencies, no 
mutations in nuclear genes encoding COX subunits have been identified thus far. 
Very recently, however, a Leigh’s syndrome complementation group has been 
identified which showed mutations in the SURFEIT-1 (SURF1) gene. The results 
of a mutational detection study in sixteen new randomly selected COX-deficient 
patients revealed a new mutation (C688T) in two patients and the earlier 
reported 845delCT mutation in two additional patients. In addition, we evaluated 
the diagnostic value of two-dimensional blue native gel electrophoresis. We 
showed that this technique reveals distinct patterns of both fully and partially 
assembled COX complexes and is thereby capable of discrimination between 
COX-deficient SURF1 and non-SURF1 mutated patients. 
 
 
Introduction 
 
Subacute necrotizing encephalomyelopathy or Leigh’s syndrome resulting from 
mitochondrial oxidative phosphorylation defects is frequently encountered in 
infancy and childhood. Necrotic lesions in the brainstem, basal ganglia, thalamus 
and spinal cord characterise progression of the disease and patients often die 
before the age of five years. Underlying biochemical defects of the disease can 
be attributed to reduced activity of respiratory chain complexes I, II, IV and the 
pyruvate dehydrogenase complex [1]. Complex I and IV are major contributors 
to Leigh’s syndrome related respiratory chain deficiencies [2;3]. Since 1995 the 
first molecular genetic defects in nuclear genes coding for complex I and II of 
the respiratory chain have been described [4-7]. Mutations in mitochondrial DNA 
and mitochondrial tRNAs are also encountered in Leigh’s syndrome patients [2]. 
The oxidative phosphorylation system consists of five enzyme complexes. With 
the exception of complex II, whose subunits are encoded by nuclear genes, all 
other complexes contain proteins encoded by mitochondrial and nuclear DNA. 
The nuclear encoded proteins are transported into mitochondria where they are 
assembled together with the mitochondrially-encoded proteins. Therefore 
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respiratory chain deficiencies can be inherited in a Mendelian fashion in the case 
of nuclear DNA or maternally, if the mutation is located in mitochondrial DNA.  
Cytochrome c oxidase (COX, complex IV) is the last enzyme of the respiratory 
chain. It couples the transfer of electrons from reduced cytochrome c to oxygen 
leading to a translocation of protons across the mitochondrial inner membrane. 
The resulting electrochemical gradient is used to drive the synthesis of ATP. 
Human COX is composed of 13 subunits; the three largest of which are encoded 
by mitochondrial DNA. The remainders are encoded by nuclear DNA [8]. The 
mitochondrial-encoded COX subunits perform proton-pumping activities whereas 
the nuclear encoded proteins that are present in all eukaryotic forms, but are 
absent in prokaryotes, have roles, which are still largely unidentified. 
Complementation studies in human cells and yeast with a COX defect pointed 
out that nuclear genes play an essential role in the proper function of COX 
[9;10]. The sequences of human genes encoding COX subunits have been 
determined in a number of patients exhibiting COX deficiency, but so far this has 
failed to reveal mutations that could explain a loss of enzyme activity [11;12]. 
This leaves open the possibility that defects in other nuclear genes encoding 
proteins, which play important roles in assembly, import or stabilisation of COX 
subunits might be candidates to investigate when there is a dysfunction of the 
complex. This view is supported by the results of genetic studies in yeast, in 
which mutants deficient in cytochrome c oxidase were found to fall into thirty-
four complementation groups, seventeen of which were suggested to be 
involved in assembly [9]. So far, only three COX complementation groups have 
been identified in man [13;14]. One of these was identified by study of Leigh’s 
syndrome patients and presents mutations in the SURF1 gene [14;15].  
The SURF1 gene is one of in a tight, evolutionarily conserved cluster of six genes 
of unrelated function, some of which share bi-directional promotors [16;17]. The 
human surfeit locus maps to chromosome 9q34.2 [18]. SURF3 encodes the 
ribosomal L7a protein [19]; SURF4 encodes for an integral membrane protein 
associated with the endoplasmic reticulum. The functions of the remaining SURF 
genes are not known. In yeast, a homologue of SURF1 called SHY1 (Surf 
Homolog of Yeast) has been identified [20]. Shy1 mutants are unable to grow on 
non-fermentable carbon sources and display inefficient electron transfer 
between bc1 and COX complexes.  
 Here we report the analysis of sixteen randomly selected patients displaying 
deficiency in COX activity. All patients display their deficiency at least in cultured 
skin fibroblasts. SURF1 mutations have been detected in four patients; clinical 
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details and the mutations present in our patients will be described. We also 
analysed COX by two-dimensional blue native gel electrophoresis in these 
patients and show that this is a tool of high diagnostic value capable of 
discriminating between SURF1 mutated and non-SURF1 COX deficient mutated 
patients. 
 
 
Materials and methods 
 
Patients  
Sixteen patients with an isolated COX deficiency were included in this study. 
Details of the four patients with a SURF1 mutation all presenting a classical 
Leigh’s syndrome are given in Table 1.  
 
Table 1: Clinical characteristics of four COX-deficient patients with SURF1 mutations 
 Patient 1 Patient 2 Patient 3 Patient 4 
Gender Female Male Male Female 
Age at presentation 
(months) 
11 10 12 10 
Initial symptoms 
Ophthalmoplegia 
Hypotonia 
Motor retardation 
Hypotonia 
Ophthalmoplegia 
Hypotonia 
Ataxia 
Hypotonia 
Course 
Progressive 
death at 1 3/4 
year 
Progressive 
alive at 2 2/12 
year 
Progressive 
death at 2 3/12 
year 
Progressive 
alive at 5 5/12 
year 
Clinical diagnosis Leigh’s syndrome Leigh’s syndrome Leigh’s syndrome Leigh’syndrome 
Blood lactate A 3.3 3.2 2.6 10 
Blood L/P ratio B 38 ndD ndD 20 
CSF lactate A 3.4 3.0 4.3 8.8 
CSF L/P ratio B 14 ndD ndD 19 
CSF protein C 1020 860 580 ndD
A reference value < 2.1 mmol/l 
B reference value 12-15 
C reference value <450 mg/l 
D not determined 
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Cell culture and biochemical measurements 
Human skin fibroblasts were cultured in medium 199 supplemented with 10% 
fetal calf serum, bicarbonate and antibiotics. The cells were cultured until 
confluency.  
The activities of the mitochondrial respiratory chain complexes were measured 
in skin fibroblasts. The method was slightly modified from that used for muscle 
tissue [21]. Values are expressed relative to the mitochondrial marker enzyme 
citrate synthase.  
 
DNA isolation, SURF1 amplification and sequence analysis 
DNA was isolated from patients’ fibroblasts and parents’ blood using salt 
extraction [22]. 
The oligonucleotide primers used for the amplification of SURF1 genomic DNA 
are presented in Table 2. Exon 1 and 2 of SURF1 were amplified using buffer C, 
12% glycerol and 0.01% gelatine from the PCR optimisation kit (Boehringer), 50 
ng primer, 2.5 mM dNTPs, 1 mM MgCl B2B and 1 unit Taq polymerase (GibcoBRL) in 
a total volume of 50µl. Other exons were amplified in 20 mM Tris-HCl and 50 
mM KCl with 50 ng primer, 2.5 mM dNTPs, 1mM MgClB2B (1.5 mM for exon 5) and 
1 unit Taq polymerase in a total volume of 50 µl. Exon 1 and 2 were amplified 
using the following protocol: 1 minute 94°C, 30 seconds 58°C, and 1 minute 
72°C for 40 cycles. The other exons were amplified 30 seconds 95 °C, 1 minute 
58°C and 1 minute 72°C for 35 cycles. Both amplifications were preceded with 
an initial step of 2 minutes 95°C and followed by 10 minutes 72°C. 
The DNA sequence was analysed on the automated ABI 377 sequencer (Perkin 
Elmer, the Netherlands) according to the manufacturer ‘s protocol.  
 
Table 2: Oligonucleotide primers used for the amplification of SURF1 genomic DNA from 5’ to 3’ 
 
 
Forward primer Reverse primer 
Exon 1 GCAACTCGCTCATGGCCGAC CACCCCGCACCCCGCACCCGGCGCT 
Exon 2 CACCCCGCACCCCGCACCCGGCGCT CCGCTCAGCCGGCAGTTGGTTCATTTCAATCC 
Exon 3 and 4 GCAGCAGGTTTTGATTGGCAG GGCAAGCTGGCCAGCAGAAG 
Exon 5 GCTGTGTAGTCTGCCACCC CAGGGTCCTACCAAGGTTGG 
Exon 6 and 7 CCTATGGGTGCCTGAGTGAC GCCACAGTAGTGACTGGGC 
Exon 8 and 9 CCATACAGGACTTCCAACTG GATGAACCAGTCATGAGCTC 
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Restriction endonuclease analysis 
The mutation present in exon 7 was confirmed with restriction endonuclease 
analysis by digestion of the fragment obtained by oligonucleotide primers F5 and 
R5. Wild type DNA could be cleaved with restriction enzyme Taq 1 (GibcoBRL) 
recognition site 5’-T↓CGA-3’. The arrow indicates the restriction site. The 
transversion in our patients eliminates the recognition site of the restriction 
enzyme. Conditions were used as recommended by the manufacturer. 
 
Two-dimensional electrophoresis 
Cells from exponentially growing cultures were collected. The cell pellet was 
resuspended in phosphate buffered saline (PBS) and the cell concentration was 
determined by use of a counting chamber. Crude mitochondrial pellets were 
obtained by incubating 1 x 10P6 P cells in 2 ml PBS for 10 min on ice with 4 mg/ml 
digitonin. The samples were centrifuged for 1 min at 12,000 x g and the pellet 
was washed with PBS. The mitochondrial pellets were stored at minus 80° C 
until further processing for two-dimensional electrophoresis (2D-PAGE). Crude 
mitochondrial pellets were resuspended in 100 µl of 1.5 M 6-aminohexanoic 
acid, 50 mM Bis-Tris, pH 7.0. 20 µl of 10% β-lauryl maltoside was added, and 
the samples were incubated 15 min on ice. Clearing of the samples was 
performed by centrifugation at 12,000 x g (20 min at 4°C). The supernatant was 
supplemented with 10 µl 5% Serva Blue G in 1 M 6-aminohexanoic acid and 
used for the first dimension. Blue native 2D PAGE was performed as described 
before [23;24]. The monoclonal antibody 1D6-E1-A8 (raised against COI) 
(Molecular Probes, Eugene) was used for Western blotting. 
 
 
Results 
 
Biochemical measurements 
All patients showed a marked decrease in the activity of complex IV the 
respiratory chain as measured in cultured skin fibroblasts. The enzyme activities 
of the patients with a SURF1 mutation are given in Table 3. All measurements 
were performed in a mitochondrial-enriched fraction except for patient 3. A 
fibroblast homogenate was used in the latter. The residual activity of the 
measured COX enzyme activity was 13-19% of the lowest control values. The 
activities of the other measured mitochondrial mitochondrial respiratory chain 
complexes were all within the normal range. In addition measurement of 
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enzymatic activities of the respiratory chain complexes has been performed in 
skeletal muscle tissue of patients 1 and 4. Also this investigation revealed an 
isolated COX-deficiency (data not shown). 
 
 
Table 3: Patients’ enzyme activities of the mitochondrial respiratory chain complexes measured in 
cultured skin fibroblasts. 
Enzyme activitiesA Patient 1 Patient 2 Patient 3 Patient 4 Controls 
NADH:Q1 oxidoreductase 0.20 0.16 ndC 0.15 0.10-0.31 
Succinate:Cytochrome c 
oxidoreductase 
0.28 0.34 ndC 0.18 0.20-0.47 
Decylubiquinol:Cytochrome c 
oxidoreductase 
2.41 2.28 ndC 1.42 1.32-2.61 
Cytochrome c oxidase 0.10 0.13 63.2B 0.09 0.68-1.19 
A Values are given in mU/U citrate synthase. 
B Control values for patient 3 are 342-627 mU/U citrate synthase. 
C not determined 
 
 
Mutation analysis 
As SURF1 mutations have been described in complex IV deficient patients 
[14;15] we tested sixteen COX deficient patients for the presence of mutations 
in the SURF1 gene. Amplification of SURF1 DNA with the described primers 
followed by direct DNA sequence analysis of the PCR products confirmed that 
SURF1 genomic DNA was amplified. Amplification of SURF1 patient DNA revealed 
two homozygous mutations. A transversion was detected in the siblings, patients 
1 and 2. The C to T transition was present in exon 7 at mRNA basepair position 
688. The mutation results in a stop codon. Sequence analysis of the DNA of the 
other two patients revealed a CT deletion in exon 9 at mRNA basepair place 845. 
This mutation leads to a frameshift causing a premature stop codon. Patient 
three also presented a G to A transition in exon 5 at mRNA basepair 370 
resulting in a replacement of a glycine by arginine.  
 
 
SURFEIT1 gene analysis and two-dimensional blue native 
gel electrophoresis in cytochrome c oxidase deficiency 
 
 83
Restriction endonuclease analysis 
The C688T mutation present in the two related patients (patients 1 and 2) could 
be confirmed by restriction enzyme analysis using Taq 1. DNA isolated from 
blood of the parents and fibroblasts of the patients was amplified with the 
oligonucleotide primers for exon 6 and 7. The fragment was digested and 
applied on a 3% agarose gel (Figure 1). The restriction enzyme can digest the 
wild type amplimer, resulting in two fragments of 154 and 339 basepairs. The 
restriction site disappears when the C688T mutation is present. So as in the 
case of the patients the intact fragment of 493 basepairs is visible. The parents 
were both heterozygous for the mutation resulting in three fragments after 
digestion, the undigested fragment (493 basepairs) is containing the mutation 
and digested wild type revealing two bands (154 and 339 basepairs).  
 
 M Father Mother P1 P2 WT 
 
 
 
 
 
Figure 1: Restriction endonuclease analysis pattern. Patient DNA (patient 1 (P1), patient 2 (P2)) 
harbouring the C688T mutation was undigested with Taq 1. Wild type DNA (WT) was digested and 
father and mother are both heterozygous for the C688T mutation. The marker (M) is Puc HaeIII the 
marker fragments correspond with 587, 458 and 434, 298, 267 and 257, 174, 102 and 80 basepairs 
from top to bottom. 
 
 
Two-dimensional gel electrophoresis 
To establish whether 2D-PAGE could be used as a diagnostic tool of certain COX 
deficiencies, fibroblasts from three COX deficient SURF1 patients, one non-
SURF1 COX deficient patient and one control person were screened for the 
distribution of COX assembly intermediates [25]. On western blots of 2D-PAGE 
gels probed with an anti-COX I antibody, we could distinguish four sub-
complexes (Figure 2). These sub-complexes have previously been suggested to 
represent assembly intermediates [25]. The control fibroblasts show normal 
levels and distribution of COX I over the different (sub) complexes. The non-
SURF1 deficient COX patient shows a general decrease of all of the sub-
complexes. SURF1 deficient patients show a typical pattern of COXI distribution 
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over the sub-complexes. Holo-COX (S4) is approximately 20-30% of the control, 
which is in line with the activity measurements, sub-complex S3 is also 
decreased. 
However sub-complex S2 and S1 are relatively increased compared to S4. Thus 
far, this distinctive pattern of COX1 distribution over the different assembly 
intermediates has only been observed in SURF1 mutated Leigh’s syndrome 
patients and can therefore be used to identify COX deficiency caused by SURF1 
mutations.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Two-dimensional electrophoresis to determine the distribution of COX1 over the diverse 
assembly intermediates of COX. A: control, B: patient with a SURF1 mutation, C: non-SURF1 deficient 
patient. S1 to S4 indicate the diverse COX sub-complexes. 
 
 
Discussion 
 
SURF1 is essential for assembly of functional COX as has recently been 
demonstrated in complementation studies with human cells [14;15]. Mutations 
in the SURF1 gene were the underlying genetic defect of the biochemical 
detected by COX deficiencies in four patients. Strikingly, all patients with 
 84
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mutations in the SURF1 gene have Leigh syndrome and the majority of the 
characterised mutations are expected to lead to the synthesis of a truncated 
protein. However not all COX deficient Leigh’s syndrome patients show SURF1 
mutations.  
We tested a group of sixteen COX deficient patients, all patients with a SURF1 
mutation presented Leigh’s syndrome. One new mutation leading to a stop 
(C688T) was detected. This is consistent with the finding that most mutations 
found so far in SURF1 are predicted to result in a truncated protein. Both related 
patients showed a homozygous mutation, whereas the parents were 
heterozygous. This has been confirmed by restriction analysis. A CT deletion at 
bp position 845 was detected in two other patients. This mutation has been 
described before [14;15]. The CT deletion leads to a premature stop at basepair 
position 867. It is difficult to speculate what the effect of the G to A transition in 
patient three is as the mutation occurs together with a CT deletion at basepair 
position 845. A basic local alignment search tool (BLAST) gave us information 
about the conservation of the protein region containing the mutated amino acid. 
The wild type glycine residue is conserved between human, mouse, fugu and 
yeast, but the directly adjacent residues in fugu and yeast are not. The yeast 
and human protein are diverse in many regions; the similarity is highest in the 
central portion of the protein [20].  
The SURF gene cluster is a special gene as it is highly conserved in human, 
mouse and chicken; these clusters are not present in fly and yeast [26]. The 
cluster contains bi-directional promotors and it has a low intergenic space. In 
mouse the SURF2 and SURF4 genes share overlapping reading frames [17]. The 
SURF gene cluster has been conserved for more than 600 million years 
suggesting that its compact organization is of functional importance [27]. It has 
been shown that the yeast SURF1 homologue (SHY-1) is necessary for 
mitochondrial respiration. Shy-1 protein has been found associated with the 
inner mitochondrial membrane [20]. Shy-1 mutations resulted in an impaired 
transfer of electrons from the bc1 complex to cytochrome c oxidase. 
Transfection studies in human fibroblasts proved that SURF1 is also necessary 
for a good functional COX in humans [14;15]. 
The Shy-1 protein is predicted to contain two hydrophobic regions of sufficient 
length to act as membrane-spanning domains. These domains are located close 
to amino and carboxy-termini of the protein and are highly conserved between 
the different species. Consistent with this, Shy-1 protein has been shown to be 
consistently associated with the mitochondrial inner membrane. The SURF1 
Chapter 4 
 86
protein has been localised to mitochondria [15]. The mitochondrial location has 
yet to be confirmed. The yeast protein is longer than its human homologue and 
has many sequence differences. This suggests that the yeast protein might have 
other functions than the human counterpart. There is also a possibility, that like 
other assembly proteins Shy1 may be partially redundant and there may be 
difference between the extent of redundancies between the different species. 
The 2D-PAGE results with patient fibroblasts clearly demonstrate the potential of 
the two-dimensional approach as a powerful diagnostic tool. As SURF1 
mutations are only detected in Leigh’s syndrome patients it can easily be used to 
pre-screen these patients for possible SURF1 mutations. Further 2D-PAGE-
screening of non-SURF1 COX deficient patients will be performed to enlarge the 
putative diagnostic value of this method.  
The identification of the importance of SURF1 in COX function represents a step 
forward in our understanding of mitochondrial disease. All SURF1 mutations 
detected so far are associated with Leigh’s syndrome. The search for other 
genes in (non-) Leigh’s syndrome patients should continue, as SURF1 only 
seems to play a crucial role in COX deficient Leigh syndrome patients. This will 
give us further insight in mitochondrial diseases, which is of great importance for 
patients with OXPHOS system deficiencies. 
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Abstract 
 
About twenty-seven years ago we described a cytochrome c oxidase (COX)-
deficient Leigh’s syndrome patient and early fatal outcome.  Mutation analysis 
for SURF1, an assembly gene most frequently mutated in COX-deficient Leigh’s 
disease, in fibroblasts stored for more than two decades in this patient showed a 
G372A mutation leading to the substitution of glycine by arginine in the SURF1 
protein. SDS-PAGE and two-dimensional gel electrophoresis of proteins from 
fibroblasts showed the characteristic patterns, which have been described before 
in patients with a mutation in SURF1. We stress the importance of collecting 
sufficient amounts of tissues and to store these properly so that even decades 
after the initial diagnosis these samples can still be used to unravel the 
underlying genetic defect.   
 
 
Introduction 
 
Cytochrome c oxidase (complex IV), the fourth complex of the oxidative 
phosphorylation (OXPHOS) system, consists of thirteen subunits, three of which 
are encoded by the mitochondrial DNA (mtDNA) and the remaining by the 
nuclear genome. The oxidation of cytochrome c and the reduction of oxygen to 
water are catalysed by cytochrome c oxidase. This multi-protein enzyme 
complex consumes two protons from the matrix and also pumps two protons 
into the mitochondrial inter membrane space, thereby contributing to the proton 
gradient across the mitochondrial inner membrane. Complex V of the OXPHOS 
system uses this proton gradient, to generate ATP, the main energy source of 
the cell. 
Different mutations have been described in genes necessary for the assembly of 
complex IV as well as in a gene probably involved in the processing and 
trafficking of mtDNA-encoded transcripts [1-7]. Mutations in SURF1, an 
assembly gene for cytochrome c oxidase, are the most frequently encountered 
ones in patients with complex IV deficiency. The majority of these patients show 
a Leigh’s disease phenotype. The effect of SURF1 on the cytochrome c oxidase 
has been extensively studied using two-dimensional gel electrophoresis [8;9]. 
We describe a patient with Leigh’s syndrome harbouring a mutation in SURF1 
who has been reported decades ago with a cytochrome c oxidase deficiency 
[10]. 
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Methods 
 
Patient 
The patient, a girl, was the first child of unrelated healthy parents [10]. The first 
year of her live was uneventful; only the rate of weight gain was diminished and 
vomiting was a regular feature. She was first hospitalised at the age of two 
years. That time she was not able to walk and could stand although unsteadily. 
She exhibited fine hair over the limbs, upper lip, and back. She was hypotonic 
and ataxic with normal deep tendon reflexes and flexor plantar responses. The 
eyes showed a vertical nystagmus. Fundoscopy revealed bilateral partial atrophy 
of the optic nerve. Very remarkably were episodes of deep sighing respirations 
and sobbing. The liver and spleen were not enlarged. Laboratory findings 
revealed a compensated metabolic acidosis and a moderate increase of lactate in 
blood. CSF lactate was 4.1 mM (normal < 1.8).  In the following years the 
child’s clinical condition gradually deteriorated leading to death at the age of 6 
years due to respiratory insufficiency. Examination of the brain showed typical 
lesions present in patients with Leigh’s disease. Enzyme measurements of the 
OXPHOS system complexes showed a reduced cytochrome c oxidase activity in 
heart muscle and a completely absent activity in peripheral muscle. Strikingly, 
25 years ago a normal cytochrome c oxidase activity was measured in liver 
tissue. Histochemical studies of muscle tissue showed an absence of cytochrome 
c oxidase activity. Electron microscopy of a skeletal muscle sample revealed 
aggregation of enlarged mitochondria in the juxta-nuclear and subsarcollemmal 
regions. [10]. These mitochondria had a bizarre shape and varied greatly in size 
and form. The large mitochondria contained an excessive number of cristae, 
which were irregularly arranged and distorted. 
 
Biochemical measurements 
The activity of complex IV was measured in the liver sample stored for 25 years. 
The measurement was performed as has been described by Srere [11]. 
 
SURF1 sequence analysis 
DNA was isolated from patient’s fibroblasts using salt extraction [12]. 
The oligonucleotide primers used for the amplification of SURF1 genomic DNA 
have been described previously [8]. 
The DNA sequence was analysed on the automated ABI 377 sequencer (Perkin 
Elmer, the Netherlands) according to the manufacturer‘s protocol.  
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SDS PAGE and western blot 
Cells from exponentially growing cultures were collected. Cells were washed 
twice in phosphate buffered saline (PBS). Fibroblasts were solubilized with 1.5% 
dodecyl-β-D-maltoside in PBS. 30 µg protein were applied on a tris-tricine SDS-
PAGE gel as has been described elsewhere [13]. The proteins were transferred 
to nitrocellulose and antibodies raised against COI, COII, and SURF1 (Molecular 
Probes, Eugene) were used for detection. 
 
Two dimensional electrophoresis 
Cells from exponentially growing cultures were collected. The cell pellet was 
resuspended in PBS and the number of cells was determined by use of a 
counting chamber. Crude mitochondrial pellets were obtained by incubating 1 x 
10P6 P cells in 200 ml PBS for 10 min on ice with 4 mg/ml digitonin. The samples 
were centrifuged for 1 min at 12,000g and the pellet was washed with PBS. The 
mitochondrial pellets were stored at minus 80° C until further processing for 
two-dimensional electrophoresis (2D-PAGE). Crude mitochondrial pellets were 
resuspended in 100 µl of 1.5 M 6-aminohexanoic acid, 50 mM Bis-Tris, pH 7.0. 
20 µl of 10% dodecyl-β-D-maltoside were added, and the samples were 
incubated 15 min on ice. Clearing of the samples was performed by 
centrifugation at 12,000 x g (20 min at 4°C). The supernatant was 
supplemented with 10 µl 5% Serva Blue G in 1 M 6-aminohexanoic acid and 
used for the first dimension. Blue native 2D-PAGE was performed as described 
before [13;14]. The monoclonal antibodies raised against CO I, COII and SURF1 
(Molecular Probes, Eugene) were used for Western blotting. 
 
 
Results 
 
The DNA of the patient was amplified with primers for SURF1, followed by direct 
sequencing. This revealed a transition of a G by an A at place 372 in SURF1 
mRNA. This mutation leads to the substitution of an uncharged glycine by a 
positively charged arginine in the protein. Protein comparison showed that the 
mutated amino acid is highly conserved (Figure 1). 
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Patient YRPVKVRRCFDHSKEL 
Human  YRPVKVRGCFDHSKEL 
Mouse  YRPVKVRGHFDHSKEL 
Fugu  YRRVKMRGKYDHSKEL 
Yeast  YRKVILTGHFLHNEEM 
 
 
 
 
Figure 1: Comparison of the protein sequence surrounding the mutated amino acid of SURF1 (patient, 
human, mouse, fugu) and Shy1 (yeast). The figure shows the sequence conservation of the glycine. 
The mutated amino acid is indicated with a box. 
 
 
Thus far all SURF1 mutations have been associated with a systemic complex IV 
deficiency. It has also been reported that SURF1 is highly expressed in liver 
[15]. Therefore we once more measured the enzyme activity in liver tissue of 
the patient. This tissue has been stored in the freezer for 25 years. This revealed 
a complex IV deficiency in liver (complex IV residual activity was 46% of the 
lowest control value).  
SDS PAGE was performed to gain insight in the steady state levels of 
mitochondrial proteins. Whole cell lysates of control and patient fibroblasts were 
applied on the gel followed by western blotting and detection using antibodies 
raised against COI, II and SURF1. This revealed that all the protein levels were 
lowered compared to control levels (Figure 2).  
 
C  P  
SURF1 
COII 
COI  
 
 
 
 
 
Figure 2: Whole cell extracts of control (C) and patient (P) fibroblasts were separated on a SDS–gel 
followed by western blotting. The western blot was stained with antibodies directed to COI, COII and 
SURF1. 
 
 
Two-dimensional gel electrophoresis was performed using patient material from 
the patient described in this report, a complex IV deficient patient with an 
unknown mutation and a control. Proteins were isolated from fibroblasts 
mitochondria after permeabilization by digitonin. Proteins were first applied on a 
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non-denaturating gel followed by a second dimension in a denaturating gel. The 
four sub complexes, which have been described elsewhere as assembly 
intermediates for complex IV, could be discriminated using an antibody directed 
to COI [16]. Material from the patient with the SURF1 mutation shows a pattern 
with lowered amount of holo-COX plus the accumulation of sub complexes S1 
and S2 (Figure 3). A general decrease of the sub complexes, without 
accumulation was detected using material form the other complex IV deficient 
patient. 
 
COI 
COI 
COI 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: Two-dimensional gel electrophoresis of proteins isolated out of fibroblast mitochondria of 
control (upper panel), patient described in this report (middle panel) and a patient with a complex IV 
deficiency which was not caused by a SURF1 mutation. Western blotting followed the electrophoresis. 
COX protein was detected using an antibody raised against COI. The arrows BNE (blue native gel 
electrophoresis) and SDS-PAGE (SDS polyacrylamide gel electophoresis) indicate the directions of the 
two electrophoretic separations. S1, S2 and S3 are assembly intermediates 1, 2 and 3 respectively. H 
indicates holo-COX. 
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Discussion 
 
The patient described in this paper harbours a SURF1 mutation resulting in the 
substitution of a glycine by an arginine. Like most patients with a SURF1 
mutation this patient suffered from Leigh’s disease. Taken into consideration 
that SURF1 is highly expressed in liver the normal cytochrome c oxidase activity 
found in liver tissue 25 years ago is remarkably [15]. Re-examination of the 
liver tissue indeed showed a reduced complex IV activity. The discrepancy could 
be caused by the technique used for the determination of complex IV activity 25 
years ago. At that time also a normal oxidation of 2-oxoglutarate was measured 
in liver. This is suggestive for normal complex IV activity as a complex IV 
deficiency in muscle tissue is always associated with lowered oxidation levels. It 
might also be possible that the complex IV activity is decreased due to the long 
storage of the material. A SURF1 knock-out mouse presents a cytochrome c 
oxidase deficiency in liver suggesting that a mutation in SURF-1 should affect 
this tissue [17]. This is in agreement with the decreased complex IV activity in 
liver in the patient established now. 
Two-dimensional gel electrophoresis shows that COI is distributed over the 
diverse assembly intermediates in a pattern specific for patients with a SURF1 
mutation [8;18;19]. COI is accumulated in sub complex one and two whereas 
the amount of holo-COX is decreased confirming that SURF1 probably plays a 
role in the formation of sub complex three. Cytochrome c oxidase assembly 
studies in yeast have confirmed this [20]. The pattern is distinct from other 
patients with a complex IV deficiency, which is not caused by a SURF1 mutation. 
This demonstrates that two-dimensional gel electrophoresis could be used to 
discriminate between the disease-causing genes in diverse complex IV deficient 
patients. 
Western blot experiments demonstrate a decrease of the steady-state levels of 
COI, COII and a lack of SURF1. This is in line with previous experiments in 
patients with a mutation in SURF1. Studies with diverse antibodies in patients 
with a cytochrome c oxidase deficiency have shown that the patterns are specific 
for mutations in specific genes [19]. This could be used as a pre-screening in 
COX deficient patients to see which gene is most likely mutated before mutation 
detection. To date, six genes have been linked to cytochrome c oxidase 
deficiency. SURF1 is the most frequently encountered mutated gene. Mutational 
analysis of all these genes is time consuming. Besides this the list of genes 
which should be analysed is still growing as more and more genes appear to be 
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necessary for the proper function of the OXPHOS system [1-7]. Five of these 
genes have a clear role in the assembly of cytochrome c oxidase or the insertion 
of prosthetic groups in the complex. LPPRC was found to be mutated in Leigh’s 
syndrome the French Canadian type. The gene encodes a mRNA-binding protein 
likely involved with mtDNA transcript processing, giving new insights in the total 
process of the formation of the mitochondrial OXPHOS system [7]. 
This report once more shows that it is of utmost importance to look for 
mutations in genes linked to mitochondrial disorders in order to resolve the 
genetic defect. Even patient material stored for many years can be used for this 
purpose. From a pathophysiological point of view it would be very interesting to 
learn whether or not the cytochrome c oxidase activity in liver of other SURF1 
mutated patients is also normal.  
 
 
Acknowledgements 
We would like to thank Eric Shoubridge for invaluable help and Antoon Janssen 
for technical assistance.  
This study was partly funded by a grant from ‘Het Prinses Beatrix Fonds’; grant 
number 98-0108.  
 
 
References 
 
 1.  Tiranti V, Hoertnagel K, Carrozzo R, Galimberti C, Munaro M, Granatiero M, Zelante L, Gasparini 
P, Marzella R, Rocchi M, Bayona-Bafaluy MP, Enriquez JA, Uziel G, Bertini E, Dionisi-Vici C, 
Franco B, Meitinger T, Zeviani M: Mutations of SURF-1 in leigh disease associated with 
cytochrome c oxidase deficiency. Am.J.Hum.Genet. 1998, 63:1609-1621. 
 2.  Zhu Z, Yao J, Johns T, Fu K, De Bie I, Macmillan C, Cuthbert AP, Newbold RF, Wang J, Chevrette 
M, Brown GK, Brown RM, Shoubridge EA: SURF1, encoding a factor involved in the 
biogenesis of cytochrome c oxidase, is mutated in Leigh syndrome. Nat.Genet. 1998, 
20:337-343. 
 3.  Papadopoulou LC, Sue CM, Davidson MM, Tanji K, Nishino I, Sadlock JE, Krishna S, Walker W, 
Selby J, Glerum DM, Coster RV, Lyon G, Scalais E, Lebel R, Kaplan P, Shanske S, De Vivo DC, 
Bonilla E, Hirano M, DiMauro S, Schon EA: Fatal infantile cardioencephalomyopathy with 
COX deficiency and mutations in SCO2, a COX assembly gene. Nat.Genet. 1999, 23:333-
337. 
 4.  Valnot I, von Kleist-Retzow JC, Barrientos A, Gorbatyuk M, Taanman JW, Mehaye B, Rustin P, 
Tzagoloff A, Munnich A, Rotig A: A mutation in the human heme A:farnesyltransferase 
gene (COX10 ) causes cytochrome c oxidase deficiency. Hum.Mol.Genet. 1998, 9:1245-
1249. 
 5.  Valnot I, Osmond S, Gigarel N, Mehaye B, Amiel J, Cormier-Daire V, Munnich A, Bonnefont JP, 
Rustin P, Rotig A: Mutations of the SCO1 gene in mitochondrial cytochrome c oxidase 
Chapter 5 
 100
deficiency with neonatal-onset hepatic failure and encephalopathy. Am.J.Hum.Genet. 
2000, 67:1104-1109. 
 6.  Antonicka H, Mattman A, Carlson CG, Glerum DM, Hoffbuhr KC, Leary SC, Kennaway NG, 
Shoubridge EA: Mutations in COX15 produce a defect in the mitochondrial heme 
biosynthetic pathway, causing early-onset fatal hypertrophic cardiomyopathy. 
Am.J.Hum.Genet. 2003, 72:101-114. 
 7.  Mootha VK, Lepage P, Miller K, Bunkenborg J, Reich M, Hjerrild M, Delmonte T, Villeneuve A, 
Sladek R, Xu F, Mitchell GA, Morin C, Mann M, Hudson TJ, Robinson B, Rioux JD, Lander ES: 
Identification of a gene causing human cytochrome c oxidase deficiency by integrative 
genomics. Proc.Natl.Acad.Sci.U.S.A 2003, 100:605-610. 
 8.  Coenen MJ, van den Heuvel LP, Nijtmans LG, Morava E, Marquardt I, Girschick HJ, Trijbels FJ, 
Grivell LA, Smeitink JA: SURFEIT-1 gene analysis and two-dimensional blue native gel 
electrophoresis in cytochrome c oxidase deficiency. Biochem.Biophys.Res.Commun. 1999, 
265:339-344. 
 9.  Zeviani M, Corona P, Nijtmans L, Tiranti V: Nuclear gene defects in mitochondrial 
disorders. Ital.J.Neurol.Sci. 1999, 20:401-408. 
 10.  Willems JL, Monnens LA, Trijbels JM, Veerkamp JH, Meyer AE, van Dam K, van Haelst U: 
Leigh's encephalomyelopathy in a patient with cytochrome c oxidase deficiency in 
muscle tissue. Pediatrics 1977, 60:850-857. 
 11.  Srere  PA: Citrate synthase. Methods Enzymol. 1969, 13:3-26. 
 12.  Miller SA, Dykes DD, Polesky HF: A simple salting out procedure for extracting DNA from 
human nucleated cells. Nucleic.Acids.Res. 1988, 16:1215-1215. 
 13.  Schagger H, von Jagow G: Tricine-sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis for the separation of proteins in the range from 1 to 100 kDa. 
Anal.Biochem. 1987, 166:368-379. 
 14.  Klement P, Nijtmans LG, Van den Bogert C, Houstek J: Analysis of oxidative 
phosphorylation complexes in cultured human fibroblasts and amniocytes by blue-
native-electrophoresis using mitoplasts isolated with the help of digitonin. 
Anal.Biochem. 1995, 231:218-224. 
 15.  Yao J, Shoubridge EA: Expression and functional analysis of SURF1 in Leigh syndrome 
patients with cytochrome c oxidase deficiency. Hum.Mol.Genet. 1999, 8:2541-2549. 
 16.  Nijtmans LG, Taanman JW, Muijsers AO, Speijer D, Van den Bogert C: Assembly of 
cytochrome-c oxidase in cultured human cells. Eur.J.Biochem. 1998, 254:389-394. 
 17.  Agostino A, Invernizzi F, Tiveron C, Fagiolari G, Prelle A, Lamantea E, Giavazzi A, Battaglia G, 
Tatangelo L, Tiranti V, Zeviani M: Constitutive knockout of Surf1 is associated with high 
embryonic lethality, mitochondrial disease and cytochrome c oxidase deficiency in 
mice. Hum.Mol.Genet. 2003, 12:399-413. 
 18.  Tiranti V, Galimberti C, Nijtmans L, Bovolenta S, Perini MP, Zeviani M: Characterization of 
SURF-1 expression and Surf-1p function in normal and disease conditions. 
Hum.Mol.Genet. 1999, 8:2533-2540. 
 19.  Hanson BJ, Carrozzo R, Piemonte F, Tessa A, Robinson BH, Capaldi RA: Cytochrome c 
oxidase-deficient patients have distinct subunit assembly profiles. J.Biol.Chem. 2001, 
276:16296-16301. 
 20.  Nijtmans LG, Artal SM, Bucko M, Farhoud MH, Feenstra M, Hakkaart GA, Zeviani M, Grivell LA: 
Shy1p occurs in a high molecular weight complex and is required for efficient 
assembly of cytochrome c oxidase in yeast. FEBS Lett. 2001, 498:46-51. 
  
  
  
Chapter 6 
 
Cytochrome c oxidase biogenesis in a patient with a 
mutation in COX10 gene 
 
Marieke J.H. Coenen, Lambert P. van den Heuvel, Cristina Ugalde, 
Marike ten Brinke, Leo G.J. Nijtmans, Frans J.M. Trijbels,  
Skadi Beblo, Esther M. Maier, Ania C. Muntau, Jan A.M. Smeitink 
 
Annals of Neurology 2004;56:560-4 
 
 
  
Cytochrome c oxidase biogenesis in a patient with a mutation in COX10 gene 
 105
Abstract 
 
We report a cytochrome c oxidase (COX) deficient patient, clinically affected with 
Leigh-like disease, with a homozygous mutation in the COX10 start codon. Two-
dimensional gel electrophoresis showed a decrease of fully assembled 
cytochrome c oxidase without the accumulation of partially assembled COX sub-
complexes. Western blot analysis with antibodies directed to COX subunits I, II 
and IV showed a decrease of these subunits in this patient compared with 
control. Over-expression of the COX10 protein in the patient’s fibroblasts proved 
that the detected mutation was indeed the disease cause.  
 
 
Introduction 
 
Human cytochrome c oxidase (COX) consists of 13 subunits; three of these are 
encoded by the mitochondrial DNA (mtDNA). Due to the bigenomic origin of the 
complex, isolated COX deficiencies can be caused by mutations in either the 
mitochondrial or the nuclear genome. In contrast to complexes I, II and III no 
mutations have been described yet in any nuclear encoded structural subunit of 
COX [1-3]. However, six genes involved in COX biogenesis have been linked to 
COX deficiency in man (SURF1, SCO1 and SCO2, COX10, COX15, LRPPRC) [4-
7;10-13]. The COX10 and COX15 proteins play a role in the mitochondrial heme 
biosynthetic pathway. COX10 catalyses the conversion of protoheme to heme O. 
COX15 exerts its role in the next step in which heme O is converted to heme A, 
which is an essential group for the functioning of complex IV [10]. 
To date three patients harbouring mutations in COX10 have been described 
[8;9]. Here we report a new patient, phenotypically classified as suffering from a 
Leigh-like disease, with a mutation in the start codon of the COX10 gene. The 
effect of this mutation on the assembly or stability of mitochondrial COX has 
been analysed by two-dimensional blue native electrophoresis.  
 
 
Case report 
 
The male patient was born at term as the first child of consanguineous parents. 
At 5 months’ age, he developed progressive failure to thrive, and pronounced 
motor agitation was noted. Gross motor development was severely delayed at 7 
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months. At this age, the patient showed generalised muscular hypotonia with 
persistent head lag at traction, ataxia, hypermetria, exaggerated tendon reflexes 
with enlarged reflex zones, low-amplitude nystagmus and saccadic eye 
movements. Ocular fixation was weak. He was not able to grasp.  
Laboratory evaluation showed metabolic acidosis with elevated serum and 
cerebrospinal fluid lactate concentrations. Magnetic resonance imaging of the 
brain showed slight atrophy and hyperintense lesions in the thalamus, olives and 
the nucleus ruber, a pattern comparable to Leigh-like disease. Biochemical COX 
activity was significantly reduced in muscle and fibroblasts (0.15 mU/U citrate 
synthase (CS), control range 0.52-2.08 and 0.22 mU/U CS, control range 0.68-
1.19 mU/U CS respectively). The boy died at 9 months of age of acute 
pneumonia and cardiorespiratory failure. Prenatal diagnosis was performed in a 
later pregnancy. Normal COX activity was found in chorionic villi and the mother 
gave birth to a healthy girl.  
 
 
Materials and methods 
 
Cell culture and biochemical measurements 
Human skin fibroblasts were cultured in M199 (Life Technologies) supplemented 
with 10% fetal calf serum and antibiotics. Mitochondrial OXPHOS complex 
activities were measured in skin fibroblasts and muscle (slightly modified from 
the method described previously [14]). 
 
Analysis of COX10 DNA 
A group of eleven patients with an isolated COX deficiency at least expressed in 
cultured skin fibroblasts were included in this study. DNA was isolated from 
patients’ fibroblasts and parents’ blood [15]. The oligonucleotide primers used 
for the amplification of COX10 genomic DNA have been described previously [8]. 
The DNA sequence was analysed on the ABI 377 sequencer (Perkin Elmer). To 
confirm the presence of the mutation we performed restriction fragment length 
polymorphism analysis with BstZ1 (Promega).  
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COX10 cDNA construct, virus production, infection and measurement of enzyme 
activity 
The retroviral vector was created as described previously [9]. COX activities 
were measured before and after overexpression of COX10 protein (as described 
by Capaldi and collegues and Srere [16;17]). 
 
Protein electrophoresis 
One- and two-dimensional blue native electrophoresis were performed with 
digitonin-isolated mitochondria [18]. Sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE) was performed according to the method from 
Schägger and von Jagow [19]. Proteins were transferred to a PROTAN 
nitrocellulose membrane (Schleicher & Schuell). Western blotting was performed 
using anti-COI, anti-COII, anti-COXIV (Molecular Probes), anti-mitochondrial 
HSP70 (Alexis Corp.) and peroxidase-conjugated anti-mouse immunoglobulin G 
(Molecular probes). The signal was detected by enhanced chemiluminescence 
with ECL Plus (Amersham Biosciences).  
 
 
Results 
 
Eleven patients with decreased COX activity established in cultured fibroblasts 
(data not shown) were analysed for mutations in the COX10 gene. A 
homozygous mutation in the COX10 start codon was detected in one patient. 
The T to C transition of the second base of the start codon (ATG) results in the 
abolition of the start site for protein translation (Figure 1A). Besides this 
mutation, two polymorphisms were detected in control and COX deficient patient 
material (cDNA G476A (dbSNP rs8077302) and A699G (dbSNP rs2230354)). The 
mutation present in the COX10 start codon was confirmed by restriction enzyme 
analysis (Figure 1B). 
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Figure 1: Molecular analysis of COX10 genomic DNA. (A) COX10 DNA sequence of control and patient 
blood, the arrow indicates the mutation in the start codon of COX10. (B) Restriction endonuclease 
analysis pattern with BstZ1. The fragment harbouring the mutation could be digested whereas the 
control was undigested. The length of the fragments (in basepairs) are indicated on the right site of the 
figure; p: patient, f: father, m: mother, w: wild type.  
 
 
To investigate the functional significance of the described mutation, we infected 
patient and control fibroblasts with a retrovirus containing human COX10 cDNA. 
COX activity was established before and after infection of the cells. Before 
infection, COX activity in patient’s fibroblasts was 0.09 mU/U CS. In the patient 
cell lines the COX activity rose to 0.51 mU/U CS. Control fibroblasts infected 
with COX10 showed a complex IV activity of 0.64 mU/U CS. This experiment 
suggests that the deficiency in the patient’s fibroblasts has been mainly rescued 
by overexpression of wild-type COX10. 
One-dimensional blue native gel electrophoresis was performed to investigate 
the effect of the mutation on the formation of COX. A reduction of the amount of 
COX could be detected in patient material compared with that in control (Figure 
2A). Blue-native electrophoresis showed that overexpression of COX10 results in 
an increase in the amount of COX holo-enzyme complex (Figure 2A). 
A two-dimensional gel (Blue Native / SDS) was also performed, as this method 
is more sensitive for the detection of COX sub-complexes. The patient’s 
fibroblasts display a general decrease of all sub-complexes as well as a lesser 
amount of holo COX (Figure 2B). This general decrease of the sub-complexes 
was also detected with an antibody directed to COII (data not shown).  
SDS-PAGE showed hardly detectable mitochondrial encoded COI and COII levels 
in the patient’s fibroblasts (Figure 2C). The nuclear encoded subunit COXIV 
steady state level was also reduced in compared with control levels. The effect 
of COX10 overexpression resulted in elevated levels of COI and COII levels in 
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patient and control material. COXIV level was increased after overexpression of 
COX10 but to a lesser extend than the COI and II levels (Figure 2C). Taken 
together, these results demonstrate that the mutation in the COX10 gene is 
responsible for the COX defect observed in the patient. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: (A) Mitochondria were extracted from fibroblasts and the protein complexes were separated 
on a 5-12% blue native acrylamide gel. The gel was blotted. An antibody directed to COXI was used to 
detect COX in control (C) and patient (COX10P-P) fibroblasts and patients’ fibroblasts over-expressing 
COX10 (COX10P+P). (B) For the separation of the individual subunits of control (upper panel) and patient 
(lower panel) in fibroblasts, a 10% tricine SDS-gel was run in the second dimension followed by 
western blotting. The directions of the first (bleu native (BN)) and second (SDS) dimension are shown 
in the upper right corner. For the positioning of COX a primary antibody against the COX subunit COI 
was used. Lanes 1-3 indicate the previously described COX assembly intermediates, lane 4 indicates 
holo-COX. (C) For SDS-PAGE thirty microgram of whole cell lysates isolated from control (C) and 
patient (COX10P-P) fibroblasts and patients fibroblasts over-expressing COX10 (COX10P+P) was used. The 
proteins were separated on a 10% tricine SDS-gel. The gel was blotted and incubated with antibodies 
raised against COX subunits COI, COII, COIV and against mitochondrial HSP70 as a loading control.  
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Discussion 
 
This article describes the results of a mutational analysis study in the COX 
assembly gene COX10. In one of eleven patients who suffered from Leigh-like 
disease, a mutation in the start codon of COX10 was found. Both parents were 
heterozygous for this mutation. Two additional in frame ATG codons are present, 
72 basepairs downstream and 174 basepairs upstream of the predicted start 
codon. These may serve as alternative translational start sites. However, these 
start sites will probably not lead to a fully functional protein as the COX enzyme 
activity was substantially increased after overexpression of the COX10 protein.  
The effect of the mutation on the formation of COX was studied using blue 
native gel electrophoresis which demonstrated that the mutation leads to a 
lesser amount of holo COX when compared with control material. This was also 
confirmed by two-dimensional gel electrophoresis in which a general decrease in 
COX assembly could be detected in patient material. Similar observations were 
obtained in other patients harbouring a mutation in COX10 [9;10]. It is clear 
from both approaches that a general decrease in COX assembly occurs when 
COX10 is mutated.  
The effect of the mutation in COX10 on COX protein levels resulted in a severe 
reduction in the steady state levels of COI, COII and COXIV subunits in patient’s 
fibroblasts. This is in line with western blot experiments of another patient with 
a COX10 mutation [8].  
The increase in COX activity after COX10 overexpression was also reflected on 
COX protein levels. SDS-PAGE shows that COXI and COII protein levels are 
increased by overexpression of COX10 in patient’s fibroblasts. The levels were 
higher than those in the control cell line. One explanation is that overexpression 
of COX10 might lead to higher than normal levels of heme. The heme-groups 
can stabilize COI, which might lead to higher COI steady state levels. In contrast 
to COI and COII the COXIV levels do not reach control levels after COX10 
overexpression. These results together suggest that COX10 overexpression 
might lead to an accumulation of the sub-complexes, which might result in a 
slightly disturbed assembly of complex IV. This is also reflected in the enzyme 
activity of complex IV. 
All COX10 patients described so far show different clinical features (Table 1). 
However the disease progression is very fast, after the first clinical symptoms 
appeared all patients died within a few months. Other general features are 
hypotonia and elevated blood lactate levels which could be detected in all 
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patients. All patients showed a residual activity of COX suggesting that COX10 is 
not essential for the formation of complex IV but is essential for the 
maintenance of wild type levels. In the previously described patients COX10 
could have some residual COX activity as all patients have missense mutations, 
in the patient described here the residual activity could be explained by the use 
of alternative start codons. However, it may also be possible that another 
mechanism converts some heme O to heme A. These observations show that it 
is difficult to establish a general clinical picture for COX10 deficient patients.[9] 
 
Table 1: Clinical presentation and disease course of COX deficient patients due to a mutation in 
COX10. 
 Patient 1 P1P Patient 2 P2P Patient 3 P2P Patient 4 P3P 
Gender Male Male Female Male 
Age of presentation (months) 18 ¼ 1 ½ 5 
Age of death (months) 24 5 4 9 
Consanguineous parents + NM P4P - + 
Convulsions + - - - 
Ataxia + - - + 
Hypotonia + + + + 
Pyramidal syndrome + - - + 
Eye fixation ↓ - - ↓ 
Hypertrophic cardiomyopathy - + - - 
Anemia (blood) NM + + - 
Blood lactate (mmol/l) P5 P 3.8 ↑ ↑ 4.6 
CSF lactate (mmol/l) P6P 3.1 NM ↑ 6.6 
CMRI P7 P NM NM Leigh Leigh-like 
Residual COX activity P8 P NM 5% 16% 29% 
 P1 P atient 1 is previously described in [8]. P2 P atient 2 and 3 are respectively patient D and S from [9]. P3 
P atient 4 is described in this report. P4 PNM= not mentioned; P5 Pcontrol range 0.6-2.1 mmol/l; P6 P 
CSF=cerebrospinal fluid control range 1.4-1.9 mmol/l; P7 PCMRI = cerebral magnetic resonance imaging. P8 
PThe residual COX activity is presented as a percentage of the lowest control value as determined in 
muscle.   
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Abstract 
 
Mitochondria are the main energy producing organelles of the cell. Five 
complexes, embedded in the mitochondrial inner membrane, together 
constituting the oxidative phosphorylation (OXPHOS) system comprise the final 
steps in cellular energy production. Many patients with a mitochondrial defect 
suffer from a so-called combined deficiency, meaning that the enzymatic activity 
of two or more complexes of the OXPHOS system is decreased. 
In the past years numerous mutations have been described in nuclear genes, 
which are involved in the functioning of a single complex of the OXPHOS system. 
However, little attention has been paid to patients with a deficiency of more than 
one complex of this particular system. In this study we have investigated four 
nuclear genes (OXA1L, MRS2L, YME1L and MIPEP), which might be involved in 
the pathology of combined enzymatic deficiencies of the OXPHOS system. Based 
on the results of yeast knock-outs of these four proteins we have sequenced the 
open reading frame of OXA1L in eight patients with an enzymatic deficiency of 
complexes I and IV. MRS2L, YME1L and MIPEP have been sequenced in three 
patients with a combined defect of complexes III and IV. No mutations were 
detected in these patients, showing that at least in these patients the OXPHOS 
system deficiency cannot be explained by a mutation in these four genes. 
 
 
Introduction 
 
The oxidative phosphorylation (OXPHOS) system, the main energy producing 
system of the cell, consists of five multi protein complexes, which are embedded 
in the mitochondrial inner membrane. The first four complexes work together to 
create a proton gradient across the mitochondrial inner membrane, which is 
used by complex V (ATP synthase) to produce energy in the form of ATP. 
Mitochondrial as well as nuclear DNA encode the OXPHOS system complexes 
except for complex II, which is only composed of nuclear encoded proteins.  
Patients with a deficiency in the enzyme activity of the OXPHOS system 
complexes can be classified as single or combined OXPHOS system enzyme 
defects. The defects in both groups can be of nuclear as well as mitochondrial 
origin. Until now much molecular genetic research has been performed in 
patients having an enzymatic deficiency of one enzyme complex. This has lead 
to the identification of mutations in nuclear as well as mitochondrial genes 
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encoding structural subunits of the complexes. Beside these, mutations have 
also been described in nuclear genes necessary for the biogenesis of the 
OXPHOS system complexes [1-4]. Patients with an OXPHOS system deficiency 
present with a wide range of clinical symptoms. The most frequently 
encountered clinical phenotype is Leigh’s syndrome [5;6].  
Mitochondrial DNA mutations are a common cause of combined deficiencies of 
the OXPHOS system [7]. Many mutations in the mtDNA are located in genes 
required for mitochondrial translation (tRNAs and rRNAs). Mutations in these 
genes affect all 13 mitochondrial-encoded polypeptides [7;8]. The most common 
encountered mutations in the translation genes are found in the tRNALeu(UUR) 
gene and tRNALys  causing MELAS (mitochondrial encephalomyopathy, lactic 
acidosis and stroke-like episodes) and MERRF (myoclonus epilepsy, with ragged-
red fibers), respectively. However, so far only limited information is available 
about nuclear genes exerting an effect on more than one enzyme of the 
OXPHOS system in man. Only one study has been published in which the 
authors searched for a disease-causing gene in a patient with a general 
mitochondrial defect [9]. The enzyme activities of the pyruvate dehydrogenase 
complex, the 2-oxoglutarate dehydrogenase complex, NADH cytochrome c 
reductase, succinate dehydrognase and succinate cytochrome c reductase were 
severely reduced. This study has lead to the assignment of a region on 
chromosome 2 were the disease causing gene should be located. 
In lower species like yeast much more is known about proteins necessary for the 
function of more than one OXPHOS system complex. For many nuclear encoded 
mitochondrial proteins it has been shown that mutations in the yeast 
homologues can result in a severe deficiency of the yeast OXPHOS system [10]. 
We have selected four genes: oxidase (cytochrome c) assembly 1-like (OXA1L), 
MRS2-like magnesium homeostasis factor (MRS2), YME1-like (YME1L) and 
mitochondrial intermediate peptidase (MIPEP) which all have been associated 
with a combined deficiency in lower species [11-14]. Studies in Saccharomyces 
cerevisiae have shown that an OXA1 defect leads to a defect in the insertion and 
processing of COX2 in the mitochondrial membrane [15;16]. OXA1 depletion in 
Neurospora crassa results in reduced protein levels of OXPHOS system 
complexes I and IV [11]. MRS2L is involved in magnesium homeostasis. Mrs2 
disruptants show defects in group II intron splicing and reduced levels of 
cytochrome complexes (CIII and CIV). YME1L, present in the mitochondrial 
intermembrane space, and a member of the triple A metalloprotease family, is 
involved in the turnover of unassembled COII [17-19]. Additional studies in 
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yeast have demonstrated that inactive YME1 has a general effect on 
mitochondria as it influences the morphology of the mitochondria and the 
growth of the yeast. MIPEP is involved in the processing of nuclear encoded 
subunits of the OXPHOS system [14;20]. The protein cleaves octapeptides from 
the precursor subunits of the OXPHOS system resulting in mature subunits. 
Disruption of this gene in yeast leads to a severe defect in complex III and IV of 
the OXPHOS system [20]. 
In these four candidate genes we have performed sequence analysis in patients 
with a combined enzymatic deficiency of the OXPHOS system in order to 
determine whether a mutation in these genes can explain the mitochondrial 
disorder. 
 
 
Materials and methods 
 
Cell culture and biochemical measurements 
Human skin fibroblasts were cultured until confluency in medium 199 
supplemented with 10% fetal calf serum, bicarbonate and antibiotics.   
The activities of the mitochondrial respiratory chain complexes were measured 
in skin fibroblasts. The method was slightly modified from that used for muscle 
tissue [21].  
 
Patients  
We have selected three patients with a combined complex III and IV deficiency 
and eight patients with a combined complex I and IV deficiency. In these 
patients the OXPHOS system defect was at least present in cultured skin 
fibroblasts. The mtDNA of the patients was analysed for the common occurring 
3243 MELAS, 8344 MERRF, 8993 Leigh/NARP mutations as well as large 
deletions. 
 
Sequence analysis 
Total RNA was isolated from patients’ fibroblasts with the use of RNAzol (Campro 
scientific), cDNA was prepared using reverse transcriptase (Invitrogen). 
Sequence analysis of the open reading frame was performed in the four genes 
OXA1L, YME1L, MIPEP and MRS2L.The sequences of the oligonucleotide primers 
used for the amplification of the cDNA are presented in Table 1. The cDNA was 
amplified in 20 mM Tris-HCl and 50 mM KCl with 25 ng forward and reverse 
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primer, 2.5 mM dNTPs, 1-2 mM MgClB2 B and 1 unit Taq polymerase (Invitrogen) in 
a total volume of 25 µl. Both strands were used for direct sequencing (ABI 
Prism, model 377 version 2.1.2), using the ABI PrismPtmP TaqDyeDeoxy terminator 
cycle sequencing ready kit (Applied Biosystems).  
 
Table 1: List of oligonucleotide primers used for the amplification of cDNA from OXA1L, MRS2L, YME1L 
and MIPEP. Oligonucleotide sequences are depicted from 5’ to 3’. 
gene forward oligonucleotides reverse oligonucleotides 
 name sequence name sequence 
OXA1L OXA1F1 ATGGCGATGGGACTAATGTGCG OXA1R1 CCTGAACCTGGACTTCTGC 
 OXA1F2 GCTCCTATTCCCAGTAGCC OXA1R2 GGTCTCCTGCTAACTTGGC 
 OXA1F3 CAGGATCCACAATCACTTGC OXA1R3 GCCAGTACATAAACACTGCC 
 OXA1F4 GTGGATGAGAAATGTCATCAG OXA1R4 CTAGCTCCAACTGATTCCGC 
 OXA1F5 GTGTTGTACATGACCTGGAC OXA1R5 GGATGAGTCTCGAAGAGAC 
MRS2L MRS2F1 CAGCGTCCGGCATGAAGG MRS2R1 GCTTGAACACCTAACTCTTGG 
 MRS2F2 GACAAACAGGGAAACGTTAC MRS2R2 CTCTGATAGACTTTTGCCATTC 
 MRS2F3 GGACCCCAAACATTCTTCTG MRS2R3 CCTCTTCAAGGGAAGATTCC 
 MRS2F4 CTACAGCTGACCATGGGAAC MRS2R4 CAGAAGTTTCCTGTAACTACC 
YME1 YME1F1 ACAGAGGGGCACAGTTTCGG YME1R1 GGATGTATGCCAATGGGAAG 
 YME1F2 GGACAGATTGATCAGCTGGTAG YME1R2 GCATCTTGGTGAGCTTCAGG 
 YME1F3 CGCCATCATTCGTGAAGGGG YME1R3 GGAACATCAGCTTCTCCCG 
 YME1F4 CTTGGAGGTAAACTTCCAAAAGG YME1R4 GTTCGACCTTTTACATCTGGC 
 YME1F5 GCCACAAACTTCCCAGAGGC YME1R5 GCACCTGTTGTAATATGGTCGG 
 YME1F6 CTAGAGCCCAGCTGCTTGC YME1R6 CAAGAATGAGGGGAAAGCGTTG 
MIPEP MIPEPF1 CGCTCCCAGCGAAAGCAGC MIPEPR1 CGAAGATCAGCACGGTCTG 
 MIPEPF2 GGAGTTCCTGAGCTGAGTGC MIPEPR2 CATTGAGGTCCACTGCTC 
 MIPEPF3 CTTGTGGATTCCCTTGATCCAG MIPEPR3 GCTATCGTTCCTTGGAGAGC 
 MIPEPF4 GAAGAATTGCTCAGCAGCAGAG MIPEPR4 GCCAGTTTTCGGACATCTTCG 
 MIPEPF5 CTTGGAGCATGCATGGAAGG MIPEPR5 GCACCTGGTCCCAGTGAC 
 MIPEPF6 GCTAACTCCTGGCATGATGG MIPEPR6 CGACCGCTCTGGACATGAG 
 MIPEPF7 GTTCCAAATACTGCCTGGCAG MIPEPR7 CAAGCTCTCACAGCTGTAGC 
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Results 
 
As studies in Neurospora crassa show that disruption of OXA1 affects complex I 
and IV we have sequenced OXA1L (genbank accession number X80695) in eight 
patients with a defect in these two enzyme complexes. No mutations could be 
detected in this gene although two polymorphisms T311C and INS1435AGC 
(base-numbers according to AJ001981) have been detected. Blast searches 
show that both polymorphisms are present in expressed sequence tags. 
The other 3 genes have been sequenced in patients with a combined deficiency 
of complex III and IV. This did not lead to the detection of any mutation in these 
genes. One polymorphism was detected in MRS2L at nucleotide position 966 
(genbank accession number: XM_011365) where an A was substituted by a G. 
This substitution did not lead to a change of the amino acid glutamine. Database 
searches showed that the polymorphism was present in dbSNP (rs2793422). 
Two variants were detected in MIPEP. One polymorphism, present in patient as 
well as control material, at nucleotide position 1019 (CGA>CAA) did not affect 
the amino acid arginine. The other variant was present at position 
671(AAT>AGT) leading to the substitution of asparagine by serine. One patient 
was heterozygous for this variation; the base substitution was not present in 
control material or expressed sequence tags (ESTs). No variations were detected 
in YME1L. 
 
 
Discussion 
 
Four genes have been selected of which it was known that they play a role in 
combined deficiencies of the OXPHOS system in lower species. Sequence 
analysis was performed in the human homologues of these four genes in 
patients with combined deficiencies of complex I and IV or complex III and IV. 
Disruption of OXA1 in yeast S. cerevisiae results in assembly failure of complex 
IV and a severe respiratory deficiency. This phenotype can be rescued by 
expression of human OXA1L suggesting that these proteins play essentially the 
same role. Additional studies in N. crassa show that OXA1 is essential for the 
viability of the organism [11]. The cells with reduced OXA1 levels grow slowly 
and show reduced levels of complex I subunits (24 kDa and 29.9 kDa) and 
complex IV subunits COX2 and COX3. After the first publication of the OXA1L 
cDNA (genbank number X80695) the sequence has been revised after the 
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detection of two additional in frame start codons at the 5’ site of OXA1L 
(genbank accession number AJ001981) [22;23]. We could not succeed in the 
amplification of this OXA1L cDNA sequence [22]. The fragment we could amplify 
from fibroblast mRNA corresponds to the first published OXA1L sequence with 
genbank number X80695 [23]. This is also the fragment that is retrieved when 
blast searches are performed with the OXA1 sequence in ESTs and protein 
databases. Therefore we propose that the OXA1L cDNA sequence described by 
Bonnefoy and co-workers is probably the cDNA expressed in fibroblasts [23]. As 
both complex I and IV are affected in N. crassa we have sequenced the OXA1L 
open reading frame in 8 patients with a combined complex I and IV deficiency. 
No mutations have been detected in these patients. However we detected 2 
polymorphisms. Blast searches show that the variations also occur in ESTs. 
Beside sequence analysis of OXA1L we also sequenced the open reading frame 
of three other genes (MRS2L, YME1L, MIPEP). Disruption of these genes in lower 
species mainly affects complex III and IV. Therefore we sequenced these genes 
in patients with a combined deficiency of complex III and IV. No mutations could 
be detected in these genes. Disruption of MRS2 in yeast leads to a severe defect 
in the mitochondrial magnesium concentrations. Besides this Mrs2p is involved 
in the splicing of group II introns in the mitochondria of S. cerevisiae, related to 
cytochrome biogenesis [24-26]. In yeast the function of YME1 has been mainly 
studied in the relation to complex IV as it is involved in the turnover of 
unassembled COII [17-19]. YME1 mutations do also affect the mitochondrial 
structure and function, suggesting a more general function for YME1 than just 
the turnover of COII [27-29]. The general effect on the mitochondria might also 
lead to a deficiency in other enzymes than complex IV. Therefore we have also 
sequenced the open reading frame of this gene in patients with a combined 
deficiency of complex III and IV. The last gene that has been sequenced in the 
patients with a defect of complex III and IV is MIPEP. This gene has a function in 
the maturation of nuclear encoded precursor proteins. When the nuclear 
encoded proteins enter the mitochondria the targeting signal is removed by 
mitochondrial processing peptidase [30-32]. This protein removes the import 
signal but leaves a characteristic octapeptide sequence at the protein amino 
terminus. The intermediate-size proteins are then processed to mature subunits 
by MIPEP, which cleaves the octapeptide sequence [14]. Therefore mutations in 
this gene might affect OXPHOS system complexes containing nuclear encoded 
subunits. 
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Although the protein products of OXA1L, MRS2L, YME1L and MIPEP clearly have 
a role in the functioning of more than one complex of the OXPHOS system in 
lower species, none of the patients harboured a mutation in the human 
homologues of these genes. This implicates that other genes involved in the 
functioning of the OXPHOS system must be mutated in these patients. The large 
number of genes involved in the whole process of OXPHOS system formation 
makes it difficult to predict which genes might be mutated in the diverse 
patients. To identify all the genes involved in mitochondrial disorders, more 
robust techniques will be needed, as it is impossible to sequence all candidate 
genes in every patient. Microcell-mediated chromosome transfer can be used to 
search for genes in patients with an OXPHOS system deficiency [33]. The 
disadvantage is that this method is very time consuming. Maybe new techniques 
like proteomics and microarrays can give us a fast clue, which genes might be 
mutated in OXPHOS system patients. This will hopefully lead to a faster 
identification of the disease-causing genes in patients with a combined 
deficiency of the OXPHOS system.  
 
 
Acknowledgements 
We thank the NCMD support-staff for measuring the enzyme activities of the 
mitochondrial complexes. This study was made possible due to a grant from the 
‘Prinses Beatrix Fonds’ (grant-number 98-0108).  
 
 
References 
 
 1.  Yano T: The energy-transducing NADH: quinone oxidoreductase, complex I. 
Mol.Aspects.Med 2002, 23:345-368. 
 2.  Borisov VB: Defects in mitochondrial respiratory complexes III and IV, and human 
pathologies. Mol.Aspects Med. 2002, 23:385-412. 
 3.  Antonicka H, Mattman A, Carlson CG, Glerum DM, Hoffbuhr KC, Leary SC, Kennaway NG, 
Shoubridge EA: Mutations in COX15 produce a defect in the mitochondrial heme 
biosynthetic pathway, causing early-onset fatal hypertrophic cardiomyopathy. 
Am.J.Hum.Genet. 2003, 72:101-114. 
 4.  Mootha VK, Lepage P, Miller K, Bunkenborg J, Reich M, Hjerrild M, Delmonte T, Villeneuve A, 
Sladek R, Xu F, Mitchell GA, Morin C, Mann M, Hudson TJ, Robinson B, Rioux JD, Lander ES: 
Identification of a gene causing human cytochrome c oxidase deficiency by integrative 
genomics. Proc.Natl.Acad.Sci.U.S.A 2003, 100:605-610. 
 5.  Rahman S, Blok RB, Dahl HH, Danks DM, Kirby DM, Chow CW, Christodoulou J, Thorburn DR: 
Leigh syndrome: clinical features and biochemical and DNA abnormalities. Ann.Neurol. 
1996, 39:343-351. 
Chapter 7 
 124
 6.  Leigh D: Subacute necrotizing encephalomyelopathy in an infant. 
J.Neurol.Neurosurg.Psychiatry 1951, 14:216-221. 
 7.  DiMauro S, Andreu AL: Mutations in mtDNA: are we scraping the bottom of the barrel? 
Brain Pathol. 2000, 10:431-441. 
 8.  Sue CM, Schon EA: Mitochondrial respiratory chain diseases and mutations in nuclear 
DNA: a promising start? Brain Pathol. 2001, 10:442-450. 
 9.  Seyda A, Newbold RF, Hudson TJ, Verner A, MacKay N, Winter S, Feigenbaum A, Malaney S, 
Gonzalez-Halphen D, Cuthbert AP, Robinson BH: A novel syndrome affecting multiple 
mitochondrial functions, located by microcell-mediated transfer to chromosome 2p14-
2p13. Am.J.Hum.Genet. 2001, 68:386-396. 
 10.  McEwen JE, Ko C, Kloeckner-Gruissem B, Poyton RO: Nuclear functions required for 
cytochrome c oxidase biogenesis in Saccharomyces cerevisiae. Characterization of 
mutants in 34 complementation groups. J.Biol.Chem. 1986, 261:11872-11879. 
 11.  Nargang FE, Preuss M, Neupert W, Herrmann JM: The Oxa1 protein forms a 
homooligomeric complex and is an essential part of the mitochondrial export 
translocase in Neurospora crassa. J.Biol Chem. 2002, 277:12846-12853. 
 12.  Zsurka G, Gregan J, Schweyen RJ: The human mitochondrial mrs2 protein functionally 
substitutes for its yeast homologue, a candidate magnesium transporter. Genomics 
2001, 72:158-168. 
 13.  Shah ZH, Hakkaart GA, Arku B, de Jong L, van der Spek H, Grivell LA, Jacobs HT: The human 
homologue of the yeast mitochondrial AAA metalloprotease Yme1p complements a 
yeast yme1 disruptant. FEBS Lett. 2000, 478:267-270. 
 14.  Isaya G, Kalousek F, Rosenberg LE: Amino-terminal octapeptides function as recognition 
signals for the mitochondrial intermediate peptidase. J.Biol.Chem. 1992, 267:7904-7910. 
 15.  He S, Fox TD: Membrane translocation of mitochondrially coded Cox2p: distinct 
requirements for export of N and C termini and dependence on the conserved protein 
Oxa1p. Mol.Biol.Cell 1997, 8:1449-1460. 
 16.  Hell K, Herrmann J, Pratje E, Neupert W, Stuart RA: Oxa1p mediates the export of the N- 
and C-termini of pCoxII from the mitochondrial matrix to the intermembrane space. 
FEBS Lett. 1997, 418:367-370. 
 17.  Nakai T, Yasuhara T, Fujiki Y, Ohashi A: Multiple genes, including a member of the AAA 
family, are essential for degradation of unassembled subunit 2 of cytochrome c 
oxidase in yeast mitochondria. Mol.Cell Biol. 1995, 15:4441-4452. 
 18.  Pearce DA, Sherman F: Degradation of cytochrome oxidase subunits in mutants of yeast 
lacking cytochrome c and suppression of the degradation by mutation of yme1. 
J.Biol.Chem. 1995, 270:20879-20882. 
 19.  Weber ER, Hanekamp T, Thorsness PE: Biochemical and functional analysis of the YME1 
gene product, an ATP and zinc-dependent mitochondrial protease from S. cerevisiae. 
Mol.Biol.Cell 1996, 7:307-317. 
 20.  Isaya G, Miklos D, Rollins RA: MIP1, a new yeast gene homologous to the rat 
mitochondrial intermediate peptidase gene, is required for oxidative metabolism in 
Saccharomyces cerevisiae. Mol.Cell Biol. 1994, 14:5603-5616. 
 21.  Bentlage HA, Wendel U, Schagger H, ter Laak HJ, Janssen AJ, Trijbels JM: Lethal infantile 
mitochondrial disease with isolated complex I deficiency in fibroblasts but with 
combined complex I and IV deficiencies in muscle. Neurology 1996, 47:243-248. 
 22.  Rotig A, Parfait B, Heidet L, Dujardin G, Rustin P, Munnich A: Sequence and structure of the 
human OXA1L gene and its upstream elements. Biochim.Biophys.Acta 1997, 1361:6-10. 
 23.  Bonnefoy N, Kermorgant M, Groudinsky O, Minet M, Slonimski PP, Dujardin G: Cloning of a 
human gene involved in cytochrome oxidase assembly by functional complementation 
Mutation detection in four candidate genes (OXA1L, MRS2L, YME1L and MIPEP)  
for combined deficiencies in the oxidative phosphorylation system 
 125
of an oxa1- mutation in Saccharomyces cerevisiae. Proc.Natl.Acad.Sci.U.S.A. 1994, 
91:11978-11982. 
 24.  Gregan J, Bui DM, Pillich R, Fink M, Zsurka G, Schweyen RJ: The mitochondrial inner 
membrane protein Lpe10p, a homologue of Mrs2p, is essential for magnesium 
homeostasis and group II intron splicing in yeast. Mol.Gen.Genet. 2001, 264:773-781. 
 25.  Koll H, Schmidt C, Wiesenberger G, Schmelzer C: Three nuclear genes suppress a yeast 
mitochondrial splice defect when present in high copy number. Curr.Genet. 1987, 
12:503-509. 
 26.  Waldherr M, Ragnini A, Jank B, Teply R, Wiesenberger G, Schweyen RJ: A multitude of 
suppressors of group II intron-splicing defects in yeast. Curr.Genet. 1993, 24:301-306. 
 27.  Thorsness PE, White KH, Fox TD: Inactivation of YME1, a member of the ftsH-SEC18-
PAS1-CDC48 family of putative ATPase-encoding genes, causes increased escape of 
DNA from mitochondria in Saccharomyces cerevisiae. Mol.Cell Biol. 1993, 13:5418-5426. 
 28.  Thorsness PE, Fox TD: Nuclear mutations in Saccharomyces cerevisiae that affect the 
escape of DNA from mitochondria to the nucleus. Genetics 1993, 134:21-28. 
 29.  Campbell CL, Thorsness PE: Escape of mitochondrial DNA to the nucleus in yme1 yeast is 
mediated by vacuolar-dependent turnover of abnormal mitochondrial compartments. 
J.Cell Sci. 1998, 111:2455-2464. 
 30.  Hawlitschek G, Schneider H, Schmidt B, Tropschug M, Hartl FU, Neupert W: Mitochondrial 
protein import: identification of processing peptidase and of PEP, a processing 
enhancing protein. Cell 1988, 53:795-806. 
 31.  Kleiber J, Kalousek F, Swaroop M, Rosenberg LE: The general mitochondrial matrix 
processing protease from rat liver: structural characterization of the catalytic subunit. 
Proc.Natl.Acad.Sci.U.S.A 1990, 87:7978-7982. 
 32.  Pollock RA, Hartl FU, Cheng MY, Ostermann J, Horwich A, Neupert W: The processing 
peptidase of yeast mitochondria: the two co-operating components MPP and PEP are 
structurally related. EMBO J. 1988, 7:3493-3500. 
 33.  Zhu Z, Yao J, Johns T, Fu K, De Bie I, Macmillan C, Cuthbert AP, Newbold RF, Wang J, Chevrette 
M, Brown GK, Brown RM, Shoubridge EA: SURF1, encoding a factor involved in the 
biogenesis of cytochrome c oxidase, is mutated in Leigh syndrome. Nat.Genet. 1998, 
20:337-343. 
  
  
Chapter 8 
 
Mutant GTP-binding domain of mitochondrial elongation 
factor G1 associated with combined oxidative 
phosphorylation deficiency and early 
 fatal hepato-encephalopathy 
 
Marieke J.H. Coenen, Hana Antonicka, Cristina Ugalde, Florin Sasarman, Rainer 
Rossi, J.G.A.M. (Angelien) Heister, Robert F. Newbold, Frans J.M. Trijbels, 
Lambert P. van den Heuvel, Eric A. Shoubridge, Jan A.M. Smeitink 
 
The New England Journal of Medicine 2004; 351:2080-2086 
 
 
 
 
  
Mutant GTP-binding domain of mitochondrial elongation factor G1 associated with combined 
 oxidative phosphorylation deficiency and early fatal hepato-encephalopathy 
 129
Abstract 
 
Although most components of the mitochondrial translation apparatus are 
encoded by nuclear genes, all known molecular defects associated with impaired 
mitochondrial translation are due to mutations in mitochondrial DNA. We 
investigated two siblings with a severe defect in mitochondrial translation, 
reduced levels of oxidative phosphorylation complexes containing mitochondrial 
DNA (mtDNA)–encoded subunits, and progressive hepatoencephalopathy. We 
mapped the defective gene to a region on chromosome 3q containing elongation 
factor G1 (EFG1), which encodes a mitochondrial translation factor. Sequencing 
of EFG1 revealed a mutation affecting a conserved residue of the guanosine 
triphosphate (GTP)–binding domain. These results define a new class of gene 
defects underlying disorders of oxidative phosphorylation. 
 
 
Introduction 
 
Oxidative phosphorylation drives the synthesis of ATP and takes place through a 
series of reactions mediated by complexes I, II, III, IV, and V, which are integral 
to the inner mitochondrial membrane. Each complex is made up of several or 
many proteins [1;2]. 
For example, complex I is made up of 7 proteins encoded by mitochondrial 
genes and at least 39 proteins encoded by nuclear genes. Some diseases result 
from a deficit in a single complex. For example, Leigh’s syndrome is caused by a 
single mutation in one of several mitochondrial and nuclear genes encoding 
proteins that make up, assemble, or maintain complexes I, II, IV, or V. The 
cause of diseases associated with a deficit in more than one complex and of 
nuclear origin has been unclear, and the prevalence of such mitochondrial 
disorders is similar to that of the aggregate of disorders caused by the deficiency 
of a single complex. In this report, we describe an association between the 
mutation of a nuclear gene encoding a protein that mediates translation of 
mitochondrial DNA (mtDNA) and the occurrence of early fatal hepato-
encephalopathy in two siblings, each with a deficit in more than one complex of 
the respiratory chain. 
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Case reports 
 
The index patient, a female, was born of consanguineous Lebanese parents (first 
cousins) by caesarean section with intrauterine growth retardation and mild 
microcephaly. She was very stiff and had few spontaneous movements. From 
day 10 of life, profound metabolic acidosis was evident (blood lactate level, 17.1 
mmol per liter [normal, <2.1 mmol per liter]; lactate:pyruvate ratio, 38 
[normal, 12 to 18]). Liver dysfunction, as measured by an elevation of direct 
bilirubin, was observed from day 7 and progressed to full liver failure on day 12 
and death on day 27. Postmortem examination of the liver showed cholestasis 
and extensive necrosis. There was hypoplasia of the corpus callosum, and 
several symmetrical cystic lesions were present in the white matter in the area 
of the basal ganglia. The heart was normal, and a histologic examination of the 
skeletal muscle showed normal mitochondrial morphology and no ragged-red 
fibers. The activities of the oxidative phosphorylation complexes in fibroblasts 
were 40 percent, 69 percent, and 18 percent of the lowest control value for 
complex I, complex III, and complex IV, respectively. In muscle, complex I 
activity was 52 percent and complex IV activity was 54 percent of the lowest 
control value. 
A male sibling of the index patient was born at 41 weeks of gestation. The 
maximal blood lactate level was 9.3 mmol per liter, with a lactate:pyruvate ratio 
of 84. An ultrasonographic examination of the brain showed generalized atrophy 
and a small corpus callosum. The child had extremely delayed growth and 
development, as well as increased muscle tone in his upper extremities. Signs of 
liver failure were present at week 7, leading to death at five months of age. The 
heart was normal. The activities of complex I and complex IV in fibroblasts were 
13 percent and 31 percent of the lowest control value, respectively. 
Analysis of mtDNA by Southern blotting showed no rearrangements or reduction 
in mtDNA levels. 
 
 
Materials and methods 
 
Controls 
Samples from 100 controls were analyzed for restriction-fragment–length 
polymorphisms and showed a pattern that was homozygous for the wild-type 
allele. 
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Cell culture 
To extend the life span of cells, we immortalized primary human skin fibroblasts 
with a retrovirus containing the E6 and E7 genes of human papillomavirus type 
16, or with E7 alone and a retroviral vector expressing the protein component of 
human telomerase reverse transcriptase [3]. Skin fibroblasts from the siblings 
and controls were cultured in Dulbecco’s modified Eagle medium supplemented 
with 10 percent fetal-calf serum, penicillin, and streptomycin. Samples were 
collected after informed consent was given. 
 
Enzyme measurements 
Complex I, complex III, complex IV, and citrate synthase activities were 
measured in fibroblast-cell extracts as described previously [4;5]. The rho0 test 
was performed, whereby 143B.TK- rho0 cells (cells without mtDNA that were 
derived from 143B.TK- cells) were cultured in Dulbecco’s modified Eagle medium 
containing 10 percent fetal-calf serum but without pyruvate or uridine. Skin 
fibroblasts from the index patient were fused with rho0 cells and selected with 
Dulbecco’s modified Eagle medium without pyruvate, 10 percent dialysed fetal-
calf serum, and uridine. Colonies were harvested for immunoblot analysis. 
 
Chromosome transfer 
The E6-and-E7–immortalized fibroblasts from the siblings were fused with 
human chromosomes isolated by microcell-mediated chromosome transfer from 
a panel of mouse cell lines containing one extra human chromosome with a 
hygromycinresistant tag [4;6;7]. 
 
Microsatellite mapping 
The short tandem-repeat microsatellite markers used for homozygosity and 
deletion mapping of chromosome 3 after chromosome transfer were derived 
from the Applied Biosystems ABI PRISM Linkage Mapping Set (version 2.5 MD-
10). The intermarker distance was about 10 cM. 
 
cDNA sequencing 
RNA was isolated from skin fibroblasts from the siblings and controls with the 
use of RNAzol. Primers were designed for the amplification of complementary 
DNA (cDNA) from MRPS22 and EFG1. The polymerase-chain-reaction (PCR) 
fragments were used for direct sequencing with the ABI PRISM 377 DNA 
Sequencer (Applied Biosystems). 
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Analysis of restriction-fragment–length polymorphisms 
Genomic DNA was isolated from skin fibroblasts from the index patient and from 
blood of the parents, the sibling, and 100 controls. The DNA was amplified and 
digested with the restriction enzyme MseI. 
 
Blue-native polyacrylamide-gel electrophoresis and immunoblotting 
Blue-native polyacrylamide-gel electrophoresis was used for separation of 
oxidative phosphorylation complexes on 5 percent to 15 percent polyacrylamide-
gradient gels [8]. Mitoplasts, which were prepared from fibroblasts by treatment 
with 0.8 mg of digitonin per milligram of protein, were solubilized with 1 percent 
lauryl maltoside, and 10 to 20 µg of the solubilized protein was used for 
electrophoresis. Complexes I through V were detected by immunoblot analysis 
with the use of monoclonal antibodies against complex III core protein 1, the α 
subunit of complex V, the 70-kD subunit of complex II (Molecular Probes), 
monoclonal antibodies against complex IV subunit IV, and a polyclonal anti-ND1 
antibody (an antibody acting against the mitochondrial- encoded ND1 subunit of 
complex I). For immunoblotting, fibroblasts were solubilized with 1.5 percent 
lauryl maltoside in phosphate-buffered saline, and 30 µg of protein was 
separated by TRIS Tricine sodium dodecyl sulfate–polyacrylamide-gel 
electrophoresis. The proteins were transferred to nitrocellulose, and antibodies 
directed against complex IV subunits II and IV and complex III core protein 2 
were used for detection. 
 
Pulse-labelling of mitochondrial translation products 
In vitro labelling of mitochondrial translation was performed as previously 
described [9]. Briefly, cells were labelled for 60 minutes at 37°C in 
methioninefree Dulbecco’s modified Eagle medium containing 200 µCi per 
milliliter of [35S]methionine and 100 µg per millilitre of emetine followed by 10 
minutes in regular Dulbecco’s modified Eagle medium. Total cellular protein (50 
µg) was resuspended in loading buffer containing 93 mM TRIS-hydrogen chloride 
(pH 6.7), 7.5 percent glycerol, 3.5 percent sodium dodecyl sulfate, 0.25 mg 
bromophenol blue per millilitre, and 3 percent mercaptoethanol, was sonicated 
for 3 to 8 seconds, and was loaded and run on 12 percent to 20 percent 
polyacrylamidegradient gels. 
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cDNA constructs 
Retroviral vectors containing the cDNA sequence of three mitochondrial 
translation factors (EFG1, EFG2,and IF3) were created with the Gateway cloning 
system (Invitrogen). We used the reverse-transcriptase PCR (OneStep RT-PCR 
kit, Qiagen) to amplify cDNA from 
EFG2 and IF3 genes with the use of specific primers modified for cloning into 
Gateway vectors. The cDNA from EFG1 was amplified from IMAGE (Integrated 
Molecular Analysis of Genomes and Their Expression) clone 5574223 with use of 
specific primers modified for cloning into Gateway vectors. The PCR constructs 
were cloned into a Gateway-modified retroviral-expression vector, pLXSH. The 
fidelity of the cDNA clones was confirmed by automated DNA sequencing. 
 
Infection with viruses 
Virus-producing cell lines were generated according to procedures described 
previously [10]. Briefly, a human 293-derived retroviral packaging cell line 
(293GPG) was transfected with a retroviral construct containing one of the 
mitochondrial translation factors. Tetracycline was removed from the medium 
two days after transfection to induce virus production. Fibroblasts from the 
siblings and the controls were infected 72 to 96 hours later by exposure to virus-
containing medium in the presence of 4 µg per millilitre of polybrene as 
previously described [3]. 
 
Genbank accession numbers 
The GenBank accession numbers for EFG1, EFG2, IF3, and MRPS22 are 
NM_024996, NM_032380, AF410851, and NM_020191, respectively.  
 
 
Results 
 
Fibroblasts from the index patient showed low levels of fully assembled 
complexes I, III, IV (complex IV), and V but normal levels of complex II (Figure 
1). To determine whether this assembly defect was of nuclear or mitochondrial 
origin, we prepared transmitochondrial cytoplasmic hybrid (cybrid) cells by 
fusing enucleated fibroblasts from the index patient with rho0 cells, which are 
devoid of mtDNA but contain a normal nuclear genome. We observed normal 
steady-state levels of complex IV subunit II, as well as complex III core protein 
2 and complex IV subunit IV in the cybrid cells (data not shown), confirming 
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that the oxidative phosphorylation deficiency was recessive and of nuclear 
origin. To map the defective gene, we used microcellmediated chromosome 
transfer to identify a normal human chromosome that could functionally 
complement the biochemical defect in the fibroblasts from the index patient 
[4;6]. 
We transferred all human autosomes and the X chromosome, one at a time, into 
an immortalized fibroblast line from the patient and used immunoblot analysis of 
complex IV subunit II as an assay for complementation. The protein levels of 
complex IV subunit II were restored only after the transfer of chromosome 3 (in 
18 of 19 clones; data not shown). Chromosomes incorporated into the genome 
of recipient cells by microcell-mediated chromosome transfer often undergo 
rearrangements and deletions. Deletion mapping of the donor chromosome in 
isolated clones can thus be used for fine mapping of the genomic region 
containing the complementing gene. Microsatellite mapping with a panel of 
polymorphic markers for chromosome 3 showed that one of the complementing 
clones contained only marker D3S1279, and that the fibroblast line from the 
patient was homozygous for markers D3S1279 and D3S1285. These data 
suggested that the candidate gene maps to the region located about 20 cM from 
marker D3S1279 at 3q22–26.2 and flanked by markers D3S1569 and D3S1614. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Analysis of fibroblasts from the index patient. Fibroblasts from the index patient and a 
control were analyzed with the use of blue-native polyacrylamide-gel electrophoresis after transduction 
with retroviral constructs expressing mitochondrial translation factors. The gels were immunoblotted to 
assess the amount of fully assembled oxidative phosphorylation complexes. The expression of EFG1 
partially rescues the assembly defect in the patient’s cells. 
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Figure 2: Analysis of EFG1. Sequence analysis of the complementary DNA of EFG1 (Panel A) shows a 
homozygous A521G mutation in the patient as compared with the control. A schematic representation 
(Panel B) of the EFG1 protein shows the GTPbinding elongation-factor signature sequence (black box) 
and the GTP-binding domain, consisting of three consensus-sequence elements with distinct spacing 
(white boxes). The consensus-sequence element NKXD is part of the GTP-binding domain and is 
responsible for base specificity. The consensus sequence of the GTPbinding domain is conserved across 
many functionally different families of GTP-binding proteins. The figure shows the absolute conservation 
of the sequence of asparagines at position 174 of the third consensus element in EFG1 factor among 
taxa as far back as prokaryotes. Agarose gel was used in the analysis of the restrictionfragment–length 
polymorphisms that confirmed the mutation (Panel C). A polymerase-chain-reaction fragment of EFG1 
encompassing the mutation was amplified from genomic DNA. The mutation eliminates an MseI 
restriction-enzyme site. Results from the patient, father, mother, sibling, and control are shown. 
A 
B 
C 
Guanine specificity
binding site motif:
Patient
Homo Sapiens
Mus musculus
Oryza sativa
Saccharomyces cerevisiae
Escherichia coli
N    K    X     D  
 
S    K    L     D (174-177) 
 
N    K    L     D (174-177) 
N    K    L     D (175-178) 
N    K    L     D (196-199) 
N    K    M    D (202-205) 
N    K    M    D (141-144) 
 
N C
  L      T       F      I     N      K      L      D
A521G 
↓
  L      T      F      I      S      K      L      D
P MF Sib C
← 239 bp 
← 139 bp 
← 100 bp 
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A database search for candidate genes in this region identified two genes, EFG1 
and MRPS22, that code for proteins that are part of the mitochondrial translation 
machinery [11;12]. 
Sequence analysis of cDNA showed a homozygous mutation (A521G) in the 
EFG1 cDNA isolated from the patient’s immortalized fibroblasts (Figure 2A), 
which predicts an amino acid substitution of serine for asparagines (N174S) at a 
position that has been absolutely conserved during evolution (Figure 2B). The 
presence of the mutation was confirmed in genomic DNA from the index patient 
and the sibling by analysis of restriction-fragment–length polymorphisms (Figure 
2C). The same analysis showed that both parents were heterozygous for the 
mutation. The mutation could not be detected in genomic DNA of 100 controls of 
Lebanese origin who were found to be homozygous for the wild-type allele by 
analysis of restriction-fragment–length polymorphisms. The index patient’s cDNA 
sequence of MRPS22 was normal. 
Pulse labelling of the mitochondrial translation products with [35S]methionine 
showed a decrease in overall mitochondrial translation to about 20 percent of 
the overall translation in the controls. The deficit in translation varied from 
protein to protein. For instance, the expression of complex IV subunits I, II, and 
III was reduced to about 15 percent of the expression of the complex IV 
subunits in the controls, and expression of ND5 and ND6 to about 10 percent of 
control equivalents, whereas the other ND subunits were less affected (30 to 60 
percent of control equivalents). Overexpression of EFG1 cDNA in fibroblasts from 
the index patient increased the overall mitochondrial translation to about 40 
percent of the expression observed in the controls (Figure 3); overexpression of 
two other mitochondrial translation factors (EFG2 or IF3) had no effect on 
mitochondrial translation. 
Rescue of mitochondrial translation in fibroblasts from the index patient was 
accompanied by a rescue of complex IV activity that ranged from 20 percent to 
72 percent of the activity in the controls. Furthermore, we observed an increase 
in the amount of fully assembled complexes I, III, IV, and V (Figure 1). 
Overexpression of EFG2 slightly increased the amount of fully assembled 
complexes I, III, and V but did not result in a substantial increase in complex IV 
activity. 
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Figure 3: Analysis of mitochondrial translation products. Fibroblasts from the index patient that were 
overexpressing the mitochondrial translation factors EFG1, EFG2, and IF3 were pulse-labeled with 
[35S]methionine in the presence of an inhibitor of cytoplasmic protein synthesis (emetine) to assess 
the rate of mitochondrial translation. The patient’s fibroblasts showed a severe defect in mitochondrial 
translation that overexpression of EFG1, as shown by Northern blotting, partially rectified (to about 40 
percent of the expression observed in the controls) but that overexpression of the other translation 
factors did not affect. The proteins include seven subunits of complex I (ND), three subunits of complex 
IV (COX), the cytochrome b subunit of complex III (cytb), and two subunits of adenosine triphosphate 
(ATP) synthase (ATPase 6 and ATPase 8). 
 
 
Discussion 
 
Synthesis of mitochondrial proteins requires a number of initiation, elongation, 
and termination (or release) factors, all of which are encoded by nuclear genes. 
The cDNA for two initiation factors (IF2, IF3), four elongation factors (EFTu, 
EFTs, EFG1, and EFG2), and a release factor (RF1) have been cloned and 
sequenced in human and other mammalian species [3;13-18]. IF2 promotes the 
binding of formyl methionyl–transfer RNA (fMet–tRNA) to the small ribosomal 
subunit in the presence of GTP and a template, whereas IF3 promotes the 
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dissociation of the two ribosomal subunits, which produces free small subunits 
for the initiation of translation[14;19]. The mammalian elongation factor Tu 
participates in the formation of the ternary complex that includes EFTu, GTP, 
and minoacyl–tRNA, which delivers the aminoacyl–tRNA to the acceptor site of 
the ribosome [20]. The energy required for this process is supplied by the 
hydrolysis of GTP, which is followed by the release of EFTu from the ribosome as 
an EFTu–guanosine diphosphate (GDP) complex. The exchange of GDP for GTP, 
which regenerates EFTu–GTP, is accomplished by EFTs [20]. 
Although the roles of the mammalian elongation factors G1 and G2 have not 
been studied, elongation factor G in prokaryotes hydrolyzes GTP and, in so 
doing, catalyzes the translocation of peptidyl–tRNA from the ribosomal-acceptor 
site to the peptidyl site after peptide-bond formation [21]. Concomitant 
movement of mRNA exposes the next codon in the acceptor site [22]. RF1 
recognizes stop codons and promotes the release of the completed protein 
chain. 
It is not clear why there are two mammalian homologues of the prokaryotic 
elongation factor G. Perhaps each catalyzes translation from a specific set of 
mRNA, or perhaps they are redundant, to ensure survival when one fails. 
Studies of yeast lend support to the latter hypothesis; deletion mutations of 
either EFG1 or EFG2 are viable, although EFG1 mutations have a phenotype of 
respiratory deficiency [23]. Our observations suggest that EFG1 
is an essential gene and that EFG1 and EFG2 have different but overlapping 
roles in mitochondrial translation (Figure 1). Although the expression of both 
proteins is ubiquitous, the proteins may have tissuespecific functions, consistent 
with the severe effect of mutant EFG1 in the liver and brain and the mild effect 
in the heart and muscles [11;13]. 
Many GTP-binding proteins contain three highly conserved consensus elements 
(Figure 2B) [24]. The A521G mutation effects the substitution of a highly 
conserved asparagine residue present in the consensus-sequence element NKXD 
(where X indicates any amino acid), which is part of the GTPbinding domain and 
is responsible for base specificity[24]. A mutant variant of another GTP-binding 
protein, Ras p21, with replacement of the equivalent asparagine by lysine or 
tyrosine, is unable to bind guanine nucleotides or to transform NIH 3T3 cells 
[25]. The mutant residue in EFG1 may also blunt GTP-binding activity, with 
consequent loss of efficiency of mitochondrial translation. 
We report a mutation affecting a nuclear-encoded component of the 
mitochondrial translation system in an oxidative phosphorylation disorder. 
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Patients with combined deficiencies of oxidative phosphorylation enzymes are at 
least as common as those with isolated deficiencies of single-enzyme complexes. 
Nuclear genes encoding the mitochondrial translation factors are good 
candidates as causative genes in these cases. 
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Mitochondrial disorders 
 
Mitochondria are the main adenosine triphosphate (ATP) producers of the cell. 
They harbour in their inner membrane the principal network of energy 
production: the oxidative phosphorylation (OXPHOS) system. This system 
consists of five enzyme complexes. Electrons, donated by NADH and FADH2, are 
transported through respectively the first four and last three complexes. During 
this transport complex I, III and IV pump protons across the mitochondrial inner 
membrane to the inter membrane space. The fifth complex uses the proton 
gradient to produce ATP. All OXPHOS system complexes, except for complex II 
consist proteins encoded by either mitochondrial (mt) or nuclear (n) DNA. 
OXPHOS system enzyme deficiencies leading to a mitochondrial disorder can be 
caused by mutations in one of the about 80 genes encoding for the structural 
OXPHOS system proteins [1]. Besides these proteins also defects in proteins 
necessary for transcription, translation, regulation or assembly of the OXPHOS 
system can lead to a mitochondrial disorder [1].  
Mutations in genes necessary for OXPHOS system functioning can lead to a wide 
variety of disease phenotypes; even mutations in the same gene can result in a 
completely different disease presentation [2-5]. The number of genes necessary 
for mitochondrial maintenance is very high. Mutations in one of these can result 
in a single enzyme deficiency or combinations of affected enzymes. Single 
enzyme deficiencies can be caused by mutations in the structural subunits of the 
complexes of the OXPHOS system encoded by either mtDNA or nDNA. The 
elucidation of the human genetic code of mitochondrial as well as nuclear DNA 
encoding for OXPHOS system subunits was the beginning of mutation screening 
of the DNA. This has led to the resolution of the underlying genetic cause of 
OXPHOS deficiencies in many patients [6;7]. Despite the fact that the OXPHOS 
system complexes consist of many nuclear encoded proteins only mutations in a 
limited number of genes for complex I, II and recently for complex III related to 
a mitochondrial disorder have been detected [8-10]. Besides mutations in DNA 
encoding for the structural subunits also mutations in genes for the assembly of 
diverse OXPHOS system complexes have been described [11;12]. Although 
many mutations in genes leading to an OXPHOS system deficiency have been 
identified, still many patients suffer from the disease in which the genetic cause 
has not been elucidated yet, which warrants further research.  
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Structural genes 
 
Mutations in structural OXPHOS system genes, either in nuclear or mitochondrial 
DNA mostly lead to an enzymatic deficiency of one of the OXPHOS system 
enzyme complexes. Although many mutations have been described in structural 
genes of the OXPHOS system the list is still growing. Most of these mutations 
are rare making it difficult to set up fast tests because all the genes should be 
checked completely in order to be sure that no mutations are missed in a patient 
with a mitochondrial disorder. Only in the mitochondrial genome some mutations 
have been described which occur rather frequently [6].  
Mitochondrial DNA is circular DNA consisting out of 16,569 basepairs and 
contains 37 genes encoding for 13 protein subunits of the OXPHOS system, 2 
ribosomal RNAs and 22 transfer RNAs. Transmittance of mitochondrial DNA does 
not follow Mendelian inheritance. First, nearly all mitochondria are transmitted 
maternally. mtDNA exists in many copies in a cell. So a person can harbour wild 
type and mutant mtDNA in the same cell. The mutation load (percentage 
heteroplasmy) in the mitochondria determines the severity of the disease [6]. 
Another aspect of mitochondrial DNA inheritance is that during cell division the 
proportion of mutant DNA can shift in daughter cells, which might lead to a 
change in phenotype. Besides this many polymorphisms have been detected in 
the mitochondrial genome making it difficult to predict whether a gene alteration 
in a patient is really the cause of an OXPHOS system deficiency. Rules have 
been established to determine whether a mitochondrial DNA alteration might be 
able to cause a mitochondrial disorder (for review see [6]). An oligonucleotide 
microarray has been developed to characterize many polymorphisms in the 
mtDNA in one reaction which could be used to screen for common mutations in 
mtDNA [13].  
Diverse studies have been performed to gain more insight in the inheritance of 
mtDNA and to answer questions concerning the heteroplasmic state of cells. It 
has been demonstrated that very low levels of a mitochondrial DNA mutation 
can lead to mitochondrial dysfunction in vivo whereas in cybrid cell lines these 
levels did not show any effect [14]. This demonstrates the difficulty to predict 
the effects of a mtDNA mutation in a patient. A simple but rather time 
consuming assay, based on fusion of patient cells with rho zero cells can be used 
to determine whether a mtDNA mutation is the disease causing mutation, or to 
exclude if a patient harbours a mitochondrial DNA mutation without knowing the 
mutated gene [15]. For such studies it is important to use patient cells which 
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have not been in culture for a long time as the mutation might disappear due to 
a shift in mutation load [16;17].  
In contrast to mtDNA mutations, mitochondrial disorders related to a nDNA 
mutation follow the traditional Mendelian patterns of inheritance. Mutations in 
nuclear OXPHOS system genes often lead to a disease of infancy or early 
childhood, whereas mtDNA mutations in general have a later onset [18]. The 
number of recognized nuclear encoded structural subunits of the OXPHOS 
system, especially those of complex I, has been increasing each year. At this 
moment it is assumed that this complex harbours 46 subunits [19]. The 
uncertainties concerning the final composition of the OXPHOS system complexes 
and the lacking knowledge of assembly genes make it difficult to study 
mitochondrial disorders. Mutations in some structural subunits of complex I, II 
and III have been identified in just a small percentage of all patients with an 
OXPHOS system deficiency [8-10]. This small percentage can partly be 
explained by mutations present in non structural genes but the reason why no 
mutations in structural subunits of complex IV and V have been found so far is 
not clear. The study in this thesis was the third one showing that mutations in 
structural genes for complex IV are not a cause of a mitochondrial disorder in 
patients with an isolated complex IV deficiency. It might be possible that 
mutations in nuclear encoded structural genes for complex IV and V are rarer 
than mutations in the other complexes. Extensive research might finally lead to 
the detection of a mutation in these genes. Most of the described mutations in 
the structural OXPHOS system subunits are within the catalytic active subunits 
of the diverse enzyme complexes. For complex IV it has been shown that the 
minimal functional structure of the complex consists of three subunits. The 
human counterparts of these subunits are the mitochondrial encoded subunits. 
So it might be possible that only mutations in the catalytic core of the OXPHOS 
system complexes result in a mitochondrial disorder. Another possibility is that 
mutations in nuclear genes of complex IV will lead to a rare non-mitochondrial 
recognized disease phenotype as is also the case for some mutations in the 
structural genes for complex II [20]. Finally, structural complex IV mutations 
might be very deleterious and may lead to early abortions or death. 
Mutations in the structural genes of the OXPHOS system can learn us a lot about 
the effect of these mutations on the assembly of the diverse complexes in the 
mitochondrial innermembrane. Various studies have addressed the effect of a 
certain mutation on the protein level and the assembly of the affected OXPHOS 
complexes. These studies give strong evidence that mutations in different 
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assembly give specific protein expression patterns. These patterns can be used 
to obtain a first clue about the mutated gene in an affected patient [21;22]. This 
is illustrated for complex IV deficiencies for which it has been shown that 
patients harbouring mutations in different assembly genes show a distinct 
assembly pattern. These patterns are also of great benefit in the understanding 
of the normal assembly of complex IV [22]. Based on these protein studies it 
was predicted that two patients might harbour a mutation in the structural 
subunits of complex IV although this still has to be proven. For complex I similar 
results have been obtained. Using antibodies directed to diverse complex I 
subunits it was possible to predict which genes might be mutated. With this 
approach it was also shown that patients harbouring mutations in different 
subunits of complex I could be distinguished from each other. Comparable 
results have been obtained with native gel electrophoresis of patients with a 
complex I deficiency [23;24]. In one of these studies it was demonstrated that it 
was possible to discriminate between complex I assembly and catalytic defects 
[23]. Therefore it is of utmost importance that patients with an OXPHOS system 
disorder are genetically characterized, as each patient may be a puzzle piece in 
the comprehension of the formation of the OXPHOS system. The discovery of 
assembly genes for the OXPHOS system has brought a new dimension to the 
understanding of the assembly process making the whole picture even more 
complex [25]. 
Another approach to study the effect of mutations in structural genes of the 
OXPHOS system is that using a microarray. Using this approach the effect of a 
mutation on the expression levels of other genes can be made [26]. A 
microarray has been used to study patient fibroblast cell lines harbouring a 
complex I mutation. The hierarchical cluster analysis of the expression data 
showed that patient cell lines could be distinguished from control cell lines using 
transcriptional data. However the applied clustering approach could not establish 
a link between patients harbouring mutations in the same subunit of complex I, 
or even a link between two patients harbouring the same mutation. However the 
results did point to some common patterns of gene expression in complex I 
deficient cell lines harbouring nuclear mutations.  
A mouse model with mutations in structural OXPHOS system genes of nuclear 
origin would be perfect to study the mechanisms of a mitochondrial disorder in 
vivo or to gain new insight in the treatment of such deficiencies. The generation 
of such a mouse might cause problems with the survival as can be seen from 
other mice models [27;28]. 
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More research using new techniques will learn us more about the OXPHOS 
system functioning. Also mutations present in patients with a mitochondrial 
disorder will help us to understand better the formation of the OXPHOS system. 
However this is still a long way to go as new subunits and mutations in genes 
leading to an OXPHOS system deficiency are continually being characterized.  
 
 
Assembly genes 
 
All the structural OXPHOS system subunits encoded by nuclear as well as 
mitochondrial DNA need to be brought together and assembled in the 
mitochondrial inner membrane. As has been established in yeast many proteins 
are necessary in order to assemble the OXPHOS system properly in the 
mitochondrial inner membrane [29]. The last years more and more proteins 
involved in the assembly of the OXPHOS system have been linked to an OXPHOS 
system disorder in man. In 1998 the first so-called assembly gene (SURF1) for 
complex IV was related to a cytochrome c oxidase deficiency in man shedding a 
complete new light on the OXPHOS system formation [30;31]. The fact that two 
groups found the SURF1 assembly gene at the same time and that mutations in 
this gene were detected in many patients shows that it is an important gene for 
the functioning of complex IV. Also in the complex IV deficient patients 
described in this thesis eight patients harboured a mutation in SURF1 (chapter 3 
and [32]). One of these patients has been reported 25 years ago and showed a 
tissue specific expression pattern of the complex IV deficiency. However re-
examination of the liver tissue revealed a reduced complex IV activity. A 
decreased complex IV activity is more in line with what is expected as SURF1 
protein is expressed in liver. Also mouse models show that a defect in SURF1 
results in a decreased complex IV activity in liver. The quest for assembly genes 
continued in other patients with a complex IV deficiency resulting in the 
discovery of four assembly genes (COX10, COX15, SCO1 and SCO2) in which 
mutations lead to a mitochondrial disorder [33-36]. Until now, however, the 
occurrence of mutations in these genes is not as common as SURF1 mutations. 
We have tested our patient population for mutations in three of these assembly 
genes SCO1, SCO2 and COX10. We have identified one patient harbouring a 
mutation in COX10, no mutations were detected in SCO1 and 2.  
A constitutive knockout mouse model of SURF1 has been made to study the 
effect of a SURF1 mutation in vivo [28]. The characterization of the mouse 
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showed that the main phenotypic characteristics were the same as in patients 
with a SURF1 mutation. The mice died at a young age, as was also the case in 
the mtDNA mouse model. In the case of the SURF1 mouse model there was a 
high post-implantation embryonic lethality and an early onset of mortality of 
post-natal animals. So it should be taken in mind that the generation of 
knockout mice related to mitochondrial disorders might fail due to the early 
lethality. Tissue specific knock out mice might be better for this purpose.  
The assembly of complex IV of the OXPHOS system has been studied most 
extensively. This is probably related to the fact that complex IV is, together with 
complex II, a relative simple complex, consisting of thirteen subunits three of 
these complexes are encoded by mtDNA. Besides the simplicity of the complex 
many assembly genes for this complex have been linked to an OXPHOS system 
deficiency and many studies in yeast have been performed for this complex. 
These yeast studies showed that many genes are involved in the formation of 
complex IV and the complex in yeast is even simpler than in human [37]. The 
assembly process in man can be easily visualised in a two-dimensional blue 
native gel showing three assembly intermediates before the holo-complex is 
formed [38].  With one and two-dimensional blue native gel electrophoresis the 
effect of mutations in the assembly genes of patients with a complex IV 
deficiency has been intensively investigated showing that the several proteins 
exerted an effect in different assembly steps. SURF1 is most probably involved 
in the formation of the third assembly intermediate for complex IV as a mutation 
in the SURF1 gene resulted in the accumulation of the first two assembly 
intermediates and a nearly complete absence of the holo-complex [32;39]. This 
could also be demonstrated with material from a patient harbouring a SURF1 
mutation described in this thesis. COX10 is thought to be involved in the 
formation of heme A. The protein farnesylates heme B in order to form heme O. 
This occurs before the assembly of complex IV is starting. The COX10 mutation 
described in this thesis leads to a general decrease of the complex IV assembly. 
This has been visualised with two-dimensional blue native gel electrophoresis. 
This also demonstrated that the diverse sub-complexes did not accumulate. 
These results are in line with the function of COX10. Also for other patients with 
COX10 mutations it was demonstrated that a mutation in this gene results in a 
general decrease of fully assembled complex IV [40]. In yeast COX15 is involved 
in the conversion of protoheme to heme A, the prosthetic group of complex IV, 
which is one step further in the heme A formation than that involving COX10. In 
a patient harbouring a mutation in COX15 it was proven that the heme A 
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content was reduced to 6% of control whereas an accumulation of heme O was 
detected [41]. In this patient no accumulation of sub-complexes could be 
visualised indicating that COX15 exerts a function in the early phase of the 
complex IV assembly, most likely at S1 [36]. This observation is similar to 
results of studies with COX10 demonstrating that these genes are involved in 
the same pathways. The role of the other two assembly genes (SCO1 and 
SCO2), in which mutations have been reported in human, is less clear. From 
yeast studies it is known that Sco2 is involved in mitochondrial copper delivery. 
In yeast copper is most probably delivered from the plasma membrane to the 
cytosolic protein COX17. This protein delivers the copper to Sco1p present in the 
mitochondrial inner membrane. With the use of the known human SCO2 
mutations it is defined that Sco1p in yeast delivers the copper to the CuA site on 
COX subunit 2 [42]. The role of Sco2p is unclear, as yeast null mutants do not 
show any OXPHOS deficiency [43;44]. Although the role of SCO2 is unclear, 
mutations in this gene cause a complex IV deficiency in man. For now no 
assembly studies have been performed with patient samples harbouring a 
mutation in SCO1 or SCO2. This would be very worthwhile, as it will extend the 
knowledge about complex IV assembly. A possible therapy for patients with a 
mutation in SCO2 came from an in vitro study where it was demonstrated that 
copper supplementation could restore the complex IV deficiency in patient cell 
lines with a SCO2 mutation [45]. The first in vivo study in a SCO2 patient with 
hyperthrophic cardiomyopathy and a reduced complex IV deficiency showed that 
supplementation with subcutaneous copper-histidine resulted in an improved 
cardiac function [46]. This suggests that mitochondrial disorders caused by 
defects in proteins which are involved in the delivery of a co-factor to the 
OXPHOS system complexes might be suitable for a supplementation therapy. 
The assembly of other OXPHOS system complexes has been studied less 
extensive than that of complex IV. Complex III and V are the only other 
complexes in which an assembly gene has been linked to an OXPHOS deficiency 
in man. Mutations in BCS1L lead to an impairment of the insertion of Rieske 
iron-sulphur protein into complex III [47], whereas a mutation in the complex V 
assembly gene ATP12 results in a disturbed function of the complex in man 
[12;48]. 
Studies in the fungus Neurospora crassa have revealed that the membrane arm 
and the matrix arm of complex I are formed independently before the whole 
complex is formed [49]. The association of two smaller assembly intermediates 
results in the formation of the membrane arm [50]. The largest of these smaller 
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intermediates is associated with two proteins CIA30 and CIA84. These proteins 
are not part of mature complex I. Disruption of these proteins leads to the 
accumulation of the matrix arm and the small membrane arm intermediate 
whereas the large membrane arm intermediate is not formed. The other 
OXPHOS complexes are not affected by the deletion of these genes proving that 
these genes have a specific function in complex I assembly. The human 
homologue of the CIA30 gene has been identified by a database search but until 
now this gene has not been linked to an assembly defect of complex I leading to 
a mitochondrial disorder in man [51]. The use of antibodies in combination with 
a sucrose gradient has revealed that mutations in complex I genes can lead to 
an impairment of the assembly of the complex [21]. The sample of one patient 
showed an antibody pattern, which was very suggestive for a severe assembly 
defect. This would be a perfect patient to investigate whether assembly proteins 
are involved in mitochondrial disorders related to a complex I deficiency. 
Recently studies have been published concerning the assembly of complex I in 
human [23;24]. The study of Antonicka et al indicated that the assembly of 
human complex I differs from Neurospora crassa. In human many more 
assembly intermediates are observed compared to the four intermediates 
present in Neurospora crassa. The results suggested that the assembly of the 
matrix and the membrane arm are not formed in separate independent 
pathways [24]. These results are in contrast to a study by Ugalde et al in which 
it is demonstrated that the assembly of complex I is a sequential process in 
which different pre-assembled sub complexes are joined to form a fully 
assembled complex [52]. The membrane part of the complex is formed in 
distinct steps. This model demonstrates that the membrane arm is formed 
followed by the assembly to a preformed peripheral arm. This pathway is similar 
to the assembly of complex I in Neurospora crassa. Assembly studies performed 
with human material shown that mutations in structural complex I subunits 
result in an impaired assembly of complex I [23]. It is also demonstrated that 
some patients with an unknown nuclear mutation do not have an impaired 
assembly of complex I [23]. This suggests a different pathogenic mechanism 
leading to a complex I deficiency. These patients may harbour mutations in 
genes which might be involved in the regulation of complex I activation. 
Antibodies directed to all subunits of complex I will be a prerequisite in order to 
obtain precise insight in the assembly of complex I. 
It will still take some time before the whole assembly process of the OXPHOS 
system will be elucidated. From yeast we know that many proteins are involved 
Discussion and future perspectives 
 153
in the assembly of the diverse OXPHOS system complexes. In man it is still 
unclear how the OXPHOS system complexes are assembled in the correct 
position in the mitochondrial inner membrane. Also the interactions between the 
diverse OXPHOS system complexes are still unclear. Besides this it still remains 
to be elucidated which proteins are necessary to establish interactions between 
the OXPHOS system complexes. These and other questions will certainly be 
answered in the future. 
 
 
Nuclear genes functioning in mitochondrial RNA translation 
 
As mitochondria have their own genome, nuclear genes have to encode for 
proteins necessary for the process of transcription and translation in the 
mitochondria. This thesis shows that a mutation in a mitochondrial elongation 
factor (EFG1) involved in the translation of mtDNA to proteins can lead to a 
mitochondrial disorder in man. This is just one protein of the whole elongation 
machinery. The discovery of the mutation in EFG1 has opened a new way to 
explore the origin of mitochondrial disorders. It was not difficult to predict that 
mutations in genes involved in the mitochondrial RNA processing might lead to a 
mitochondrial disorder. Mutations in such genes might result in non-functional 
ribosomal RNA processing in the mitochondria. However, the question is whether 
this is compatible with live. EFG1 described in this thesis has an enhancing 
function in the RNA processing, meaning that without the protein some RNA is 
processed but with a low efficiency [53]. In literature many proteins have been 
described involved in the mitochondrial translation system which might be 
possibly mutated in patients with an enzymatic deficiency of complexes I, III, IV 
and V. Complex II should not be affected when genes involved in mitochondrial 
RNA processing are mutated as the genetic information for this complex is 
completely located on nuclear DNA. 
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Figure 1: Initiation of the protein synthesis on the ribosome. The acceptor (A), peptidyl (P) and E 
(exit) site are indicated in the ribsome. The initiation phase can be divided in three steps. During the 
first step IF3 promotes the dissociation of the two ribosomal subunits, providing free small subunits for 
the translation. Step 2 involves the binding of fMET-tRNA to the small ribosomal subunit. This is 
promoted by IF2 and takes place in the presence of GTP and a template. IF2 is released during the 
third step due to the exchange of GTP by GDP resulting in the formation of the 55S ribosomal initiation 
complex.  
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 The process of protein synthesis on the ribosomes consists of three phases: 
initiation, elongation and termination [54;55]. Different proteins are involved in 
each of these three phases. Although the complete mechanism in human 
mitochondria has not been completely established yet the process most likely 
resembles the bacterial protein synthesis route. The initiation phase involves so-
called initiation factors (IF), which form a complex with the ribosome subunits, 
GTP and the initiator tRNAMet in order to form the so-called pre-initiation 
complex (figure 1) [56-58]. In bacteria three such initiation factors have been 
identified whereas in human mitochondria only two (IF2 and IF3) have been 
described so far [59;60]. The latter might be explained by the fact that the 
missing initiation factor homologue (IF1) is a small protein and therefore difficult 
to identify in databases [59]. Another explanation could be that the IF1 protein 
might not be necessary in mitochondria, as studies have demonstrated that 
mitochondrial IF2 and IF3 can work efficiently in the absence of Escherichia coli 
IF1 [59]. 
The second phase, the elongation phase is controlled by four elongation factors 
(EF). This phase of the protein synthesis is best studied in prokaryotes. The 
mitochondrial elongation factors are named after their prokaryotic homologues 
and all mitochondrial elongation factors have been cloned [61-64]. EF-Tu forms 
a ternary complex with GTP and amino acylated tRNAs. It protects tRNA against 
hydrolysis and it transports it to the ribosomal aminoacyl (A) site for the 
decoding of messenger (m) RNA by codon-anticodon interactions (Figure 2). 
When the codon-anticodon recognition occurs, GTP hydrolysis on EF-Tu is 
stimulated by the ribosome resulting in the release of EF-Tu:GDP. The 
nucleotide exchange factor EF-Ts converts EF-Tu:GDP in active EF-Tu:GTP. After 
a proofreading step, the amino acylated tRNA is brought in the ribosomal 
peptidyl (P) site, where peptide bond formation is catalysed adding one amino 
acid to the growing peptide. After this the tRNA leaves the ribosome via the exit 
(E) site. The elongation factor, EFG together with GTP controls the translocation 
of tRNAs and mRNA on the ribosome. EFG:GTP mimics the EF-Tu:GTP with tRNA 
complex. Therefore it is likely that EFG:GTP makes an imprint on the ribosome 
for the EF-Tu complex leaving the site behind as a perfect fit for the EF-
Tu:GTPcomplex. Translocation takes place by a conformational change in EFG so 
that its ‘tRNA mimicking part’ will occupy the anticodon region of the A-site. 
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Figure 2: The elongation phase of the protein synthesis. The elongation factor EFTu participates in the 
formation of the (EFTu-GTP-aminoacyl-tRNA) ternary complex, allowing the aminoacyl-tRNA to bind to 
the acceptor site of the ribosome (2)[65]. The exchange of GDP with GTP in the released EFTu-GDP is 
accomplished by EFTs (1)[65]. EFG catalyzes the translocation of peptidyl-tRNA from the ribosomal A 
(acceptor) site to the P (peptidyl) site following peptide bond formation (3). Concomitant movement of 
the mRNA exposes the next codon in the A site (4).  
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The last phase is the termination phase. This requires a stop codon in the RNA 
at the ribosomal A site and release factors (RF). In bacteria four release factors 
have been identified; RF1 and 2 are responsible for stop codon recognition, RF3 
stimulates these two factors whereas the fourth factor RRF (ribosome recycling 
factor) is essential for the release of ribosomes after the stop codon [66]. 
Human mitochondria only use one stop codon, which may account for the fact 
that only RF1 is necessary to give release from the ribosome. These release 
factors recognize the stop codon followed by the binding of a second release 
factor leading to the hydrolysis of the peptidyl-tRNA, generating a free nascent 
protein and a free (uncharged) tRNA followed by the release of these 
components from the ribosome. 
In this thesis we presented a patient with a deficiency in complexes I, III and IV 
who harbours a mutation in the elongation factor EFG1. This is the first time that 
a gene involved in the formation of proteins on the ribosome is linked to a 
mitochondrial disorder. The mutation in EFG1 is present in a highly conserved 
domain for GTP binding. As the whole process of elongation is dependent on the 
hydrolysis of GTP it is very likely that the function of the protein is affected by 
this mutation. The function of the ribosome might be normal as EFG1 protein 
has an enhancing function. For that reason it would be worthwhile to search for 
a treatment strategy able to induce the protein formation on the ribosome as 
the whole machinery is supposed to be intact even with mutated EFG1 [53].  
Chomyn and colleagues have shown that the pathogenic mtDNA mutation 
tRNAleu(UUR) A3243G associated with MELAS shows a reduced association of the 
tRNA with the mitochondrial ribosome having an effect on the mitochondrial 
translation [67]. A study by Feuermann has proven that this defect can be 
abolished by overexpressing EF-Tu in yeast cells harbouring the ‘human A3243G’ 
MELAS mutation [68]. They show that EF-Tu suppresses the phenotypic signs of 
the mutation in yeast cells whereas the mutated tRNA does not seem to have an 
effect on the formation of the ternary complex. So the effect of EF-Tu should 
probably be found in stabilisation of the tRNA conformation. This study suggests 
that it should also be possible to correct for tRNA MELAS mutations in human 
cells; a first attempt for this was performed by Toompu [69]. Over-expression of 
mitochondrial translational elongation factor EF-Tu had no effect on the mutant 
phenotype. This might be related to the kind of mutation, in this case 742insC, 
that might lead to such a conformational change in the mRNA that the complex 
cannot be stabilised or the experimental design was not optimal for this study.  
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Figure 3: Termination of the protein synthesis. Release factor 1 (RF1) recognizes the stop codon 
present in the mRNA (1). Hydrolysis of GTP results in the release of the complete protein chain (2). 
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Defects in the building blocks of mitochondrial ribosomes might also lead to a 
mitochondrial disorder in which all mitochondrial complexes with nuclear 
encoded proteins can be affected. Two ribosomal (r) RNAs (12S and 16S) are 
encoded by mtDNA. The mammalian mitochondrial ribosomes are composed of 
55-60S particles and these particles consist of small 28S and large 39S subunits. 
The small subunit contains the 12S rRNA and about 30 other proteins whereas 
the large subunit consists of 16S rRNA and about 50 proteins [70;71]. Last 
years many mitochondrial ribosomal proteins (MRPS) have been identified [72-
74]. Some of the MRP genes have been located to critical regions for hearing 
loss, retinitis pigmentosa and neuronal dysfunction [72;75]. These symptoms 
are frequently encountered in patients with a mitochondrial disorder suggesting 
that mutations in these genes might lead to an OXPHOS system deficiency. 
Recently, a mutation has been described in a gene necessary for the synthesis 
of complex IV protein in patients with French Canadian Leigh syndrome. This 
gene probably exerts its function one step before the translational system. 
Information about DNA, messenger (m) RNA and protein was used to identify 
the gene. The DNA information came from a previous study were the candidate 
region was identified [76]. The second data set came from microarray databases 
were the expression levels of the genes located in the identified region were 
compared to the expression levels of mitochondrial genes. This was used to 
predict which genes were possibly involved in mitochondrial functioning. 
Furthermore tandem MS/MS was performed with purified mitochondria to 
identify mitochondrial proteins. These three datasets were joint leading to the 
identification of the gene LRPPRC [77]. The precise role of the protein is not 
known but it is probably involved in the maturation and trafficking of mRNA. 
Further investigation will be needed to identify the role of the protein precisely. 
Yeast Pet309 shows a weak homology to LRPPRC. Pet 309 which is in S. 
cerevisiae embedded in the mitochondrial inner membrane is necessary for 
initiation of translation of mature COXI RNA and for production or stability of 
mature transcripts from intron-bearing alleles [78;79]. A pet309 null mutant 
presents a defect in the accumulation of CO1 pre-RNA, and in translation of COI 
RNAs. These similarities between yeast and human proteins show that in 
studying the human OXPHOS system lower species are important model 
systems. Before performing expensive studies just simple sequence similarities 
can give a clue about the gene possibly involved in an OXPHOS system disorder.  
Studies in yeast have shown that many proteins are involved in the process of 
mitochondrial RNA translation. These genes may be related to mitochondrial 
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disorders as seen in man. The study in this thesis and the identification of 
LRPPRC shows that the mitochondrial research starts to expand in the direction 
of mitochondrial RNA processing. 
 
 
Diagnostics 
 
Diagnostics related to OXPHOS system disorders is expanding each year. This 
concerns not only more requests for enzyme diagnostics but also encompasses 
that more genes have to be analysed in patients as the list of genes involved in 
OXPHOS system deficiencies in man grows each year. Therefore it is of utmost 
importance to develop techniques, which will help to perform the diagnostics as 
fast and reliable as possible. 
The diagnostics for patients with a strong suspicion on a mitochondrial disorder 
is a long and time-consuming project. At the end in many cases only the 
affected complexes are characterized without any clue of the underlying genetic 
cause of the disease. Measuring all enzyme activities of the OXPHOS system is 
laborious. Therefore faster and simpler techniques to determine which complex 
is affected are of utmost importance. A way to reduce the number of enzymes to 
be measured might be obtained by a simple pre-screening of the affected 
complexes in fibroblasts or muscle tissue. This could be achieved using SDS-
PAGE or blue native gel electrophoresis. Another disadvantage of the enzymatic 
measurements is that the enzyme activities are determined in muscle tissue 
(which is very invasive for the patient) or in cultured skin fibroblasts. Cultivation 
of these cells is time consuming before enough material is available to be able to 
determine the OXPHOS system enzyme activities. Development of micro-assays, 
using less muscle tissue or cultured fibroblasts, would be beneficial for the 
patient.  
Once the defect complexes have been characterized the next step is DNA 
diagnostics to establish the genetic defect. The mitochondrion has its own 
genome, so the search for defect genes should be focussed on nuclear as well as 
mtDNA. Because of the availability of high throughput techniques substantial 
progress may be expected in the near future. Recently the first commercial 
microarray to screen the more than 15,000 bases of the mtDNA in one simple 
test has been developed. This will give a better clue whether a mitochondrial 
mutation is present in the mtDNA of a patient. 
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The search for mutations in nuclear genes is more difficult. First of all it is still 
unclear how many nuclear genes will be involved in mitochondrial disorders. In 
our lab we only screen for mutations in genes in which a mutation related to a 
mitochondrial disorder has been described. In the future fast techniques are 
necessary to put up with the demand for DNA diagnostics. As more and more 
research is performed it becomes clear that protein patterns of the OXPHOS 
system complexes may give an indication for the mutated genes [21-24]. This 
could be used as a pre-screen in order to reduce the number of genes that 
should be sequenced. Although more investigation is needed to establish the 
usefulness of this technique it certainly offers possibilities for the future. Besides 
a pre-screen the development of techniques to analyse many genes in a short 
time period will be useful to stay in line with the demand for diagnostics. 
After an enzyme complex deficiency has been established in a patient both in 
muscle as well as in fibroblasts prenatal diagnostics may be offered to the 
parents in a future pregnancy. For this it is necessary to establish whether the 
gene defect originates from mtDNA or nDNA. If mtDNA mutations have been 
excluded it is possible to measure the OXPHOS system enzymes activities in 
chorionic villi in order to determine if one of the complexes is affected [80]. The 
ideal situation for prenatal diagnostics is the presence of a known nuclear DNA 
mutation, as this will give a 100 percent reliable diagnosis. Until now we can 
only offer counselling to most patients with a mitochondrial disorder and their 
parents. Therefore it is of utmost importance that the mutated gene is known in 
patients with a mitochondrial disorder in order to be able to offer reliable 
prenatal diagnosis. 
 
 
Directions of research 
 
In order to help patients and their parents to answer their questions about the 
underlying genetic defect of the mitochondrial disorder it is of utmost 
importance to gain information about the genes involved in mitochondrial 
dysfunction. This can be achieved in several ways:a simple method is looking for 
human homologues of genes that might be involved in the ATP production in 
lower species [48;81-83]. This may be a fast and simple method to gain 
information about affected genes. Another possibility to search for genes 
involved in mitochondrial disorders is microcell mediated chromosome transfer 
[84]. The disadvantage of this technique is that it is very time consuming [85]. 
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This information together with all the information about genes coming available 
in public databases might lead to the identification of the correct gene in the 
future. A different approach has been used by Antonicka and co-workers where 
vectors expressing diverse genes involved in complex IV assembly have been 
used to elucidate the genetic defect in patients with a complex IV deficiency 
[36;40].  
The use of techniques like microarrays and proteomics will probably learn us 
more about the genes and proteins involved in mitochondrial disorders. 
Microarray is also a great tool to find relations between the expression patterns 
of diverse genes and a disease, making it possible to study effects of OXPHOS 
system deficiencies on many genes in the cell [26]. Another described method is 
based on the identification of proteins localised in mitochondria with the use of 
green fluorescent protein (GFP). This technique has not yet the potential to be 
used to identify many genes/proteins in a short time period but it has been 
shown that it can be used to identify novel proteins with mitochondrial targeting 
information [86]. More proteomics related approach to search for genes has 
been described by Taylor and colleagues; they used highly purified mitochondria 
for their tests [87]. This led to the detection of 615 proteins with mass 
spectrometry. This technique also identified proteins of which the biochemical 
function was not defined yet. This shows that combining different techniques can 
lead to the identification of many mitochondrial proteins.  
The focus of this thesis has been on nuclear DNA mutations and the 
consequences on the protein levels of the diverse subunits and assembly of the 
OXPHOS system complexes. The effects on the cell biological consequences of 
mitochondrial diseases are subject of other studies. 
 
 
Mitochondrial disorders and future treatment strategies 
 
The main question for the future will be whether we will be able to develop a 
rational successful treatment for patients with a mitochondrial disorder. In order 
to achieve this we will first have to gain a good insight in all the functions of 
mitochondria. Not only the biogenesis of the OXPHOS system has to become 
clear but also the biochemical pathways in which mitochondria are involved 
should be studied in detail in order to be sure that intervention in patients with 
an OXPHOS deficiency will not influence other pathways in which mitochondria 
are involved.  
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Mitochondrial disorders might be treated in different ways. Mutations in 
structural OXPHOS system genes might be overcome with the use of gene 
therapy. Studies with an alternative NADH dehydrogenase present in 
Saccharomyces cerevisiae have demonstrated that this protein is able to restore 
NADH oxidase deficiency in human complex I deficient cells [88;89]. For defects 
in, for instance, genes involved in the delivery of co-factors the way to a therapy 
might be shorter: supplementation might be sufficient to achieve a proper 
assembled OXPHOS system. This strategy has been used in a patient with a 
mutation in SCO2. Copper supplementation resulted in an improved cardiac 
function [46]. A different approach for a therapy is the treatment of the effects 
of a mutation, e.g. radical scavenging or correction of the calcium homeostasis. 
Radical scavenging could be accomplished by the delivery of bioactive molecules 
to mitochondria in vivo [90]. This approach has been positively tested in 
fibroblasts from patients with Friedreich’s ataxia [91]. The correction of calcium 
homeostasis can be achieved with benzothiazepine CGP37157, an inhibitor of 
the mitochondrial sodium-calcium exchanger [92]. CGP37157 completely 
restored the aberrant calcium signalling in fibroblasts from complex I deficient 
patients. The effect mentioned was accompanied by a restoration of the 
hormone-induced increases in calcium homeostasis and ATP production. 
The future has to point out if these treatments will also work in vivo. However all 
these studies demonstrate that the first promising steps in the direction of a 
cure/treatment for patients with a mitochondrial disorder have been made. 
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De cellen waaruit ons lichaam is opgebouwd bevatten subcellulaire organellen, 
waartoe ook de mitochondriën behoren. De belangrijkste functie van 
mitochondriën is de productie van adenosine trifosfaat (ATP), de brandstof van 
de cel. Mitochondriën hebben twee membranen: het buitenmembraan en het 
binnenmembraan die de matrix van het organel omgeven. De laatste stap van 
de ATP productie vindt plaats met behulp van vijf multi-eiwitcomplexen, gelegen 
in het mitochondriële binnenmembraan. Deze vormen samen het oxidatieve 
fosforylerings (OXPHOS) systeem. De productie van ATP begint met de oxidatie 
van NADH en FADH2 door respectievelijk complex I en II van het OXPHOS-
systeem. Hierbij worden elektronen afgegeven, deze worden via complex III 
naar complex IV getransporteerd. Complex IV gebruikt de elektronen voor de 
vorming van water uit zuurstof. Tijdens dit elektronentransport worden protonen 
door complex I, III en IV naar de tussenmembraanruimte gepompt. Deze 
protonengradiënt wordt door het vijfde complex gebruikt voor de productie van 
ATP dat in de cel nodig is voor energie vereisende processen. Het ligt voor de 
hand dat een defect in de ATP productie in de cel kan leiden tot een 
levensbedreigende situatie. Ziekten waarbij een defect optreedt in het OXPHOS 
systeem worden mitochondriële aandoeningen genoemd. Deze stoornissen 
leiden meestal tot een vroege dood van de patiënt.  
OXPHOS-systeemstoornissen worden veroorzaakt door mutaties in het 
genetische materiaal (het DNA) van de mens. Het genetische materiaal van de 
mens is verdeeld over 46 chromosomen, die weer onder te verdelen zijn in 
kleinere stukjes, die zorg dragen voor de vorming van eiwitten. Deze stukjes 
worden ook wel genen genoemd. Als het genetisch defect bekend is kan deze 
kennis gebruikt worden voor het stellen van de diagnose. Bij de meeste 
patiënten is het enzymatisch defect nog niet genetisch verklaard. Dit is te 
verklaren door het feit dat de volledige samenstelling van het OXPHOS-systeem 
maar ook van heel veel andere eiwitten die betrokken zijn bij de functie van het 
OXPHOS-systeem nog niet genetisch gekarakteriseerd is.  
Het goed functioneren van het OXPHOS-systeem is alleen mogelijk als alle 
zogenaamde structurele eiwitten, dit zijn de bouwstenen van het OXPHOS-
systeem, op een juiste manier in het mitochondriele binnenmembraan worden 
samengebracht. Hiervoor is een goed samenspel tussen alle eiwitten die 
betrokken zijn bij de vorming van het OXPHOS-systeem nodig. Om dit proces 
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goed te laten verlopen zijn er speciale eiwitten in de mitochondriën aanwezig die 
zorgen voor een goede vorming van het OXPHOS-systeem. 
Het unieke van de OXPHOS-systeem complexen is dat ze niet alleen eiwitten 
bevatten die door het aflezen van het DNA in de kern van de cel gemaakt 
worden, maar ook eiwitten welke gecodeerd worden door DNA dat zich in de 
mitochondriën bevindt. Mitochondriën zijn samen met de kern de enige 
organellen in de humane cel die hun eigen DNA bevatten. Dit heeft tot gevolg 
dat mitochondriële ziekten kunnen ontstaan door mutaties, zowel in het 
mitochondriële als in het kern DNA. 
Aan het begin van dit project was er een redelijke kennis van genen die een 
onderdeel zijn van de vijf complexen van het OXPHOS-systeem, terwijl er 
relatief weinig bekend was over genen die betrokken zijn bij het goed in elkaar 
zetten, de assemblage, van de verschillende complexen. Hiervoor zijn diverse 
eiwitten nodig, zoals is gebleken uit onderzoek van het vierde complex van het 
OXPHOS-systeem. Deze groep eiwitten wordt assemblage-eiwitten genoemd. 
Een fout in het DNA dat codeert voor deze assemblage-genen leidt tot een 
defect in de formatie van complex IV. Bij deze patiënten is alleen de functie van 
complex IV verminderd. Dit heeft tot gevolg dat de productie van energie in de 
cel ernstig is verstoord. Bij de door ons onderzochte patiënten met een complex 
IV defect hebben we gekeken of zij een defect hebben in één van de bekende 
assemblage-eiwitten. 
Veel patiënten vertonen ook een verlaagde activiteit van meer OXPHOS-systeem 
enzymen. Het is dan ook zeer waarschijnlijk dat er eiwitten bestaan die nodig 
zijn om meer dan een complex op de juiste manier in de mitochondriële binnen 
membraan te zetten of te assembleren. Daarom zijn we op zoek gegaan naar 
genen die hiervoor verantwoordelijk zouden kunnen zijn. 
In dit proefschrift ligt de nadruk op de assemblage van het vierde OXPHOS 
systeem complex. Er werd in één patiënt uitgebreid onderzoek verricht naar een 
gen dat kan leiden tot een verlaagde activiteit van meer dan een complex van 
het energieproducerende systeem. 
In hoofdstuk 1 en 2 wordt de achtergrond van het onderzoek uitgelegd. In het 
tweede hoofdstuk wordt de nadruk gelegd op wat er bekend is over de 
assemblage van het OXPHOS-systeem. 
Hoofdstuk 3 richt zich op de kern gecodeerde structurele eiwitten van complex 
IV. Hoewel bij veel patiënten mutaties zijn gevonden in de kern gecodeerde 
structurele eiwitten van het OXPHOS-systeem is dit nog niet het geval voor 
complex IV. Wij hebben in een groep van tien patiënten met een defect in 
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complex IV onderzocht of er mutaties aanwezig zijn in het kern DNA dat nodig is 
voor de vorming van de structurele eiwitten voor complex IV. In geen van deze 
tien patiënten is een mutatie gevonden, wat aangeeft dat mutaties in de 
structurele subunits van complex IV tot nu geen oorzaak zijn voor het ontstaan 
van een verlaagde ATP productie door het falen van complex IV, althans in onze 
patiëntenpopulatie. In dit hoofdstuk wordt gespeculeerd over de reden waarom 
tot nu geen mutaties zijn gevonden in de genen die coderen voor de structurele 
subunits van complex IV. 
In hoofdstuk 4 en 5 zijn vijf patiënten beschreven die een mutatie hebben in het 
SURF1 gen. Dit gen is mede verantwoordelijk voor de juiste formatie van 
complex IV in het mitochondriële binnenmembraan. Al deze patiënten vertonen 
hetzelfde ziektebeeld. Dit is zeer uniek, omdat de meeste defecten in het 
OXPHOS systeem leiden tot veel verschillende klinische presentaties. Uit 
onderzoek is gebleken dat de dertien structurele subunits van complex IV in 4 
stappen bij elkaar worden gebracht. Door een mutatie in SURF1 vindt er een 
blokkade van de assemblage plaats tussen de tweede en derde stap. Dit is met 
een vrij simpel experiment aan te tonen en kan daarom eenvoudig in de 
diagnostiek toegepast worden. Dit heeft als groot voordeel dat het heel snel 
duidelijk is welk gen defect is, hetgeen aanzienlijk minder werk vereist om een 
DNA mutatie te vinden. 
Hoofdstuk 6 behandelt een ander assemblage-gen voor complex IV. Dit gen, 
COX10, is betrokken bij de formatie van haem A. Bij de formatie van complex IV 
wordt haem A ingebouwd, wat nodig is voor een goede functie van het complex. 
Ook bij deze patiënt is gekeken naar het effect van de mutatie in het gen op de 
formatie van complex IV. 
In de volgende hoofdstukken is onderzoek verricht naar een gen dat mogelijk 
betrokken is bij het ontstaan van een OXPHOS defect, waarbij meer dan een 
complex een verminderde functie laat zien. Hiervoor zijn twee verschillende 
benaderingen gebruikt.  
In hoofdstuk 7 is nagegaan of er genen in gist en bacteriën bekend zijn die, als 
ze niet werken, een defect aan meer complexen van het OXPHOS-systeem 
veroorzaken. We hebben vier genen geselecteerd die aanleiding geven tot een 
verlaagde functie van complex I, III en IV en een gen dat betrokken is bij de 
werking van complex I en IV. Van deze geselecteerde genen is de humane 
homoloog ook bekend. Logischerwijs zou het niet functioneren van het humane 
gen tot hetzelfde defect moeten leiden als te zien is in gist en bacteriën. We 
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hebben echter geen gen defect gevonden bij de patiënten die wij hebben 
geanalyseerd. 
In hoofdstuk 8 is een geheel andere route gevolgd om te onderzoeken welk gen 
betrokken kan zijn bij een defect aan meer dan een complex van het OXPHOS-
systeem. Hiervoor hebben we gebruik gemaakt van cellen van de huid van een 
patiënt met een defect aan complex I, III en IV. Deze cellen kunnen op speciaal 
medium groeien en zijn daarom eenvoudig te gebruiken voor experimenten. Ten 
eerste hebben we met behulp van een test aangetoond dat het slecht 
functioneren van het OXPHOS-systeem in de patiënt veroorzaakt wordt door een 
mutatie in een van de vele kern DNA genen. Vervolgens hebben we wederom 
met behulp van de cellen bepaald op welk chromosoom het defecte gen 
aanwezig zou moeten zijn. Dit was chromosoom drie. Met behulp van 
zogenaamde markers hebben we een relatief klein gebied op chromosoom drie 
kunnen identificeren dat het defecte gen zou moeten bevatten. De volgende stap 
was het opzoeken van genen in dit chromosoom gebied, die een functie hebben 
in de mitochondriën. Dit kan met behulp van databases op het Internet. Zo 
hebben we twee genen geïdentificeerd. In een van deze genen bleek een 
mutatie aanwezig te zijn die de oorzaak zou kunnen zijn voor het niet 
functioneren van het OXPHOS-systeem bij deze patiënt. Het gen dat defect is, is 
nodig voor de vorming van het eiwit EFG1. Dit nucleair gecodeerde eiwit is 
betrokken bij het omzetten van eiwitten die gecodeerd worden door het 
mitochondriële DNA. Een defect in dit gen kan tot gevolg hebben dat het 
mitochondriële DNA niet adequaat wordt omgezet in eiwit, wat vervolgens leidt 
tot een defect in de energieproductie.  
 
Samenvattend blijkt dat veel genen betrokken zijn bij het goed functioneren van 
het OXPHOS-systeem in de mens. In dit proefschrift worden verscheidene genen 
beschreven die hiervoor nodig zijn. Hoewel de vorming en de werking van het 
OXPHOS-systeem steeds duidelijker wordt, blijkt dat er steeds meer nieuwe 
genen ontdekt worden die nodig zijn bij de productie van energie. Dit geeft aan 
dat er nog een lange weg te gaan is voordat de precieze werking van het 
OXPHOS-systeem duidelijk is. Met de ontdekking van mutaties in genen, zoals 
EFG1, betrokken bij de energieproductie komen we steeds een stapje dichter bij 
de waarheid betreffende de werking van het OXPHOS systeem. Hopelijk zal dit in 
de toekomst bijdragen aan de ontwikkeling van medicijnen die het leven van 
patiënten met een OXPHOS-systeem defect aanzienlijk kan verbeteren.
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Summary 
 
Mitochondria are the main energy producing organelles of the cell. Energy is 
produced by the oxidative phosphorylation (OXPHOS) system in the form of 
adenosine triphosphate (ATP). The OXPHOS system consists out of five multi-
protein subunits. The first four complexes, except for complex II, are involved in 
the generation of a proton gradient over the mitochondrial innermembrane, 
which is used by the last complex to produce ATP. The complexes of the 
OXPHOS system are, except for complex II, encoded by mitochondrial (mt) as 
well as nuclear DNA (n). The nuclear and mitochondrial encoded subunits have 
to be assembled in the mitochondrial inner membrane in order to form a 
functional OXPHOS system. 
One in approximately 10,000 children are born with a severe deficiency in the 
energy producing system. Such deficiencies lead to a reduced energy production 
mainly affecting organs with a high energy-demand, most of the times resulting 
in an early death. One complicating factor is that many disease phenotypes are 
associated with mitochondrial disorders. Therefore it is difficult to predict which 
gene is the disease cause in patients with an OXPHOS system deficiency. It is of 
utmost importance for the patients and their parents to identify the enzymatic 
defect and the disease-causing gene as soon as possible, because besides 
supportive care, the only thing we can offer for affected families is prenatal 
diagnosis. 
A few years ago most research has been focussed on the structural buildings 
blocks of the OXPHOS system in patients with a single enzyme deficiency. This 
has lead to the identification of many mutations in nuclear as well as 
mitochondrial encoded structural building blocks of the OXPHOS system. Until 
now mutations have been described in nuclear genes encoding for the structural 
building blocks of complex I, II and III. The fact that no mutations in the 
structural building blocks of complex IV have been detected is probably the main 
reason for a search to other nuclear encoded proteins involved in the functioning 
of the OXPHOS system. This has resulted in the discovery of many proteins 
involved in the assembly of the OXPHOS system complex IV. The first described 
mutated gene involved in the proper assembly of complex IV was SURF1, a gene 
frequently mutated in patients with a deficiency of complex IV. Most of these 
patients suffer from Leigh disease. Besides this gene five other genes (SCO1, 
SCO2, COX10, COX15 and LRPPRC) have been linked to a mitochondrial disorder 
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leading to a severe isolated deficiency of complex IV. The association of these 
genes with mitochondrial disorders has directed the mitochondrial research to 
non-structural OXPHOS system genes.  
The aforementioned assembly genes all lead to an enzymatic defect of only one 
of the OXPHOS system complexes, whereas many of the affected patients suffer 
from a deficiency involving more than one complex. Until now little effort has 
been put to elucidate the cause of a combined enzyme deficiency of the OXPHOS 
system. In this thesis we address the question whether genes with a general 
role in mitochondrial functioning may be the cause of an OXPHOS system defect 
in patients with a combined deficiency of two or more OXPHOS system 
complexes. 
Chapter one and two give an introduction to the functioning of the OXPHOS 
system. Chapter two is a review of the literature focussing on genes involved in 
the assembly process of the OXPHOS system. 
Chapter three till six all deal with patients with an isolated enzymatic deficiency 
of complex IV. Until now no nDNA mutations have been described in the 
structural building blocks of complex IV. We have sequenced all the nuclear 
encoded subunits for complex IV in order to investigate if one of the ten patients 
included in the study harboured a mutation in one of these subunits. In chapter 
three we once more show that mutations in the nuclear encoded structural 
building blocks are not a major cause of an enzymatic deficiency of complex IV. 
Besides mutation screening in the nuclear encoded structural building blocks of 
complex IV we also show that none of these patients harbour a mutation in the 
complex IV assembly genes SCO1 and SCO2.  
In chapter four and five mutation detection in SURF1 has been described. SURF1 
is often mutated in patients with a complex IV deficiency. We have identified 
mutations in this gene in five patients with a complex IV deficiency. All these 
patients show a Leigh’s syndrome phenotype. This phenotype is most often 
described when a patient harbours a mutation in SURF1. We also demonstrated 
that patients with a mutation in SURF1 have a very specific defect in the 
assembly of complex IV. This assembly defect can be visualized with two-
dimensional blue native gel electrophoresis. This technique might be used as a 
pre-screen to determine whether a patient with a complex IV deficiency 
harbours a mutation in SURF1. 
Chapter six deals with an other gene (COX10) related to a complex IV 
deficiency. COX10 is involved in the formation of heme A, a prosthetic group of 
complex IV. Heme A is inserted in complex IV during the assembly process of 
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the complex. In our patient group we have identified one patient harbouring a 
mutation in the start codon of COX10. With retroviral infection studies we 
demonstrated that the mutation is the disease causing one and that no 
alternative startcodon is used to generate COX10 protein. Two dimensional gel 
electrophoresis shows that the assembly is disrupted in an early step, as there is 
no accumulation of sub-complexes but a general decrease in the formation of 
complex IV. 
The second part of this thesis deals with patients, who have a combined 
deficiency of complexes of the OXPHOS system. To investigate which genes 
might play a role in the disease we have followed two approaches.  
In chapter seven we have selected four genes, which are involved in combined 
deficiencies in lower species. We have looked for the human homologues and 
have checked whether our patients harboured mutations in these genes. None of 
these genes are mutated in the investigated OXPHOS system deficient patients.  
In chapter eight we have followed a different approach to address the question 
which genes might be involved in a combined enzymatic deficiency of the 
OXPHOS system. We used the fibroblasts of a patient with a combined deficiency 
of complex I, III and IV. First we excluded the presence of mutations in the 
mtDNA. This was done with a rho zero test. Secondly we performed microcell 
mediated chromosome transfer to investigate which chromosome harboured the 
gene, which might be the cause of the deficiency seen in the patient. With this 
experiment we have shown that chromosome three should harbour the mutated 
gene. Subsequently we have refined the region with the use of microsatellite 
markers for chromosome three. Two genes involved in the functioning of the 
OXPHOS system were present in this region. Sequence analysis of these genes 
has led to the identification of a mutation in EFG1. The protein encoded by this 
gene is involved in the formation of protein from RNA on the mitochondrial 
ribosome. This is the first time that a mutated nuclear gene has been identified 
in a patient with a combined deficiency of complex I, III and IV of the OXPHOS 
system. 
 
In summary we have identified the underlying genetic cause of mitochondrial 
disorders in patients with a single deficiency of complex IV but also in a family 
with a combined deficiency of complex I, III and IV. The identification of these 
mutations is of utmost importance as we now can reliably offer prenatal 
diagnosis to the parents. Until now we have not been able to develop a 
treatment strategy for patients with a mitochondrial disorder. Genetic 
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counselling and prenatal diagnostics necessitate identification of the defective 
gene. Hopefully based on these findings further cell biological studies might give 
clues to develop future therapeutics to slow down the disease progress or even 
cure the patients from their disturbance in cellular energy production. 
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Nu ben ik aangekomen bij het belangrijkste deel van het proefschrift. Een 
onderzoek doe je nooit alleen. Daarom wil ik iedereen, die hier een steentje aan 
heeft bijgedragen, bedanken.  
 
Ten eerste Jan. Je hebt vaak tegen me gezegd: uiteindelijk komt alles goed. En 
inderdaad ! Ook al ging het voor mijn gevoel niet snel genoeg; het boekje is af. 
Ondanks je drukke werk kon ik altijd aankloppen. Door al je goede contacten 
heb ik drie maanden op het lab van Eric in Canada kunnen doorbrengen hetgeen 
uiteindelijk zeer belangrijk is geweest voor de resultaten van alle experimenten. 
Zonder jou hulp had mijn proefschrift er heel anders uitgezien. 
 
Bert, ook al heb je het altijd erg druk. Gelukkig heb je een pieper en de telefoon 
neem je altijd op. Als het nodig was om naar het lab te komen dan kwam je er 
zo snel mogelijk aan. Ik ben blij dat je altijd positief bleef ook al ging het niet 
altijd goed met de proeven. Je had altijd een heel aantal ideeën om de 
problemen eventueel op te lossen. Bedankt voor alle hulp. 
 
Prof. Trijbels, u stond altijd klaar voor mij. Ook al was dat voor een saai klusje 
zoals het nakijken van een artikel en niet te vergeten de laatste versie van mijn 
proefschrift. Alle opmerkingen zijn zeer nuttig geweest. Het is niet te merken 
dat, zoals u zelf zegt, u niet veel verstand heeft van de experimenten die ik 
deed. Ook de praatjes op de gang waren altijd zeer gezellig. Ik hoop u nog vaak 
te ontmoeten om even bij te kletsen. 
 
In het bijzonder wil ik mijn beide paranimfen bedanken. Sandy, ik heb altijd veel 
steun aan je gehad. Als een experiment niet lukte kwamen we er vaak samen 
toch uit. Maar ook kon ik altijd bij jou terecht als ik even moest “ontladen”. Het 
bijpraten na het weekeinde mis ik. Gelukkig zien we elkaar nog regelmatig om 
alle nieuwtjes uit te wisselen. Cris, al hadden we in het begin van onze 
samenwerking last van miscommunicaties, na een tijdje begrepen we elkaar 
perfekt. Ik heb altijd met veel plezier met je samengewerkt, volgens mij waren 
we een goed team voor experimenten met een tijdreeks. Hopelijk vind je een 
leuke baan in Spantje en mocht je ooit tijdrovende experimenten willen 
uitvoeren, je weet me te vinden. We komen jou en Amadeo zeker opzoeken. 
 
Ook wil ik iedereen bedanken die mij heeft geholpen met het kweken van de 
cellen, vooral toen mijn arm gebroken was. Op dat moment stonden twee 
stoven vol met cellen van experimenten die ongeveer drie maanden in beslag 
hadden genomen. Zonder jullie hulp had ik alles moeten herhalen, hetgeen een 
hels karwei was geweest. 
Iedereen van de DNA-groep bedankt voor alle hulp maar in het bijzonder de 
gezellig tijd op het lab. Ik heb altijd met plezier met jullie samengewerkt. Er was 
maar een min-puntje……………de kerstboom had wat mij betreft een andere 
Dankwoord 
 186
plaats mogen hebben. Gelukkig stond hij maar een paar weken per jaar in het 
lab.  
Marike en Jeanette, jullie hebben tijdens de stage zo hard gewerkt dat ik twee 
artikels heb kunnen schrijven. Zelf had daar tussen het kweekwerk door zeker 
geen tijd voor gehad. 
Maja, je hebt heel wat “afwas” voor mij gedaan, heel erg bedankt hiervoor en 
ook voor je luisterend oor. 
Ook wil ik de mensen van de weefselkweek en de spiergroep bedanken. Zonder 
jullie had ik helemaal geen onderzoek kunnen doen. Wat moet je beginnen je als 
je niet weet of de enzymen van het oxidatieve phosphoryleringssysteem niet 
aktief zijn. Of als je geen cellen van de patiënten hebt om te kweken. 
Alle andere collega´s van het laboratorium kindergeneeskunde en neurologie, 
waar ik tijdens mijn werk niet veel contact me had, wil ik bedanken voor de 
gezelligheid en de interesse in mijn onderzoek. 
 
Eric thanks for giving me the opportunity to work in your lab. I have learned a 
lot during my stay in Montreal. But also afterwards you and everybody from 
your laboratory have helped me a lot. Isla thank you for teaching me the 
chromosome transfer but also for the nice trips during my stay. 
 
Ook wil ik mijn nieuwe collega’s niet vergeten. Bedankt dat jullie me zo 
gesteund hebben en dat jullie nooit gedacht hebben dat het proefschrift niet 
meer afkwam. 
 
Papa en mama, jullie wil ik bedanken voor alle steun. Jullie hebben altijd gezegd 
dat het erg belangrijk is om te leren en daar ben ik jullie erg dankbaar voor. Ook 
zien jullie je enige dochter soms maar een uur per week, jullie klagen nooit. 
Hopelijk krijg ik nu weer wat meer tijd om langs te komen. 
 
Johan, nooit was het een probleem als ik weer heel het weekeinde achter de 
computer zat of naar Nijmegen moest. Je was er altijd om naar me te luisteren 
vooral als het werk niet liep zoals ik het graag zou willen. De laatste tijd heb ik 
het zo druk gehad dat het moeilijk was om mijn gedachten van het werk los te 
maken. Ik beloof je dat ik vanaf nu weer alle aandacht voor jou zal hebben. 
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